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6Abbreviations
ANOVA analysis of variance
APC antigen presenting cell
BB Bandrowski's base
BQ benzoquinone
CYP cytochrome P450
ELISA enzyme-linked immunosorbent assay
FACS fluorescence activated cell sorter
FITC fluorescein isothiocyanate
HAPA N-hydroxylamino-procainamide
ICAM intracellular adhesion molecule
IFA incomplete Freund's adjuvant
IFN interferon
IL interleukin
mAb monoclonal antibody
MACS magnetic activated cell sorter
MAO monoamine oxidase
MHC major histocompatibility complex
MPO myeloperoxidase
NAT N-acetyltransferase
NK natural killer (cell)
NKT natural klller T (cell)
invNKT natural killer T cell using the invariant Vα14-Jα281 TCR
PA procainamide
PAP 3-(N-phenylamino)-1,2-propanodiol
pAP para-aminophenol
PBS phosphate buffered saline
PE phycoerythrine
PGE2 prostaglandine E2
PGHS prostaglandine H synthase
PLN popliteal lymphnode
PMA phorbol myristate acid
PMN polymorphonuclear leukocyte
PMϕ macrophage
pPD para-phenylenediamine
RT-PCR reverse transcriptase-polymerase chain reaction
SD standard deviation
SI stimulation index
SLE systemic lupus erythematosus
STZ streptozotocin
TCDD 2,3,7,8-tetrachlorodibenzo-p-dioxin
TCR T cell receptor
Thd thymidine
TMB 3,3'-5,5'-tetramethyl benzidine
TNBS 2,4,6-trinitrobenzene sulfonic acid
TNCB 2,4,6-trinitrochlorobenzene
TNF tumor necrosis factor
TNP 2,4,6-trinitrophenyl
TOS toxic oil syndrome
WBMC white bone marrow cells
CHAPTER 1
General introduction
Principles of innate and adaptive immunity
The immune system is the body's defense against invading pathogens and
microorganisms. The immune response in mammals is classically divided into
innate and adaptive immunity. The phagocytes of the innate immune system
provide a fast, unspecific defense mechanism, but cannot always eliminate
infectious organisms. The lymphocytes of the adoptive immune system provide a
more specific defense and, in addition, memorize their 'defense strategy', so that
subsequent infections with the same organism can be handled more efficiently.
The two key features of the adaptive immune response are thus specificity and
memory (1).
Antigen recognition by cells of the innate and adaptive immune system
The innate immune system can only combat bacteria carrying highly conserved
surface molecules, that can be recognized by receptors on the surface of
phagocytes (2). Unsurprisingly, many bacteria have evolved ways to disguise
these molecules, so that they no longer are recognized by phagocytic cells. The
recognition mechanism used by the lymphocytes of the adaptive immune system
has overcome these problems. Lymphocytes do not recognize conserved
microbial surface molecules, but instead, each lymphocyte entering the blood
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stream bears unique receptors with a certain specificity. The specificity of a
lymphocyte is randomly generated by a unique genetic mechanism called gene
rearrangement. As there are more than a thousand million lymphocytes in a
human body, the adaptive immune system is capable of recognizing a huge
diversity of antigens (1-3). 
Clonal expansion and lymphocyte memory
As each single lymphocyte carries a unique specific receptor, the number of
lymphocytes that recognize a given antigen is very small. To enable the adaptive
immune system to effectively combat invading organisms, there must be an
amplification mechanism; this mechanism is called clonal expansion. Upon
encounter with their specific antigen lymphocytes proliferate and produce
around a thousand daughter cells of identical specificity which then differentiate
into effector cells. Lymphocytes can be divided in two major categories:
T lymphocytes, or T cells, and B lymphocytes, or B cells, which have a different
role in the immune response to microorganisms. T cells can, after activation and
expansion, differentiate into cytotoxic effector cells or into T helper cells which
provide help to B cells to enable them to proliferate and produce antibodies. The
antibodies produced by B cells bind to the microorganism and thereby facilitate
recognition and uptake of these organisms by the phagocytes of the innate
immune system. After eliminating the organism from the body most of the
involved lymphocytes die. However, some persist and form the basis of
immunological memory, which ensures a more rapid and effective response
upon a second encounter with the same pathogen (1).
Lymphocyte activation
Recognition of antigen alone is not sufficient to activate lymphocytes. To fully
arm a lymphocyte it takes two signals, called signal 1 and signal 2 (4,5). The
first signal is the specific binding of the receptor to the antigen, the second
signal an unspecific costimulatory signal.  T cells receive signal 2 from
professional antigen presenting cells (APC), i.e., dendritic cells, macrophages,
and B cells (6,7). After activation, T cells can provide signal 2 to B cells,
thereby helping them to proliferate and produce antibodies (8,9). The signals
that lead to "activation", i.e. upregulation of costimulatory molecules of APC
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and subsequent signal 2 delivery to T cells are not completely elucidated; they
may involve recognition of conserved microbial structures by the APC, or
induction of stress, e.g., through free radicals formed by chemical
transformation (6,7,10). Lymphocytes that receive signal 1 without co-
stimulation are deleted or anergized, a term used for the non-responsive state of
lymphocytes (11). The requirement for signal 2 is one of the mechanisms
protecting man against lymphocytes that have an autoimmune potential (12). 
Self tolerance and autoimmunity
Thus, activation and subsequent clonal expansion of lymphocytes expressing
randomly generated receptors is the main principle of adaptive immunity.
However, this principle in its most basic form bears a significant danger:
recognition of self-antigens on the tissues of the body and subsequent reaction
towards them (4). This is partially prevented by clonal deletion, a mechanism by
which maturing lymphocytes in the thymus are tested for potential auto-reactive
behavior and consequently deleted (13-15). The adaptive immune system,
therefore, consists of lymphocytes that recognize a wide variety of different
foreign-antigens without reacting to self-antigens. However, some auto-reactive
lymphocytes escape clonal deletion and become activated during their lifespan,
thereby initiating autoimmune diseases like diabetes (16), systemic lupus
erythematosus (SLE) (17), or autoimmune arthritis (18). In the periphery,
autoreactive lymphocytes normally encounter their self-antigens without
costimulation, leaving them unresponsive. The mechanism by which these auto-
reactive lymphocytes do become activated after years of slumbering in the body
is not always known, but in some cases viruses, chemicals or trauma are thought
to be involved (18-21).
NKT cells, the bridge between the innate and adaptive immune system?
Recently a specialized population of T cells was discovered, that coexpress
receptors of the natural killer (NK) cell lineage (22-24). These NKT cells have
unique potential to very rapidly secrete large amounts of cytokines (25),
providing early help for effector cells and regulating the adaptive immune
response. Murine NKT cells have a biased TCR repertoire; 85% of all murine
NKT cells are Vα14-Jα281+ (26). NK T cells do not recognize peptides on
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MHC molecules, like classical T cells do, but instead recognize hydrophobic
antigens on transmembrane molecules distantly related to MHC-encoded
antigen-presenting molecules. These molecules, called CD1, can present lipid
antigens, e.g., glycolipids from mycobacteria, to NKT cells (27). As NKT cells
can rapidly secrete cytokines upon recognition of bacterial glycolipids,  they
seem to straddle the adaptive and innate immune system (28). It was shown
recently that NKT cells do not only play a role in induction of immunity but also
in tolerance (29,30). Since NKT cells can recognize non-classical antigens and
play an ambiguous role in the induction of immune responses, they may be
involved in the pathogenesis of drug-induced autoimmunity.
Induction of allergy and autoimmunity by chemicals
Chemical induced allergy or autoimmunity is often observed after
administration of certain drugs, e.g.,  procainamide (20), sulfonamides (31), and
diphenylhydantoin (32), or after contact with industrial or environmental
chemicals like HgCl2 (21) or azo-dyes (33). T cells play a central role in the
development of drug-induced adverse immune reactions (34-37). If the TCR of a
certain T cell recognizes its cognate antigen on the surface of an APC, the T cell
will respond with clonal expansion, cytokine production, and / or cytotoxicity
(Fig. 1). A major difficulty in studying T-cell reactions to sensitizing chemicals
is the fact that in most cases the ultimate neoantigen recognized by "drug-
specific" T cells is unknown.
Neoantigen formation
As most T cells can only recognize peptides on MHC molecules, chemicals have
to bind to a protein carrier in order to be recognized by T cells (38,39). The
neoantigen thus formed is called the hapten-carrier complex which can be
degraded by APCs. Parts of the neoantigen are presented on MHC molecules on
the surface of the APC and can be engaged by T cells (40-42). Two different
possibilities arise during processing and presentation of hapten-carrier
complexes: (i) the part which is processed and presented on the surface of APCs
is the part which has bound the hapten (43), or (ii) binding of the hapten to the
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Figure 1. CD4+ T cells can only be activated by peptide-MHC-complexes presented to
them on APCs. Proteins, including self-proteins, are processed, cleaved and the resulting
peptides presented on MHCII molecules on the surface of APC. CD4+ T cells that engage
self-peptides do not react upon contact with APC (left part), whereas peptides from
pathogens, i.e. foreign peptides, elicit a T cell dependent immune reaction (right part).
self-protein influences the processing of this carrier (44,45). In the latter case,
self-peptides which are normally not presented can be presented on the APC's
surface. Because these so called cryptic self-peptides (46) are normally not
presented, T cells are not tolerant against them and would react upon encounter
with these "foreign" peptides. The two above mentioned possibilities,
presentation of hapten-peptide adduct or cryptic peptide, respectively, are
depicted in Fig. 2. 
Metabolism of prohaptens
Chemicals that need to be activated in order to bind to proteins are called
prohaptens (47). In their prohaptenic form they enter the human body where
they are either metabolized in the liver, or in other cells that contain a panel of
drug-metabolizing enzymes. The liver is believed to be an immune-privileged
site concerning drug-induced adverse effects. Two mechanisms may account for
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Figure 2. Processing and presentation of self-proteins and altered self-proteins,
respectively. Self-proteins that are taken up by APC are processed and one ore more dominant
peptides are presented on MHC molecules on the surface (upper part). Self-proteins that are
altered by, e.g., haptens, are processed differently. This may lead to either presentation of an
haptenated self-peptide, or presentation of a self-peptide, that normally is not presented after
processing of the self-protein. As the T cells did not come in contact with this cryptic peptide
before, tolerance does not exist and T cells are activated upon contact with it.
this: (i) the specialized function of the liver in detoxifying possibly harmful
compounds; protein-reactive metabolites formed in the liver are quickly bound
to special molecules like glutathion and acetyl, abundantly present in the liver
(48); (ii) the environment in the liver is thought to be tolerogenic rather than
immunogenic (49,50); T cells that come into contact with their antigen in this
environment, would not be activated but rather deleted or anergized. Although
the liver is specialized in drug-metabolism (48), it therefore does not seem to
play an important role in drug-induced allergy and autoimmunity. In contrast,
cells from the immune system itself can do both, oxidize the prohapten into the
hapten, and present the so formed neoantigen together with the proper
costimulation to T cells (37). Several studies have shown that neutrophils and
monocytes are involved in drug-metabolism prior to drug-induced adverse
immune effects (51-53). 
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Specificity versus cross-reactivity of single T cell clones
As mentioned before, specificity is one of the key-features of adaptive
immunity. A few years ago it was generally accepted that a single T cell can
only recognize one single peptide. Such specificity can be compared with a key
fitting only a single key-hole. Recent publications, however, undermined this so
called "one clonotype, one specificity" dogma. Theoretical considerations led to
the conclusion that one single T cell clone must be able to react with a few
thousand different peptides in order to efficiently react to the multitude of
invading pathogens (54). Experimental evidence for this theory was provided by
several other groups (55-57). Although T cells seem to recognize several
hundreds or thousands of different peptides, this has not been described with
haptens. On the contrary, T cell clones seem to specifically distinguish between
changes in hapten side-chains (43,58) or even between stereoisomers (59). 
Scope of this thesis
In this study we investigated the mechanisms involved in chemical-induced
allergy and autoimmunity. Although from a first point of view there is a
difference between allergy and autoimmunity, there is no clear-cut border
between these two, especially when chemicals are the causative agent.
Chemical-induced allergy can develop into autoimmunity by mechanism like
molecular mimicry or presentation of cryptic peptides. On the other hand,
symptoms of chemical-induced autoimmune diseases like procainamide-induced
lupus disappear after discontinuation of drug-therapy, implying allergy instead
of autoimmunity. A difficulty in studying the mechanism of drug-induced
adverse immune effects is the fact that the ultimate neoantigens are unknown.
Most chemicals have to be metabolized before they are capable of eliciting
immune reactions. Another phenomenon that is not completely understood is
cross-sensitization, which means that patients allergic to a given compound react
positive in patch tests to compounds that are similar, but with which they had
not been in contact with before.
In this thesis we have tried to elucidate some of the mechanisms involved
in chemical induced adverse immune effects. Chapter 2 reviews several aspects
of neoantigen formation by xenobiotics. It deals with metabolism of chemicals,
the polymorphism of metabolizing enzymes involved, induction of
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costimulatory signals, and sensitization of T cells. In Chapter 3 we show, that
specific T cell reactions in the popliteal lymph node (PLN) assay could be
obtained by injection of the protein-reactive metabolites hydroquinone and
benzoquinone, but not by the parent compound benzene. The missing link in this
chapter, metabolism, is shown in Chapter 4, were we used the lupus-causing
drug procainamide (PA) to show that phagocytes metabolize PA to its protein-
reactive metabolite N-hydroxyl-amino-procainamid (HAPA), which
consecutively forms adducts with self-proteins. Furthermore, T cells from long-
term PA-treated mice reacted to both, the metabolite HAPA, as well as the
neoantigen formed in PA pulsed peritoneal macrophages. Chapter 5 also deals
with metabolism and with non-classical haptens: fatty acid anilides and
phenylaminopropanodiol (PAP)-esters of fatty acids. They are suspected to be
the cause of the toxic oil syndrome (TOS), an epidemic-like disease in Spain in
1981. This disease induced a graft-vs-host-like disease in several thousand
people after ingestion of rape seed oil contaminated with aniline. In Chapter 6,
our hypothesis of NKT cell involvement in the pathogenesis of TOS was tested
using mice deficient in NKT cells. In Chapter 7 we investigated the principles
of cross-sensitivity to chemicals by studying single T cell clones specific for a
given hapten coupled to a model self-protein. Three different mechanisms that
can account for cross-sensitization and their possible consequences for
autoimmunity are discussed. In Chapter 8, a new faster method is described to
screen T cell hybridomas for specificity, the CellELISA. Finally, Chapter 9
summarizes and discusses the contents of this thesis.
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CHAPTER 2
Allergic and autoimmune reactions to xenobiotics: how do they evolve? 
Peter Griem, Marty Wulferink, Bernhardt Sachs, José B. González and Ernst Gleichmann
Induction of allergic and autoimmune reactions by drugs and other chemicals
constitutes a major public health problem. Elucidation of the mechanisms might help
improve diagnostic tools and therapeutic approaches. Here, Peter Griem and
colleagues focus on several aspects of neoantigen formation by xenobiotics:
metabolism of xenobiotics into reactive, haptenic metabolites; polymorphisms of
metabolizing enzymes; induction of costimulatory signals; and sensitization of T cells.
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Introduction
Immune reactions to xenobiotics (i.e. drugs, metals, industrial and naturally
occurring chemicals) can give rise to allergy and autoimmunity. These reactions
are frequent and encompass a broad spectrum of different diseases and organs.
In order to decrease the health risks associated with exposure to xenobiotics, it is
important to understand the pathogenic mechanisms involved and to identify
human populations at risk. In view of the striking clinico-pathological similarity
between adverse immune reactions to xenobiotics and graft-versus-host
reactions, there is little doubt that adverse reactions to xenobiotics are initiated
and maintained by T cells (1). For immunologists, a major difficulty in trying to
study T-cell reactions to sensitizing xenobiotics is the fact that the ultimate
neoantigens formed by xenobiotics are not known, even though considerable
progress has recently been made in this respect using the classical hapten
trinitrophenyl (TNP) (Refs. 2,3) and 3-pentadecyl-catechol, a representative
catechol derivative in urushiol, the sensitizing component of poison ivy (4). In
extension of these findings, it is assumed that adverse immune reactions to other
xenobiotics also involve formation of protein adducts (in the toxicological
terminology) or hapten-carrier conjugates (in the immunological terminology). 
Reactive organic compounds most often bind covalently; that is, their
electrophilic properties enable them to react with protein nucleophilic groups
such as thiol, amino and hydroxyl groups (reviewed in Ref. 5). Examples of
such reactive, haptenic compounds that frequently lead to sensitization after
dermal contact or inhalation are toluene diisocyanate, trimellitic anhydride,
phthalic anhydride, benzoquinone, formaldehyde, hexyl cinnamic aldehyde,
ethylene oxide, dinitrochlorobenzene, picryl chloride, penicillins, and
D-penicillamine. Sensitizing metal ions react somewhat differently in that they
oxidize proteins or form stable protein-metal chelate complexes by undergoing
multipoint binding with several amino acid side-chains (Fig. 1). Since all of
these compounds have long been known as sensitizers, protection measures are
being taken in order to decrease the risk of sensitization (e.g. at workplaces).
In contrast to haptenic compounds, most xenobiotics eliciting adverse
immune reactions are unable to bind to proteins when entering the body.
However, they can do so after conversion to reactive metabolites (Table 1).
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Figure 1.   Haptens comprise organic compounds as well as metal ions and bind to proteins
forming either covalent bonds (a) or coordination complexes (b). These two types of chemical
bonds differ in the amount of energy required to break the bond (bond strength). (a) Organic
haptens forming covalent bonds bind to a single amino acid side-chain. Depicted is the
covalent binding of trinitrophenyl (TNP) to lysine. (b) Metal complexes consist of a center
placed metal ion and a set of atoms, ions or small molecules, regarded as ligands. These
ligands are aligned in a characteristic geometric form, e.g., a plane square or a octahedral. The
interactions between a metal ion and ligands allow the electron-rich ligands to transfer part of
their electron densitiy to the positively charged metal ion (coordination bond) in order to
increase complex stability. Depicted is a square planar complex of nickel with three histidines
and one cysteine. (c) Alternatively, reactive chemicals can irreversibly oxidize protein side-
chains, such as those of cysteine and methionine. Shown is a methionine monosulfone.
These xenobiotics can be considered as prohaptens. This article takes into
account that neoantigen formation by prohaptens involves an initial pharmaco-
toxicological phase that is determined by metabolic conversion of xenobiotics.
This phase precedes the T-cell-sensitization phase, and this, in turn, is followed
by an immune-effector phase that leads to the various clinico-pathological
manifestations of adverse immune reactions to xenobiotics. There are several
model xenobiotics for each phase in this pathogenic cascade. The reader should
be aware, however, that no single xenobiotic has yet been analyzed so
extensively that it could serve as a universal example for the entire cascade.
Therefore, different xenobiotics will have to illustrate the individual phases
described. 
Preimmunological phase 
Hepatic metabolism of xenobiotics
As the main organ for metabolism of xenobiotics, the liver is well-equipped
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Table 1. Examples of adverse immune reactions to xenobiotics that involve
reactive metabolites a
Parent compound Adverse immune reaction Candidate metabolite involved Ref.
Procainamide Drug-induced lupus N-Hydroxyprocainamide (M,H) (6,7)
Propylthiouracil Vasculitis, drug-induced lupus Propyluracilsulfonic acid (M,H)(8,9)
Halothane Autoimmune hepatitis Trifluoroacetylchloride (R,H) (10,11)
Tienilic acid Autoimmune hepatitis Thiophene sulphoxide (H) (12)
Dihydralazine Drug-induced lupus, Hydralazine radical (R,H) (13)
autoimmune hepatitis 
Gold(I) antirheumatics Dermatitis, glomerulonephritis Gold(III) (M,H) (14,15)
Practolol Oculomucocutaneous syndrome Practolol epoxide (H) (16)
Urushiol Contact dermatitis 3-pentadecyl-o-quinone (M) (4)
p-Phenylenediamine Contact dermatitis Bandrowski’s base (H) (17)
a The adverse immune reactions listed in the table were observed in humans, while
identification of candidate metabolites was achieved in: M, mice; R, rats; H, humans
with xenobiotic-metabolizing enzymes and is prepared for detoxifying reactive
metabolites. Compared with its high metabolic activity, adverse immune
reactions in the liver are relatively rare. Nevertheless, such reactions do occur,
one example being the autoimmune hepatitis caused by long-term treatment with
the diuretic drug tienilic acid (a prohapten). This side-effect is associated with
the production of autoantibodies directed against the cytochrome P450 (CYP)
isoenzyme 2C9 (CYP2C9), and interestingly this is the very enzyme that
catalyzes hepatic metabolism of the prohapten to its reactive metabolite (12,18).
This short-lived, haptenic metabolite was found to bond covalently to CYP2C9.
A similar mechanism is assumed for other cases of drug-induced autoimmune
hepatitis, such as those caused by halothane (10) or dihydralazine (13), in which
autoantibodies are directed against the enzymes converting these prohaptens to
the respective haptens (CYP2E1 and CYP1A2, respectively). T-cell recognition
of the haptenated enzymes in drug-induced hepatitis is likely, but has not been
formally demonstrated.
Extrahepatic metabolism of xenobiotics
In quantitative terms, extrahepatic metabolism of xenobiotics is less important
than hepatic metabolism. However, as far as adverse immune reactions to
prohaptens are concerned, extrahepatic metabolism appears to play a crucial
role. Rather than being metabolized to reactive, haptenic metabolites in the
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liver, and subsequently traveling to distant extrahepatic sites, such as the skin,
lung, or bone marrow, it is likely that reactive metabolites are formed at the very
sites where adverse immune reactions to xenobiotics manifest themselves.
Hence, the xenobiotic-metabolizing capacity of extrahepatic tissues merits
special attention in the present context. One example here is the skin, a barrier
organ which has a considerable metabolic capacity in conjunction with
immunological competence, and is often involved in adverse immune reactions
to xenobiotics, be it after dermal or systemic application (19). Interestingly,
dermal Langerhans cells contain CYP1A isoenzymes and are able to metabolize
prohaptenic xenobiotics, such as the polyaromatic hydrocarbon dimethylbenz-
[a]-anthracene, to haptens. They can activate specific T cells that mediate
contact hypersensitivity, presumably by presentation of haptenated peptides
(20). Similarly, urushiol, a mixture of allergenic 3-alkyl and 3-alkenyl catechols
from the plants poison ivy and poison oak, can be oxidized in the skin to
reactive o-quinones that can elicit specific T-cell responses after adduct
formation with protein (4,21,22). Another chemical frequently involved in
allergic contact dermatitis is p-phenylenediamine, which is oxidized to a reactive
metabolite termed Bandrowski’s base. Specific T-cell reactions to this hapten
have been demonstrated in vitro: peripheral mononuclear cells of sensitized
patients responded to Bandrowski’s base, but not to the prohapten
p-phenylenediamine (17).
Xenobiotic metabolism in phagocytes
Phagocytes include polymorphonuclear leukocytes (PMN), monocytes,
macrophages, and resident Langerhans cells. While the latter three can
themselves act as antigen-presenting cells (APC), PMN die after they have been
activated in inflammatory sites; the dead cells and debris are phagocytosed and
processed by APC. Hence, the capacity of phagocytes to metabolize xenobiotics
is particularly relevant in the present context. For instance, there is indirect
evidence that metabolism in phagocytic cells may be involved in systemic
adverse immune reactions caused by procainamide (PA) (6), propylthiouracil (8)
and disodium gold(I) thiomalate (14). Whereas the respective parent
compounds, or prohaptens, themselves proved unable to elicit T-cell reactions in
mice, their reactive metabolites generated in macrophages were able to do so. 
Generation of reactive metabolites in neutrophils and monocytes has
been attributed to metabolizing enzymes with a broad substrate specificity, such
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as myeloperoxidase (MPO), prostaglandin H synthase, and various CYP
isoenzymes (19,23-25). For PA, it has been shown in mice that T cells sensitized
to the reactive metabolite N-hydroxy-PA, which can easily be further oxidized to
nitroso-PA (another reactive, unstable metabolite), recognized macrophages
incubated with the nonreactive parent compound (i.e. the prohapten), indicating
generation of the hapten and hapten-protein adducts in these cells (6).
Additionally, in vivo bioactivation of PA in macrophages to N-hydroxy-PA and
nitroso-PA was indirectly demonstrated by successful restimulation of N-
hydroxy-PA-primed T cells with peritoneal cells of long-term PA-treated mice
(6) (Fig. 2). Similar findings were obtained with a chemically different
compound, the antirheumatic drug gold(I) thiomalate. Using gold(III)-specific T
cells as detection probes in in vivo and in vitro assays, indirect evidence was
provided for the generation of the short-lived, reactive metabolite gold(III) in
macrophages (14,26). Hence, in view of the multiple functions they can fulfill,
macrophages, and presumably other types of APC, appear to serve as a
connecting link between the preimmunological phase, which includes regional
xenobiotic bioactivation and neoantigen formation, and the phase of T-cell
sensitization to these neoantigens.
Genetic polymorphisms of xenobiotic-metabolizing enzymes
Metabolism of xenobiotics can be divided into two phases. Phase I
reactions, such as those carried out by CYP isoenzymes, usually lead to insertion
of functional groups into xenobiotics, or lead to demasking of such groups, and
thus can result in formation of reactive metabolites (part of which can act as
haptens). In phase II reactions, metabolites are conjugated with small
endogenous molecules, such as glucuronic acid, glutathione, acetate, or sulfate
in order to increase water solubility and facilitate elimination from the body.
Unlike larger haptenated peptides, these conjugates are too small to make stable
contact with the MHC binding groove and thus are unable to cause sensitization.
Several genetic polymorphisms of xenobiotic-metabolizing enzymes have been
identified, some of which cause expression of defective enzymes, or enzymes
with a reduced (or increased) metabolic activity (30). These inter-individual
differences in the generation of reactive metabolites among humans may
influence formation of protein adducts and, hence, may result in a different
susceptibility to chemically induced allergy and autoimmunity.
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Figure 2.   Hypothetical scheme of the initial immunotoxic steps underlying PA-induced SLE, based
on experimental results (Ref. 6, C. Goebel, C. Vogel, B. Sachs, S. et al., unpublished). (a) Hepatic
metabolism of the arylamine PA consists of two competing pathways (27,28). N-acetylation of the
amino group, catalyzed by NAT-2, leads to formation of N-acetyl PA, a stable metabolite that can be
eliminated. By contrast, oxidation of the amino group by CYP isoenzymes yields HAPA and, through
further oxidation, yields nitroso-PA (not shown); the latter can haptenate proteins and thus can induce
the adverse immune reactions seen in PA-induced SLE. However, in the liver, probably due to its high
detoxicating capacity, PA-induced adverse immune reactions fail to develop. Because of genetic
polymorphism, individuals differ in their NAT-2 activity, resulting in the slow- and fast-acetylator
phenotype. In slow-acetylator individuals, hepatic acetylation of PA is reduced, thereby increasing the
amount of substrate available for extrahepatic PA metabolism. (b) Extrahepatic metabolism of PA can
occur in phagocytic cells containing enzymes with a broad substrate specificity, such as PGHS-1,
PGHS-2, MPO and CYP isoenzymes (19,23-25). Importantly, phagocytic cells, like monocytes and
macrophages, which are capable of oxidizing PA to HAPA and further to nitroso-PA, can process
proteins and present hapten-conjugated peptides to T cells. Interestingly, PA was shown to induce
expression of PGHS-2 in mouse macrophages and thus can probably enhance its own oxidation to
HAPA and nitroso-PA. Moreover, the PA-induced enhancement of the generation of PGE2 by
PGHS-2 might skew the immune reaction toward a Th2-type response (29), thereby favoring
formation of (auto)antibodies.
Abbreviations: CYP, cytochrome P450 isoenzyme; HAPA, N-hydroxylamine PA; MPO,
myeloperoxidase; NAT-2, N-acetyl transferase 2; PA, procainamide; PGE2, prostaglandin E2; PGHS,
prostaglandin H synthase; SLE, systemic lupus erythematosus; Th2, T helper 2.
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Whether a genetic polymorphism of a xenobiotic-metabolizing enzyme
has clinical relevance depends on its functional role in the metabolism of a given
compound (i.e. its bioactivation or detoxication), and on whether other enzymes
can compensate for the defect. Individuals carrying certain genetic
polymorphisms, especially combined phase I and phase II defects, might be at
higher risk for allergic and autoimmune disorders induced by xenobiotics (31-
33). However, it should be noted that, besides genetic determination, the
individual activity of xenobiotic-metabolizing enzymes can also be influenced
by nongenetic factors such as drugs, diet, alcohol, smoking and cytokines. 
Table 2 presents selected examples of polymorphic enzymes that
metabolize drugs associated with adverse immune reactions in humans. Thus far,
the clearest association between a genetic polymorphism and adverse immune
reactions to certain drugs has been found for N-acetyltransferase-2 (Fig. 2).
Approximately half of the Caucasian population is homozygous for the mutant
alleles and exhibits the slow-acetylator phenotype. In individuals exhibiting the
slow-acetylator phenotype, the incidence of dihydralazine- or PA-induced
systemic lupus erythematosus (SLE) is higher than in those exhibiting the fast-
acetylator phenotype (27,28). Furthermore, of patients developing severe
erythema multiforme variants (Stevens-Johnson syndrome and toxic epidermal
necrolysis) following sulphonamide treatment, 90% compared with 45% in
controls exhibited the slow-acetylator phenotype (34). It remains to be studied
whether or not adverse immune effects caused by the other xenobiotics listed in
Table 2 are also associated with certain polymorphisms of the metabolizing
enzymes listed. As far as idiopathic autoimmune diseases are concerned,
associations with genetic polymorphisms of xenobiotic-metabolizing enzymes
would indirectly point to xenobiotics as etiological agents of such diseases and
provide information as to the type of chemical compound to be searched for.
Sensitization phase
Only few of the different hapten-protein conjugates formed in the body will
induce a clinically manifest allergy or autoimmunity. Whether an immune
response is initiated depends on several factors such as dose, metabolism,
protein binding, type and activation state of APC, antigen processing and
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Table 2. Polymorphisms of xenobiotic-metabolizing enzymesa
Enzyme Substrates associated with adverse (immune)
reactions
Phase-I enzymes
CYP1A2h Aromatic aminesb,e
CYP2A6g Coumarinb
CYP2C9g Nonsteroidal anti-inflammatory drugs (diclofenacb, 
tienilic acidd , piroxicamb,c, tenoxicamb,c, ibuprofenb, 
naproxenb), phenytoinb,b,e, tolbutamideb,c
CYP2C19g Omeprazolb, proguanilb,c, propranololb,c, imipramineb,c,
citalopramb, moclobemideb, diazepamb, hexobarbitalb
CYP2D6g Antiarrhythmicsf, beta-blockersf, antihypertensivesf, 
neurolepticsf, tricyclic antidepressantsf, MAO 
inhibitorsf, analgeticsf, miscellaneous agentsf
CYP2E1g Dapsoneb,c,e, carbamazepineb,e, quinidinee, 
acetaminopheneb, halothaned
Phase-II enzymes
N-Acetyltransferase-2g Isoniazidb,e, dihydralazinee, procainamidee,
dapsoneb,c,e, sulfasalazinec,e
Glutathion-S-transferases M1 and T1g Halothaned
NAD(P)H-quinone reductaseg Azo dyesb, nitroaromatesb, quinonesb
Phenolsulfphotransferase (P-PST)h Aromatic hydroxylaminesb
a Data are from Refs 30,35, and 36; selected adverse (immune) reactions to single drugs or
certain, not necessarily all, members of classes of compounds are as follows: b skin reactions
(e.g. exanthema, urticaria, dermatitis); c hematological adverse effects (aplastic anemia,
leukopenia, agranulocytosis); d autoimmune hepatitis; e drug-induced lupus; f chemically
heterogeneous drugs with versatile adverse effects; polymorphisms influencing enzyme
activity as follows: g characterized at molecular level; h mutation not discovered yet,
described by distinct phenotypes. 
Abbreviations: CYP, cytochrome P450 isoenzyme; MAO, monoamine oxidase; NAD(P)H,
reduced form of nicotinamide adenine dinucleotide or nicotinamide adenine dinucleotide
phosphate.
peptide density on APC, some of which are presented in this article in more
detail.
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T cells are activated when they receive both signal 1 and signal 2 (37,38).
Signal 1 is triggered by T-cell recognition of peptides embedded in major
histocompatibility complex (MHC) molecules on the surface of APC and
involves signal transduction via the T-cell receptor (TCR)-associated CD3
complex and coreceptors such as CD4. Signal 2 is an abstract, generic term for a
variety of different accessory or costimulatory signals transmitted during T cell-
APC interaction. During this crosstalk, exchange of signal 1 and signaling via
the CD40-CD40L interaction, upregulates membrane molecules on the APC,
such as intercellular adhesion molecule 1 (ICAM-1), CD80 and CD86, that
contribute to signal 2 for T-cell activation. 
Dendritic cells residing in tissues have to get activated in order to
migrate to lymph nodes and prime T cells. While residing in nonlymphoid
organs, dendritic cells such as skin Langerhans cells efficiently take up and
process material, including haptenated protein, from their vicinity, but their
T-cell-stimulating capacity during this developmental stage is poor. Specific
signals, such as tumor necrosis factor α (TNF-α) and interleukin 1 (IL-1), which
may originate, for example, from activated or damaged keratinocytes, can switch
the functional state of dendritic cells. Dendritic cells then migrate to the draining
lymph nodes, lose their capacity to take up and process antigen, upregulate
MHC class I and class II molecules as well as accessory molecules on the cell
surface, and thereby differentiate into immunostimulatory dendritic cells that
can efficiently trigger naive T cells (38,39).
Activation of dendritic cells following exposure to xenobiotics
The two-signal requirement for T-cell activation poses the interesting question
of how sensitizing xenobiotics can induce activation of dendritic cells.
Dendritic-cell maturation might be triggered by a casual infection at the site of
exposure, implicating activation of APCs by, for instance, lipopolysaccharide,
glycans, double-stranded RNA and N-formylmethionyl peptides (39).
Presumably, however, xenobiotics themselves can act in a similar way by
inducing keratinocytes to produce TNF-α, IL-1α, IL-6 and other cytokines.
Keratinocyte activation could be achieved by cytotoxicity of the sensitizing
chemical itself or its reactive metabolite (24), or by concomitant exposure to
chemical or physical noxae, such as sodium dodecyl sulfate, dimethylsulfoxide,
phorbol myristate acetate, and ultraviolet light (39-41). In addition to exerting
these unspecific toxic effects, sensitizing xenobiotics may lead to activation of
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dendritic cells and more efficient costimulation of T cells by specific
mechanisms (Table 3). Having outlined how xenobiotics can activate dendritic
Table 3. Selected examples of how xenobiotics can contribute to costimulation
of T cells
Chemical Effects observed Ref.
TNCB, DNCB Induction of IL-1β mRNA in Langerhans cells, (40)
induction of IL-1α and TNF-α mRNA in keratinocytes
DNFB, nickel sulfate Induction of IL-1β in Langerhans cells (42)
Nickel sulfate Stabilizing TNF-α mRNA in keratinocytes (41)
Nickel sulfate, Expression of adhesion molecules on endothelial cells (43)
cobalt sulfate
Mercuric chloride Secretion of IL-1 from macrophages (44)
Abbreviations: DNCB, dinitrochlorobenzene; DNFB, dinitrofluorobenzene; IL-1,
interleukin-1; TNCB, trinitrochlorobenzene; TNF-α, tumor necrosis factor α
cells (i.e. elicit signal 2 for T-cell activation) this article will now discuss
signal 1 - the mode of how T cells 'see' xenobiotics or, more exactly, their
footprints on self-proteins.
T-cell reactions to haptenated peptides
Activation of αβ T cells that recognize peptides in the context of MHC class I or
class II molecules involves signaling through the TCR. This requires the
3-dimensional structure of its antigen-binding site to be complementary to that
of the peptide-MHC complex and, thus, allows ionic, dipole, aromatic and
hydrophobic interactions. Bonding of a xenobiotic to a peptide-MHC complex
alters its structure and the number, type and distribution of possible interactions
with the TCR. A neoantigen is thus created and can be specifically recognized
by T cells.
TNP derivatives were the first haptens for which T-cell reactions against
haptenated peptides presented by MHC class I or class II molecules were
demonstrated (2,3,45-47). These studies clearly demonstrated that both MHC
class I- and class II-restricted, hapten-specific T cells recognize TNP-conjugated
peptides irrespective of the exact amino acid sequence of the peptides. The only
requirements were 1) that the haptenated peptides carried appropriate side-
chains for anchoring in the MHC groove and 2) that the TNP-coupled lysine
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side-chain of the peptide was correctly positioned relative to these anchors so
that TNP could make contact with the TCR. The first
requirement by definition is fulfilled by all self-peptides presented and the
second requirement is apparently met by a variety of different self-peptides.
Thus, after exposure to trinitrobenzene sulfonic acid (TNBS) or
trinitrochlorobenzene (TNCB) both of which form TNP-protein conjugates, a
large pool of MHC-bound, haptenated self-peptides becomes available for T-cell
recognition (2,47). A recent publication suggests that some TNP-specific human
T cells can even recognize TNP in context of different MHC class II molecules
(47). Taken together, these findings may explain the extraordinary strength of
immune reactions against TNP derivatives, which are comparable with those
seen in alloreactions (2). T-cell reactions to the 3-alkyl and 3-alkenyl catechols
contained in urushiol follow the same rules laid down for TNP, namely
recognition of the correctly positioned hapten irrespective of the amino acid
sequence of the peptide (4). 
Specific reactions of human T cells from patients with drug allergies
have been shown for a large number of drugs, such as β-lactam antibiotics
(penicillin) (48-51), sulphonamides, nonsteroidal anti-inflammatory drugs, and
aromatic anticonvulsants such as phenytoin and carbamazepine (52). There is
evidence that the TCR of penicillin-specific T cells can interact with both the
thiazolidin ring, which is common to all β-lactam antibiotics, and the penicilloyl
side-chain, which is specific for a particular antibiotic (49-51). T-cell reactions
to structurally-defined haptenated peptides have also been shown for diazotized
p-aminobenzene arsonic acid (53) and photoreactive azido compounds (54).
Interestingly, in some autoimmune disorders T-cell responses against endoge-
nously haptenated peptides, i.e., physiologic protein modifications, were found
(55,56). MHC-restricted recognition of noncovalently bound organic xeno-
biotics is rare and has so far only been proposed for sulfamethoxazole (57).
Despite the fact that various metal salts can induce hypersensitivity and/or
autoimmune reactions (58), knowledge of how metal ions elicit the specific
T-cell reactions underlying these conditions is very limited. Although there is
experimental evidence that nickel(II) (59,60), beryllium(II) (61), gold(I) (62)
and some other metals might act as haptens in that they are recognized as metal-
peptide complexes, demonstration of T-cell recognition of a structurally defined
metal-peptide-MHC complex is still lacking. Theoretically, reactive chemicals
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and metal ions could also elicit specific T-cell responses by binding to the MHC
molecule itself rather than to an embedded peptide. Beryllium ions are good
candidates for this alloreactive-like T-cell reactions: it has been proposed that
beryllium ions might bind directly to the critical glutamate residue in position 69
of the HLA-DPB1*0201 molecule, which shows a strong positive correlation
with berylliosis (61); but again conclusive experimental proof is lacking. 
T-cell reactions to cryptic peptides uncovered by xenobiotics
Chemical modification of self-proteins can change their processing in APCs and
lead to presentation of cryptic peptides that may elicit autoimmune T-cell
reactions. While T-cell reactions to cryptic peptides have been shown in
humans, the induction of T-cell responses to cryptic peptides by xenobiotics as
so far only been demonstrated in mouse models. Analysis of T-cell hybridomas
prepared after immunization of mice with phosphorylcholine-conjugated hen
egg lysozyme revealed that some clones reacted against a cryptic lysozyme
peptide such that modification of the protein led to presentation of a novel
peptide which itself was not haptenated (63). The same peptide was presented
when lysozyme was pretreated with other diazotized aromatic amines, all of
which bind to tyrosine side-chains, but not when lysine-reactive fluorescein
isothiocyanate was used.
Similar results were obtained following investigation of the murine
T-cell response to bovine ribonuclease A that had been pretreated with gold(III)
this being the reactive metabolite of gold(I)-containing antirheumatic drugs (26).
T-cell hybridomas reacting specifically against gold(III)-pretreated ribonuclease
recognized one of two cryptic peptides of this protein. When these clones were
tested with ribonuclease pretreated with other metals, they only showed
crossreactivity with palladium(II), palladium(IV), nickel(IV), and platinum(IV)
salts indicating these metals, but not others, induced presentation of the same
cryptic peptides to T cells. A conformational change of ribonuclease A treated
with the crossreacting metals was detectable by circular dichroism spectrospopy,
suggesting that these changes are the molecular basis for the observed alteration
of antigen processing (P. Griem, K. Panthel, S.L. Best, P.J. Sadler, and C.F.
Shaw III, unpublished). 
Experimental evidence suggests that in vivo treatment with mercury(II)
can lead to the presentation of cryptic peptides of fibrillarin (64), a nucleolar
protein recognized by autoantibodies of mice treated with mercury(II), gold(I),
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or silver(I) and also by autoantibodies of scleroderma patients (58). The
observation that mercury(II) can alter the protein structure of fibrillarin (65),
could explain the presentation of cryptic fibrillarin peptides. 
By definition, T cells recognizing cryptic self-peptides are autoreactive
and, moreover, some hapten-specific T cells also recognize the nonhaptenated
peptide after priming (46). Hence, the possibility arises that an immune response
may be extended and lead to overt autoimmunity even if the offending
xenobiotic has been cleared from the body. On the other hand, some xenobiotics,
especially metals, can persist for years in the body and might continuously
activate T cells. 
CD4+ versus CD8+ T-cell responses to xenobiotics
Defining rules as to whether a given xenobiotic will predominantly activate
CD4+ or CD8+ T cells is a difficult task. From current knowledge about hapten
recognition by T cells, we can conclude that reactivity and lipophilicity of
xenobiotics will determine in which extra- or intracellular compartment
haptenated proteins will be formed and which presentation pathway these will
enter. Reactive xenobiotics that can directly bind to proteins and modify
peptide-MHC complexes, seem to induce both CD4+ and CD8+ T-cell responses,
as has been observed for TNP derivatives (2,66), penicillins (48) and nickel
(59,60). Likewise, nonreactive xenobiotics, such as urushiol, that can be
converted into reactive metabolites nonenzymatically or extracellularly were
found to activate both CD4+ and CD8+ T cells (4,22). 
Xenobiotics such as PA and propylthiouracil, that are metabolized inside
APCs by enzymes localized along the exogenous processing pathway might be
preferentially presented in the context of MHC class II molecules. The same is
true for xenobiotics that can be metabolized extracellularly, such as during the
oxidative burst of phagocytes (23), and then bind to extracellular proteins or
membrane proteins. This explanation might account for CD4+ T-cell help to B
cells and thus for the production of autoantibodies. However, other drugs such
as sulphonamides, carbamazepine and phenytoin, which can also be metabolized
via myeloperoxidase-dependent oxidation in phagocytes, have been shown to
induce specific activation of both CD4+ and CD8+ T cells (52). 
Xenobiotics that are lipophilic enough to cross the cell membrane and
are metabolized inside the cell (e.g. by CYP isoenzymes at the endoplasmic
reticulum) tend to modify proteins inside the cytoplasm that preferentially enter
the class I-processing pathway. Examples of this type of xenobiotic are
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polyaromatic hydrocarbons (20). Similarly, tienilic acid is metabolized by
CYP2C9 into reactive metabolites that haptenate this CYP isoenzyme.
Considering the intracellular localization of the CYP2C9 isoenzyme at the
endoplasmic reticulum, one would expect involvement of CD8+ T cells in the
immune reactions against tienilic acid. However, in tienilic acid-induced
autoimmune hepatitis, anti-CYP2C9 IgG autoantibodies were found, implying
participation of CD4+ T helper cells and the class II-processing pathway (12,18).
The proposed involvement of CD4+ T cells in this situation could result from
hepatocytes that were killed by highly reactive, toxic metabolites of tienilic acid
or by hapten-specific CD8+ cells, and that were subsequently taken up by APC,
thus entering the class II pathway.
Direct recognition of xenobiotics by γδ and αβ T cells ?
Recent investigation of the antigen recognition of T cells expressing γδ TCRs
revealed that these cells, unlike most αβ T cells, recognize antigens in an
immunoglobulin-like fashion. Interestingly, human γδ T cells can react to
nonproteinaceous microbial components, such as isopentenyl pyrophosphate and
γ-substituted 5´-triphosphorylated thymidine (67). Moreover, it has been
established that human CD4- CD8- (double-negative) αβ T cells can also react to
hydrophobic nonpeptide antigens, such as lipoarabinomannan and mycolic acids
bound to MHC-related CD1 molecules on APC (67). These findings open up the
possibility that T cells might also recognize 'free' xenobiotics, which are not
reactive enough to bind covalently to proteins. This hypothesis is supported by
recent publications describing human γδ T cells specific for lidocain (68) and
human CD8+ αβ T cells recognizing a pollen antigen-derived carbohydrate on
CD1 molecules (69). 
Effector phase in adverse immune reactions to xenobiotics
Specific T-cell reactions to xenobiotic-induced neoantigens comprise both
T helper 1 (Th1) and Th2 responses and can trigger an array of effector
mechanisms that are not different from those of immune reactions to
conventional protein antigens. As with protein antigens, factors such as the route
of administration, dose and genetic background of individuals play a role in
determining the type of effector mechanisms triggered by xenobiotics. Some
examples underlining the importance of these factors will be mentioned below.
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Administration route
It has long been known that cutaneous sensitization of mice to the classical
hapten dinitrofluorobenzene (DNFB) does not occur if the animals are orally
pretreated with DNFB (70), and the same is true for Ni(II) (71). In contrast to
feeding DNFB to normal littermates, feeding of either MHC class II-deficient or
CD4-depleted mice with DNFB did not tolerize but primed to the hapten (72).
This indicates that oral application of DNFB, and possibly of other haptens as
well, generates both hapten-specific CD8+ T cells, which act as effector cells in
contact hypersensitivity, and hapten-specific CD4+ T cells, which suppress
activity of the CD8+ T cells in normal mice so that tolerance results. This is in
line with other studies on contact hypersensitivity to DNFB and oxazolone that
have shown that cutaneous application of sensitizing doses of these haptens
induces two opposing T-cell populations: interferon γ (IFN-γ)-producing Th1-
like CD8+ T cells as effector cells; and IL-4- and IL-10-producing CD4+ Th2
cells as downregulatory cells (73). 
Dose
The type of effector mechanism induced by xenobiotics is also dose-dependent:
while cutaneous application of sensitizing doses of oxazolone induces effector
mechanisms leading to contact hypersensitivity in mice, cutaneous application
of low, subsensitizing doses of oxazolone induces tolerance that is solely
mediated by specific CD8+ cells expressing a Th2-like cytokine pattern (74). It
is proposed that this mechanism may be valid for other xenobiotics as well, and
that this might explain why most individuals fail to show signs of sensitization
after continuous exposure to low concentrations of xenobiotics on the skin
although an immune response is induced. However, exposure to relatively high
concentrations of xenobiotics would break tolerance and lead to sensitization.
Genetic background
The genetic background also influences the probability of immune reactions and
the kind of immunopathological lesions. The importance of polymorphisms of
xenobiotic-metabolizing enzymes has long been known in chemical
carcinogenesis and their relevance in immune reactions to xenobiotics has
already been mentioned above. Another illustrative example is the striking MHC
dependence of susceptibility to the systemic autoimmune syndrome induced by
mercury and gold salts in mice and rats (1,58). Treatment with mercuric chloride
or the antirheumatic drug gold(I) thiomalate induces a Th2-like effector
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response in susceptible H-2s mice, causing production of autoantibodies and
increased levels of serum IgG1, IgG2A and IgE, whereas resistant H-2d  mice
showed a Th1-like response (1,75). The susceptibility of
H-2s mice is dependent on the presence of the MHC class II As molecule (76). In
the rat, mercury induces activation of autoreactive T-cells in the Brown Norway
strain and the Lewis strain. However, the latter does not develop the
autoimmune syndrome because the activated T cells produce tumor necrosis
factor α (77). As mentioned above, the beryllium-induced lung disease in
humans is strongly associated with the HLA-DPB1*0201 molecule (61).
Outlook
In chemically induced carcinogenesis, the role of reactive metabolites acting as
ultimate carcinogens has been firmly established decades ago. Accordingly,
metabolite-generating systems are used in mutagenicity screening tests. By
analogy, reactive metabolite-generating systems that can render prohaptens into
haptens, should be used in tests designed to detect the sensitizing potential of
xenobiotics. Thus, liver microsomes have been successfully used for
bioactivation of nonreactive xenobiotics to haptens in the lymphocyte
transformation test in humans (19) and in the popliteal lymph node assay (78).
Conceivably, the blood monocytes present in the routine lymphocyte
transformation test fulfill a similar function within the limits of their xenobiotic-
metabolizing capacity. The development of prognostic tools based on genetic
polymorphisms of xenobiotic-metabolizing enzymes could help protect people
with an increased risk for adverse immune reactions to certain classes of
xenobiotics that are substrates of those enzymes.
Finally, immune responses to xenobiotics, just like those to conventional
antigens, can be subject to tolerance induction. In mouse models, tolerance was
induced by oral administration of DNCB (70) and nickel (71), parenteral
treatment with a peptide haptenated with 3-pentadecyl catechol from urushiol
(4) and topical application of low doses of oxazolone (74). Furthermore, TNP-
specific T cells could be inhibited by altered peptide ligands carrying alterations
either in the peptide sequence or the hapten (79). In view of these findings, new
therapeutic approaches such as tolerance induction and modulation of immune
responses by altered peptide ligands might also be feasible with xenobiotics.
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CHAPTER 3
T Cell-Dependent Immune Reactions to Reactive Benzene Metabolites in Mice
Susanne Ewens, Marty Wulferink, Carsten Goebel, and Ernst Gleichmann
Using the popliteal lymph node (PLN) assay in mice, we studied the sensitizing
potential of benzene and its metabolites. Whereas benzene and phenol failed to induce
a PLN reaction, catechol and hydroquinone induced a moderate, and p-benzoquinone
a vigorous response. Following a single injection of the reactive metabolite
p-benzoquinone (100 nmol/mouse), cellularity in the draining PLN was increased
more than 15-fold, and it took about 100 days until it reverted back to normal.
Although the PLN response was T cell-dependent, flow cytometric analysis revealed
that the increased cellularity in the PLN after a single injection of p-benzoquinone
was mainly due to an increase in B cells. Mice primed to p-benzoquinone and
challenged with a small dose of p-benzoquinone (0.1 nmol/mouse) mounted a
secondary PLN reaction, indicating hapten specificity of the reaction; this was
confirmed by results obtained in the adoptive transfer PLN assay. An unexpected
finding was the secondary PLN response to benzene (1 nmol/mouse) observed in mice
primed to p-benzoquinone. This finding suggests that some of the benzene (at least
10%) was locally converted into p-benzoquinone which then elicited the secondary
response observed. In conclusion, the reactive intermediate metabolites hydroquinone
and p-benzoquinone can act as haptens and sensitize, their precursors, benzene and
phenol, may be considered as prohaptens.
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Introduction
Due to the presence of benzene in petrol and its use as industrial solvent there is
significant benzene emission into the environment, resulting in continuous,
relevant uptake by humans living in industrialized areas. In the body, benzene is
metabolized in several steps, starting in the liver by epoxidation through
cytochrome P450 2E1 (1-3) and subsequent conversion into phenol. Phenol can
be further oxidized by cytochrome P450 into catechol and hydroquinone. Via
the bloodstream these intermediates reach other organs, such as the bone
marrow, where they are further oxidized by the myeloperoxidase of phagocytes,
and perhaps other peroxidases, into the highly reactive benzoquinones, p- and
o-benzoquinone (4) (Fig. 1). Benzene metabolites have been shown to bind
covalently to proteins in blood, liver, spleen, and bone marrow (5-7), and they
are likely to exert much of the toxicity of benzene (8,9).
Little is known about the effects of benzene and its metabolites on the
immune system. Nonspecific immunotoxic effects were reported by
MacEachern and Laskin (10) who noticed modulation of cytokine production in
bone marrow leukocytes of benzene-exposed mice. A different question is
whether benzene metabolites are contact sensitizers. This was first investigated
by Benezra et al. (11) in a systematic search for structure-activity relationships
of skin contact sensitizers. Using a database, they were unable to find evidence
for the assumption that benzoquinones are sensitizers. This evidence was
provided by Basketter and Goodwin (12) who studied dermal sensitization to
1,4-substituted benzene derivatives in guinea pigs. With three different,
adjuvant-based test methods they showed that hydroquinone and
p-benzoquinone possess sensitizing potential. Subsequently, Basketter and
Liden (13) investigated the sensitizing potential of benzene derivatives in
humans using the patch test. Surprisingly, reactions to hydroquinone were
negative, but p-benzoquinone yielded a number of positive test results.
However, in the latter reactions it proved difficult to distinguish between the
toxic and the sensitizing potential of p-benzoquinone. From their results one
cannot deduce that the positive patch test reactions were specific recall
responses, because it was unknown whether or not prior sensitization to
p-benzoquinone had taken place in these indivuals, prior to challenge.
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Figure 1.   Pathway of bioactivation of
benzene. In the liver, benzene epoxide,
formed by cytochrome P-450
monooxigenases, spontaneously converts
into phenol which is further oxidized to
catechol and hydroquinone, respectively.
Extrahepatically, catechol and hydroquinone
are converted by the myeloperoxidase of
phagocytes into the highly reactive
benzoquinones, o- and p-benzoquinone.
NQOR: NADPH-quinone-oxidoreductase;
PGHS: prostaglandin H synthase
In view of this somewhat scanty knowledge of the sensitizing potential of
the widespread pollutant benzene and its metabolites, we studied their
sensitizing potential, using the PLN assay in mice. In contrast to sensitization
tests in guinea pigs, the PLN assay allows to quantify immune responses to
sensitizing chemicals, does not require the use of adjuvant, and can measure
both primary and secondary T cell-dependent immune responses to such
compounds (14).
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Materials and Methods
Chemicals   Benzene, p-benzoquinone, hydroquinone, catechol, phenol, and streptozotocin
were purchased from Sigma-Aldrich Chemie GmbH (Steinheim, Germany); ethanol was
purchased from E. Merck (Darmstadt, Germany); sterile, pyrogen-free phosphate-buffered
saline (PBS) was obtained from Gibco GmbH (Karlsruhe, Germany); and sterile, pyrogen-
free 0.9% NaCl was purchased from Fresenius AG (Bad Homburg, Germany).
Mice   Specific pathogen-free female C57BL/6J mice, obtained from Harlan Winkelmann
GmbH (Borchen, Germany), were used throughout, unless mentioned otherwise. In one
experiment female BALB/c mice (wildtype), BALB/c nu/nu mice and their BALB/c nu/+
littermates, obtained from Harlan CPB (Austerlitz, Netherlands), were used. Animals were
kept under specific pathogen-free conditions and had free access to standard diet (Ssniff
Spezialdiäten GmbH, Soest, Germany) and tap water; they were 6 to 8 weeks old at the onset
of experiments.
Antibodies   Fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse Thy1.2 (clone 53-
2.1), FITC-conjugated rat anti-mouse CD4 (clone RM4-5), phycoerythrin (PE)-conjugated rat
anti-mouse CD8a (clone 53-6.7), PE-conjugated rat anti-mouse B220 (clone RA 3-6B2), and
PE-conjugated anti-mouse NK cells (clone 2B4) monoclonal antibodies for FACScan
analyses were purchased from Pharmingen (Hamburg, Germany). Anti-mouse-B220
monoclonal antibodies with magnetic microbeads were purchased from Miltenyi Biotec
GmbH (Bergisch Gladbach, Germany).
Primary response PLN assay   This assay was performed as described (14-16). Briefly, test
compounds were dissolved in ethanol and diluted in PBS to a concentration of 0.1 % ethanol;
this solvent is referred to as ethanol/PBS. On day 0, animals (5 to 6 mice per group) received
a single sc injection (50 µl) of the compound indicated into the left hindfoot pad, control
animals received ethanol/PBS only. On day 6, PLNs of both treated and untreated sides were
removed and cell numbers of individual PLNs were determined using a Casy 1 automatic cell
counter (Schärfe Systems GmbH, Reutlingen, Germany). The PLN cell count index from each
mouse was calculated by dividing the cell count of the treated side by that of the untreated
side. 
Secondary response PLN assay   In order to determine secondary PLN responses of mice,
groups of animals were primed with the test compounds on day 0, as described above. After
complete regression of the primary PLN reaction, mice were challenged by a second sc
injection into the same hindfoot pad. The dose of test compounds used for recall was
suboptimal, that means it was just too small to induce a primary PLN response. Four days
after the second sc injection, PLN cell count indices were determined. For control of
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specificity, streptozotocin was used for priming (0.5 mg/mouse) and challenge (0.05
mg/mouse), as described before (17).
Treatment of prospective T cell donors   On days  -14 and  -7 before the adoptive cell
transfer, C57BL/6J donor mice received an iv injection of p-benzoquinone (50 nmol/mouse)
into the tail vein, and on day -6 they received an sc injection of p-benzoquinone (100
nmol/mouse) at the base of tail. Control groups of prospective T cell donors were treated with
ethanol/PBS. On day 0, spleens were removed, and splenic T cells enriched as described
below.
Enrichment of splenic T cells   For enrichment of T cells, B cells were depleted from spleen
cell suspensions using a magnetic cell separator (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany), as described (18). In short, 1 x 108 spleen cells were incubated (15 min at 4 °C) in
1 ml PBS containing 50 µl anti-mouse-B220 antibody coupled with magnetic microbeads
(Miltenyi Biotec GmbH). Stained cells were withdrawn from the cell suspension in a high
gradient magnetic field. After separation, the cell fraction was tested for T cell purity with
FITC-labeled monoclonal anti-Thy1.2 antibody (Pharmingen) using a FACScan flow
cytometer (Beckton Dickinson, San Jose, California, USA). Cells in the unstained fraction
after separation contained 85 to 95% Thy1.2-positive cells and are referred to as enriched
T cells. These enriched T cells were used in the adoptive transfer PLN assay.
Adoptive transfer PLN assay   This test system allows to detect anamnestic T cell responses
of donor animals to chemicals of low molecular weight (14,15,17,19). Enriched T cells of
donor animals were irradiated (20 Gy) using a 137Cs source (Gammacell 2000, Molsgaard,
Copenhagen, Denmark); this step was introduced in order to decrease the nonspecific PLN
reaction occasionally seen after transfer of unirradiated T cells from recently immunized
donors (20). On day 0, 50 µl PBS containing 1 x 107 irradiated enriched T cells was injected
sc into the left hindfoot pad of syngeneic recipients. On day 1, these animals received an
additional sc injection (50 µl) into the same foot pad: these injections contained a suboptimal
dose of p-benzoquinone or streptozotocin, or the control compounds indicated. On day 6,
PLN cell count indices were determined.
Flow cytometric analysis   PLN cells (2 x 105 cells/well) were transferred into 96-well plates
and marked with the FITC- and PE-labeled antibodies indicated. Antibody-marked probes
were incubated for ten minutes at 4 °C, washed twice with PBS, and analysed in a FACScan
flow cytometer (Becton Dickinson).
Statistical analysis   All experiments were performed twice to assure reproducibility of the
data. Results of individual experiments are shown as arithmetic means + standard deviation
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(SD) of 5 to 6 animals. One-way analysis of variance (ANOVA) with Newman-Keuls
comparison was used to calculate statistically significant differences.
Results
Differential capacity of benzene and Its metabolites to elicit primary PLN
responses
Primary PLN responses to benzene (100 nmol/mouse) and equimolar doses of
the benzene metabolites indicated were determined in C57BL/6J mice (Fig. 2).
Benzene, phenol, and catechol failed to induce a PLN reaction, whereas
hydroquinone elicited a weak and p-benzoquinone a vigorous PLN response.
When compared with hydroquinone, p-benzoquinone was found to induce a five
times higher PLN response at the same dose of 100 nmol. Both metabolites
showed a dose-response relationship in the primary PLN assay.
Kinetics of primary PLN responses to benzene and p-benzoquinone
As shown in Fig. 3, benzene failed to elicit increased PLN cell count indices at
any of the ten time points tested. In marked contrast, p-benzoquinone induced a
PLN response that was 15-fold above normal on day 6 and still 6-fold on day
14; from then on it gradually decreased reaching normal values at day 105 after
injection.
T-Cell dependence of the PLN response to benzene metabolites
To answer the question if the observed PLN reaction to hydroquinone and
p-benzoquinone is T cell-dependent, the PLN assay was performed in BALB/c
nu/nu mice and BALB/c nu/+ littermates. Hydroquinone and p-benzoquinone
failed to induce a PLN response in nu/nu mice, whereas they elicited significant
PLN reactions in nu/+ littermates (Fig. 4). Hence, the PLN enlargement
observed after injection of hydroquinone and p-benzoquinone, respectively, is a
T cell-dependent reaction.
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Figure 2.   Primary PLN response to reactive benzene metabolites. On day 0, groups of mice
received a single sc injection of the indicated test compound at the dose specified into one
hindfoot pad; control animals received a single sc injection of solvent (ethanol/PBS) only. On
day 6, PLN cell count indices were determined. Asterisks denote significant difference
between groups marked with brackets (*p<0.05, **p<0.01).
Flow cytometric analysis of primary responses to p-benzoquinone
Cell populations and T-cell subpopulations involved in the primary PLN
response to p-benzoquinone were analysed by immune-flow cytometry. Table 1
shows that up to a dose of 100 nmol p-benzoquinone/mouse the absolute
numbers of B and T cells in the draining PLN were increased and that the
increase in B cells was higher than that in T cells. Absolute numbers of CD4+
and CD8+ cells also increased, but the ratio CD4+/CD8+ did not change.
Secondary PLN responses to p-benzoquinone and benzene
The results described above established that reactive benzene metabolites,
especially  p-benzoquinone,  are  able  to  elicit  significant  PLN  reactions  that
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Figure 3.   Kinetics of the primary PLN response to benzene and p-benzoquinone. On day 0,
C57BL/6J mice received a single sc injection of 100 nmol benzene or p-benzoquinone into
the left hindfoot pad; control animals received solvent only. At the time points indicated on
the abcissae, PLN cell count indices were determined. Asterisks denote significant difference
between the group injected with p-benzoquinone and both control groups (*p<0.05,
**p<0.01, ***p<0.001).
require participation of T cells. Next, we studied whether or not the observed
PLN reactions to p-benzoquinone were due to specific T cell reactions to this
metabolite. This was done by two different experimental approaches.
In the first approach, we asked whether mice primed to p-benzoquinone
were able to mount a secondary response upon challenge with a suboptimal dose
to induce specific secondary PLN reactions (17). Groups of C57BL/6 mice were
primed with either p-benzoquinone (100 nmol/mouse) or, for control, benzene
(100 nmol/mouse), streptozotocin (0.5 mg/mouse), or ethanol/PBS. After 13
weeks, when the primary PLN response seen in the p-benzoquinone-primed
group had disappeared (cf. Fig. 3), groups of mice were challenged by
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Figure 4.   T cell dependence of the primary PLN response to hydroquinone and
p-benzoquinone of benzene. On day 0, athymic (nu/nu; open bars) and euthymic (nu/+;
closed bars) BALB/c received a single sc injection containing 100 nmol of either benzene,
hydroquinone or p-benzoquinone, or 1 x 107 SRBC into the left hindfoot pad; control animals
received solvent (ethanol/PBS) only. On day 6, the PLN cell count indices were determined.
Asterisks denote a significant difference (*p<0.05, **p<0.01, ***p<0.001) between the
groups marked with brackets.
Table 1. Flow cytometric analysis of PLN cells in the draining lymph nodes after injection
of benzquinone or solventa
Dose injected
(nmol p-benzo-
quinone/mouse)
PLN
cell count
(x105)
% B cellsb % T cellsc % CD4+
of T cellsd
% CD8+
of T cellse
0 (solvent) 5.3 ± 2.2 19 ± 0.6 78.7 ± 0.8 52.6 ± 0.6 45.0 ± 0.7
0.1 6.4 ± 4.6 19.6 ± 3.6 78.0 ± 4.2 49.3 ± 5.4 45,8 ± 5.3
10 22.4 ± 9.9 36.9 ± 3.3 59.6 ± 3.2***,f 47.6 ± 1.2 48,8 ± 0.3
100 41.8 ± 12.1* 46.9 ± 16.3*** 48.6 ± 15.7*** 52.2 ± 7.5* 47.2 ± 4.2
a Arithmatic means ± standard deviations of triplicate determinations. b Marked with
PE-conjugated rat anti-mouse B220, c FITC-conjugated rat anti-mouse Thy1.2, d
PE-conjugated rat anti-mouse CD4, e FITC-conjugated rat anti-mouse CD8. f Significantly
different from solvent group: *p<0.05, ***p<0.001.
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Figure 5.   Secondary PLN response against p-benzoquinone. On day 0, groups of mice were
primed with a single sc injection (100 nmol/mouse) of benzene or p-benzoquinone into the
left hindfoot pad; control animals were primed with solvent or with streptozotocin (0.5
mg/mouse). After thirteen weeks, groups of mice received a second sc injection containing
0.1 or 1 nmol benzene (benzenea and benzeneb, respectively), 0.1 nmol p-benzoquinone,
solvent, or 0.05 mg/mouse streptozotocin into the same hindfoot pad. Four days later the PLN
cell count indices were determined.. Asterisks denote significant difference (**p<0.01,
***p<0.001) between the black bar indicated and any of the open bars.
injection of either p-benzoquinone (0.1 nmol/mouse), benzene (0.1 or 1
nmol/mouse), solvent, or streptozotocin (0.05 mg/mouse). Four days after recall,
PLN cell count indices were determined. As can be seen in Fig. 5, animals
primed with solvent or benzene failed to mount a significant PLN response to
the compounds used for recall (groups 1 to 9). By contrast, mice which were
primed with p-benzoquinone exhibited a secondary PLN response upon recall
with the suboptimal dose of p-benzoquinone, but not of streptozotocin (cf.
groups 13 and 14). An unexpected finding was the significant response to 1
nmol benzene/mouse detected in p-benzoquinone-primed animals (group 12).
No response was elicited when the benzene dose used for recall was equimolar
to that of p-benzoquinone, that is,
0.1 nmol/mouse (group 11). Whereas the dose of 1 nmol/mouse elicited a
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Figure 6.   Adoptive transfer PLN assay demonstrating the transferability of T cell memory
for p-benzoquinone. On day -14 and -7, the prospective T-cell donors received an injection of
p-benzoquinone (50 nmol/mouse) into the tail vein. In addition, they were injected with 100
nmol p-benzoquinone/mouse sc at the root of the tail on day -6. On day 0, spleens were
removed for T cell enrichment, and 1 x 107 T cells per mouse were injected sc in the left
hindfoot pad of syngeneic recipient mice; control mice received T cells of untreated donor
mice. On day 1, recipients received an sc injection into the same foot pad containing either
benzene(0.1 nmol/mouse), a suboptimal dose of p-benzoquinone (0.1 nmol/mouse), or
solvent. On day 6, PLN cell count indices were determined. Asterisks denote significant
difference (***p<0.001) between the closed bar and any of the open bars.
significant secondary response in mice primed with p-benzoquinone, it failed to
do so in animals primed with benzene or PBS (cf. groups 3, 8, and 12).
In the second experimental approach, the adoptive transfer PLN assay was
used in order to test if memory T lymphocytes specific for p-benzoquinone can
be transferred from primed donors to naive recipients. Prospective T-cell donors
were primed with two iv injections of 50 nmol p-benzoquinone/mouse and, in
addition, an sc injection of 100 nmol p-benzoquinone. Six days after the last
injection (day 0), spleens of donor mice were obtained and T cells enriched by
magnetic cell separation. Immediately after cell separation, enriched T cells (1 x
107/mouse) were transferred to syngeneic recipients by sc injection into one
hindfoot pad. Control recipients received an sc injection containing enriched
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splenic T cells (1 x 107/mouse) obtained from untreated donor mice. On day 1,
groups of mice received an sc injection containing a suboptimal dose of either
p-benzoquinone (0.1 nmol), benzene (0.1 nmol), or solvent into the same foot
pad. On day 6, PLN cell count indices were determined. Fig. 6 shows that a
secondary PLN response was only detectable in those mice which had received
both p-benzoquinone-primed T cells and a suboptimal dose of p-benzoquinone
for challenge.
Discussion
Benzene is a toxicologically relevant compound whose uptake, toxicokinetics,
and metabolism have been well characterized in rodents as well as men. The
results presented here confirm and extend the findings of Basketter and
Goodwin (12), who established the sensitizing potential of hydroquinone and
p-benzoquinone in guinea pigs. We found that the parent compound benzene
and its early intermediate, phenol failed to induce primary immune reactions in
the PLN assay, whereas the reactive metabolites hydroquinone and
p-benzoquinone were able to do so. No adjuvants were used in this test system.
Moreover, p-benzoquinone was found to elicit  vigorous secondary reactions in
animals sensitized to p-benzoquinone. These structure-activity relationships
noted in the PLN assay conform with the protein reactivity of the test
compounds: while protein reactivity of benzene and phenol is known to be low,
that of catechol and hydroquinone and, in particular, p-benzoquinone is high (5-
7,21). Hence, benzene and phenol may be considered as prohaptens and
hydroquinone and p-benzoquinone as haptens in the terminology introduced by
Landsteiner and Jacobs (22) and also used by others (23,24). Thus, benzene is
comparable with other prohaptens tested in the PLN assay, such as procainamide
(19,25), propylthiouracil (15), and gold(I) thiomalate (16,20). In all cases, the
parent compounds failed to elicit a PLN reaction, whereas their reactive
metabolites were able to do so. Hydroquinone and p-benzoquinone were found
to sensitize in a dose-dependent and T cell-dependent fashion. Albeit T cell-
dependent, the majority of cells in the enlarged PLN analyzed after injection of
p-benzoquinone were found to consist of B cells. In this respect, too, the PLN
reaction to p-benzoquinone resembles that to previously studied compounds,
such as diphenylhydantoin (26) and D-penicillamine (27).
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The PLN reaction to p-benzoquinone was unusually long-lasting and
strong. Whereas the PLN enlargement seen after injection of other sensitizing
chemicals mostly reverted to normal after 3-4 weeks (14), that seen after
injection of p-benzoquinone persisted for more than 14 weeks. Injection of 100
nmol p-benzoquinone per mouse induced a 15-fold increase in cell number in
the draining PLN. Such strong PLN reactions were rarely seen with other test
compounds and certainly not at such low doses of test compound (14,28). In
general, there is good correlation between the capacity of test compounds to
evoke a response in the PLN assay and their known ability to induce allergy or
autoimmunity in men (14). It is likely, therefore, that p-benzoquinone is a potent
sensitizer not only in mice and guinea pigs, but in humans as well. This
conclusion conforms with reports on contact allergy in photographic technicians
exposed to developing agents containing hydroquinone (29).
Benzene and its metabolites are notorious for inducing aplastic anemia.
However, the doses of benzene and p-benzoquinone used in the present study
failed to induce anemia in C57BL/6 mice thus treated (data not shown), and this
conforms with published data on the dose requirements for myelotoxicity of
these compounds. In the present paper, the maximal doses of benzene,
hydroquinone, and p-benzoquinone used for PLN assay were 100 nmol per
mouse, corresponding to approximately 0.5 mg benzene, hydroquinone, or
benzoquinone per kg b.wt. As far as benzene is concerned, the doses required
for induction of aplastic anemia in mice (9,30) were orders of magnitude higher
than those used in the present investigation. As far as p-benzoquinone is
concerned, Rao et al. (31) were able to induce aplastic anemia in mice by ip
injection of 2 mg p-benzoquinone/kg b.wt. once a day for six weeks, six days
per week. Again, a single dose of 2 mg p-benzoquinone/kg b.wt. is already four
times higher than the maximal dose used in the PLN assay. A different question
in this context is, however, whether or not T cells sensitized to benzene
metabolites might contribute to the myelotoxicity of benzene through production
of myelosuppressive cytokines, such as interferon-γ, or through the activity of
hapten-specific cytotoxic T cells. This question is not unreasonable in view of
the myelosuppressive potential of activated T cells (32-34), but it has not been
explored up to now.
Interestingly, mice which were primed to p-benzoquinone and 13 weeks
later received an injection of 1 nmol benzene into the same hindfoot pad
mounted a secondary response. This was unexpected, as benzene itself failed to
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induce a primary response in the PLN assay. A possible explanation for this
finding is that a certain amount of the benzene used for challenge was
metabolically converted into p-benzoquinone in the anatomical region ranging
from the injection site to the draining PLN. As a dose of 0.1 nmol
p-benzoquinone per mouse was able to elicit specific secondary PLN responses
in p-benzoquinone-primed mice, metabolic conversion of 10% of the benzene
dose (1 nmol/mouse) used for challenge would be sufficient for elicitation of the
anamnestic response observed. This hypothesis raises the question which
extrahepatic enzymes are able to convert benzene into hydroquinone and further
hydroquinone into p-benzoquinone. Benzene can be oxidized to hydroquinone
by cytochrome P450 isoenzyme 2E1 which is constitutively expressed in murine
skin (35). The conversion of hydroquinone to p-benzoquinone can be catalyzed
by prostaglandin H synthase (PGHS) which is found in almost every mammalian
tissue including lymph nodes and skin (36,37). Involvement of PGHS in
benzene metabolism has been reported by Gaido and Wierda (30) and Pirozzi et
al. (38), who noted that the myelotoxicity exerted by benzene and hydroquinone
was ameliorated by PGHS inhibitors. Direct PGHS-driven metabolic conversion
of hydroquinone into reactive metabolites was described by Schlosser and
colleagues (39,40). Another issue relevant in this context is that activation of
antigen-specific T cells is known to require a minimal number of identical
epitopes on a given antigen-presenting cell (41,42). Apparently, local injection
of p-benzoquinone is able to generate this threshold number of identical
neoantigens. However, it is unknown whether or not this threshold number can
also be reached after systemic exposure to benzene and local metabolism to
p-benzoquinone.
Our results do not provide information as to the nature of neoantigens that
are recognized by T cells specific for p-benzoquinone. In view of its low
molecular weight and strong protein reactivity (5,21), p-benzoquinone is
supposed to act as a hapten and as such follow the rules laid down for T cell
recognition of the classical haptens trinitrochlorobenzene and trinitrobenzene
sulfonic acid (43,44). These electrophiles can covalently bind to the nucleophilic
amino acid lysine in protein, thereby forming trinitrophenyl (TNP)-adducts (45).
It has been established that both CD4+ and CD8+ TNP-specific T cells recognize
TNP when coupled to lysine in MHC-embedded self-peptides. The latter were
found to carry lysine in a position such that the TNP coupled to it could make
direct contact with the T cell receptor for antigen recognition (45). T cell
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recognition of the hapten 3-pentadecyl-catechol, which is a major allergen in
poison ivy, follows the rules established for TNP. The catechol component of
this hapten can spontaneously be oxidized to the electrophilic quinone which,
like p-benzoquinone, shows great affinity for covalent bonding to cysteine,
another nucleophilic amino acid (46). For p-benzoquinone, adducts to rat liver
protein and mouse hemoglobin sulfhydryl groups have been detected using
specific antibodies and hapten-specific T cell clones, respectively (47,48).
Characterization of the neoantigens generated by p-benzoquinone cannot be
achieved by experiments in vivo, as performed in the PLN assay, but requires
hapten-specific T cell clones for analysis in vitro. Such experiments are now in
progress in our laboratory (48).
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CHAPTER 4
Procainamide, a Drug Causing Lupus, Induces
Prostaglandin H Synthase-2 and Formation of T Cell-Sensitizing
Drug Metabolites in Mouse Macrophages
Carsten Goebel, Christoph Vogel and Marty Wulferink, Stephanie Mittmann, Bernhardt
Sachs, Sabine Schraa, Josef Abel, Gisela Degen, Jack Uetrecht, and Ernst Gleichmann
Procainamide (PA) may cause drug-induced lupus, and its reactive metabolites,
hydroxylamine-PA (HAPA) and nitroso-PA are held responsible for this. Here, we
show that N-oxidation of PA to these metabolites could take place in macrophages and
lead to formation of neoantigens that sensitize T cells. Murine peritoneal macrophages
(PMϕ) exposed to PA in vitro generated neoantigens related to HAPA, as indicated by
1) their capacity to elicit a specific recall response of HAPA-primed T cells in the
adoptive transfer popliteal lymph node (PLN) assay and 2) the appearance of
metabolite-bound protein in PA-pulsed PMϕ, as determined by Western blot. Analysis
of five phase-I enzymes that might be responsible for HAPA formation by PMϕ pointed
to prostaglandin H synthase-2 (PGHS-2) as a likely candidate. Experimental evidence
that PA can be oxidized to HAPA by PGHS was obtained by exposing PA to PGHS in
vitro. The resulting metabolites were determined by mass spectral analysis and
covalent protein binding in ELISA, respectively. In vitro, PA exposure of PMϕ of slow
acetylator A/J and fast acetylator C57BL/6 mice failed to show significant strain
differences in enzyme mRNA expression, enzyme activities, or formation of HAPA-
related neoantigens. By contrast, after long-term PA treatment in vivo only in slow
acetylators the PMϕ harbored HAPA-related neoantigens and T cells were sensitized
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to them. PMϕ of fast acetylator C57BL/6 mice only contained HAPA-related
neoantigens and their T cells were only sensitized to them if, in addition to long-term
PA treatment, their donors had received injections of phorbol myristate acetate
(PMA), a known enhancer of oxidative enzymes in phagocytes. In conclusion, PA
treatment leads to N-oxidation of PA by enzymes, in particular PGHS-2, present in
antigen-presenting cells (APC) and, hence, to generation of neoantigens which
sensitize T cells. The enhanced neoantigen formation and T cell sensitization seen in
slow acetylators might be explained by their higher concentration of PA substrate that
is available for extrahepatic N-oxidation in APC.
Introduction
The antiarrhythmic drug procainamide (PA) is frequently associated with drug-
induced lupus, the pathogenesis of which is not understood (1-5). PA is an
arylamine, a class of compound widely used in industry and medicine and
notorious for its potential to cause allergy and autoimmunity (6) Arylamines can
be considered as prohaptens, i.e., before they can act as haptens that form
neoantigens and trigger adverse immune reactions, they first have to be
N-oxidized to chemically reactive hydroxylamines and nitroso derivatives (7-9).
The nitroso derivative of PA, nitroso-PA, is capable of covalent bonding to
(self-)proteins, whereas PA is not (10). The aqueous solution of the
hydoxylamine derivative of PA used in the present investigation actually
consists of hydroxylamino-PA (HAPA) and nitroso-PA, because a portion of the
former is readily oxidized to the highly reactive nitroso-PA, a compound that is
difficult to isolate because of its instability (5,7). For the sake of brevity, this
mixture is referred to as HAPAaq. In a previous paper, we showed that a single
injection of HAPAaq induced a specific T cell response in mice, whereas a
single injection of the prohapten PA failed to do so (11). Moreover, T cells from
mice sensitized against HAPAaq specifically reacted against homogenized
peritoneal cells of syngeneic animals that had received long-term PA treatment,
indicating that their peritoneal cells contained HAPA-related neoantigens
formed after metabolic conversion of PA to HAPA and nitroso-PA, respectively.
We will use the term HAPA-related neoantigens to describe hitherto unknown
neoantigens that must have been generated in the presence of HAPA and/or
nitroso-PA.
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Several groups of phase-I enzymes have been implicated in N-oxidation of
arylamines, in particular the cytochrome P4501A subfamily and cytochrome
P4502D6 (12,13), as well as peroxidases, such as myeloperoxidase (MPO) and
prostaglandin H synthase (PGHS), also termed cyclooxygenase (3). Cytochrome
P4501A2 and cytochrome P4502D6 are constitutively expressed in the liver. In
extrahepatic tissues, including macrophages and other immune cells, mainly
cytochrome P4501A1 is expressed (14-16). In neutrophils and monocytes, MPO
was shown to N-oxidize arylamine drugs, such as PA, to the reactive
hydroxylamine and nitroso derivatives (9,17,18). PGHS-1 is constitutively
expressed and present in nearly all cell types and tissues. In contrast, PGHS-2,
also termed inflammatory PGHS, is expressed only after induction, for instance
by LPS, and is confined to certain cell types, especially macrophages (19).
Whereas N-oxidation by PGHS of arylamines to reactive intermediates such as
nitroso derivatives has been described (20), it is unknown whether arylamines
can induce PGHS-2, thereby increasing their extrahepatic bioactivation. 
While N-oxidation converts arylamine prohaptens to haptens and thus
toxifies them, the competing N-acetylation pathway usually prevents, or retards,
formation of reactive metabolites (8). Due to genetic polymorphism of
N-acetyltransferase-2 (NAT-2) in both humans and mice, carriers of certain
alleles show reduced N-acetylation capacity for several arylamine substrates,
including PA (14,21). In humans, the slow acetylator phenotype is associated
with a higher incidence of extrahepatic adverse immune reactions to arylamine
drugs (22) and a more rapid development of PA-induced lupus (23) than the fast
acetylator phenotype. Consistent with this, in the previous paper (11) we
reported that PA treatment of mice for a period of 16 weeks led to the
appearance of HAPA-related neoantigens in peritoneal cells of the slow
acetylator, but not of the fast acetylator mouse strain studied.
However, it was not determined in the previous paper whether
macrophages were among the peritoneal cells carrying the HAPA-related
neoantigens and, if so, whether peritoneal macrophages (PMϕ) themselves had
generated them or whether these came from phagocytosis of proteins that were
modified by HAPA- or nitroso-PA generated by other cells. Moreover, it was
not investigated which enzymes might be involved in the N-oxidation of PA to
HAPA in macrophages and whether the HAPA-related neoantigens detectable
after chronic PA treatment of slow acetylators would, indeed, sensitize their
T cells. Here, using RT-PCR and tests of enzymatic activity for analysis of drug-
Macrophages form T cell-sensitizing procainamide metabolites70
metabolizing enzymes, and the murine popliteal lymph node (PLN) assay for
assessment of T cell sensitization (11,24), we tried to answer these questions.
We provide novel experimental evidence for 1) induction of PGHS-2 mRNA
expression and PGE2 synthesis in PA-treated PMϕ, 2) N-oxidation by PGHS of
PA to HAPA, 3) generation of HAPA-related neoantigens in PA-treated PMϕ, 4)
spontaneous T-cell sensitization to the HAPA-related neoantigens formed during
chronic PA treatment in vivo, and 5) the slow N-acetylator genotype as a
predisposing factor for in vivo generation of HAPA-related neoantigens and T
cell sensitization to them.
Materials and Methods
Mice   Specific pathogen-free female C57BL/6J mice and female A/J mice were purchased
from Harlan Olac Ltd. (Bicester, Oxon, UK). Animals were kept under specific pathogen-free
conditions until the onset of the experiments. They had free access to a standard diet (no.
1324, Altromin GmbH, Lage, FRG) and tap water and were 6 to 8 weeks-old at the onset of
the experiments. C57BL/6 mice are fast acetylators, whereas A/J mice are slow acetylators
(25).
Chemicals and media   PA, PMA, N-acetyl-PA, and casein were purchased from Sigma
Chemicals (Taufkirchen, Germany); PA was obtained as PA/HCl. HAPA was prepared as
previously described (7). In aqueous solution, HAPA undergoes spontaneous oxidation by
molecular oxygen with approximately 50% conversion to nitroso-PA in 30 min at room
temperature (7). We refer to the preparation of HAPA in pyrogen-free saline (0.9 %;
Fresenius AG; Bad Homburg, Germany) as HAPAaq here. 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) was obtained at 99.9 % purity from Oekometrie (Bayreuth, Germany) and
kept as a stock solution in DMSO. Sterile, pyrogen-free phosphate-buffered saline (pH 7.2),
RPMI 1640 medium, FCS, penicillin, streptomycin, pyruvate, and non-essential amino acids
were purchased from Gibco (Eggenstein, Germany).
Preparation and cultivation of PMϕ   Prospective donors of PMϕ were injected ip (500 µL)
with sterile 6 % casein solution in distilled water (pH 7.4). Four days after the injection, mice
were killed by CO2 anesthesia and their cells collected by peritoneal lavage with 5 ml of ice-
cold phosphate-buffered saline (pH 7.2). Cells were washed and suspended in RPMI 1640
medium (supplemented with 10 % FCS, 200 IU penicillin/streptomycin, 2 mmol/500 mL of
L-glutamine, pyruvate, and nonessential amino acids) and cultured at a density of 1 x 106
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cells/mL in plastic tissue culture flasks (500 mL) (Greiner, Frickenhausen, Germany). After
20 h, nonadherent cells were removed by vigorous washing; about 90 % of adherent cells
were macrophages as determined by Pappenheim's stain.
PA treatment of PMϕ in vitro   After removal of nonadherent cells, PMϕ were incubated in
culture medium (see above) in the absence or presence of either 1 mM PA, 1 mM N-acetyl-
PA, 1 µg/mL LPS plus 25 U/mL IFN-γ, or 10 nM TCDD. After 48 h, PMϕ  were washed
extensively and used either for injection as antigenic material in the PLN assay, total RNA
extraction and RT-PCR analysis, or Western blot analysis. 
Preparation of homogenates of PA-treated PMϕ for use in the PLN assay   Once
incubation of PMϕ with PA was completed, cells were washed in phosphate-buffered saline
(pH 7.2) and harvested using a rubber policeman (Greiner). Cells (5 x 106 in 1 mL of
phosphate-buffered saline, pH 7.2) were stored in liquid nitrogen. Prior to injection, cells
were kept on ice and homogenized by ultrasonication (10 x 10 sec at 50 kHz) using a
Labsonic V 2000 (B. Braun Melsungen AG, Melsungen, Germany). Homogenized PMϕ (50
µL) were used, because live cells, when transferred, might produce immunomodulators, such
as PGE2 (19) , that could affect the transferred T cells or the recipient tissue in an antigen-
independent fashion and thus increase nonspecific background values in the PLN assay.
Direct PLN assay   The assay was performed as described (11,24). Test compounds were
dissolved in saline; homogenates of PMϕ (see above) were prepared in phosphate-buffered
saline (pH 7.2). On day 0, animals received a single sc injection (50 µL) of the test substance
into the left hindfoot pad. On day 6, mice were sacrificed, and the PLN from both the treated
and the untreated side were removed. Cell numbers in the individual PLN were counted using
a CASY 1 TT automatic counter (Schaerfe System, Reutlingen, Germany). The PLN cell
count index of each mouse was calculated by dividing the cell number obtained from the
treated side by that obtained from the control side of the same animal.
Treatment of T cell donors   Prior to the adoptive cell transfer, prospective T cell donors
were treated with either HAPAaq or PA according to one of the following protocols, as
reported previously (11). HAPAaq: At intervals of 2 days, mice received three sc injections
(100 µL) of either saline or 8 µmol HAPAaq at the base of tail. One day after the third
injection, their spleens were removed for preparation of T cells. PA: For a period of 16
weeks, one group of fast acetylator C57BL/6 mice received three sc injections (100 µL) a
week, each consisting of 16 µmol PA/ mouse. For the same period of time, another group of
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C57BL/6 mice received an i. p. injection of 100 µL PMA/mouse/week in addition to the PA
treatment. PMA was kept in a stock solution of 50 % ethanol/saline (1 mg/mL), and prior to
use it was diluted with saline to the final of 600 ng/100 µL. Age-matched controls received
the same number of injections consisting of saline (given sc) and PMA (given ip). Slow
acetylator A/J mice, which fail to tolerate repeated doses of 16 µmol PA (11), were treated
with three sc injections (100 µL) of 8 µmol PA/mouse/week, or of saline alone, over the same
period of time. Mice were killed and their spleens removed for T cell separation and adoptive
transfer one week after the last injection. 
Enrichment of donor T cells to be used for adoptive transfer   For preparation of T cells,
splenic B cells were removed from spleen cell suspensions by using a magnetic cell sorter
(MACS) (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), as described (11). Minimal
purity of the resulting T cell population was 90 %, as determined by staining with FITC-
labeled anti-Thy1.2 mAb (Becton Dickinson, San Jose, CA, USA) and analysis in a FACScan
flow cytometer (Becton Dickinson). Staining of T cells with PE-labeled anti-L3T4 and anti-
Lyt-2 mAb (Becton Dickinson) yielded 50 ± 5 % CD4+ cells and 35 ± 4 % CD8+ cells.
Preparation of homogenates of peritoneal cells from PA-treated donor mice for use in
the adoptive transfer PLN assay   As described above for treatment of T cell donors (PA
protocol), mice were treated by three sc injections of PA or saline a week, and certain groups
of C57BL/6 mice received an additional, ip injection of PMA once a week. Two days after the
last injection, mice were killed by CO2 anesthesia and their peritoneal cells prepared by
peritoneal lavage as described for PMϕ. Collected peritoneal cells were counted and stored in
liquid nitrogen until use. Prior to injection the peritoneal cells were sonicated (5 x 107 cell in
1 mL phosphate-buffered saline, pH 7.2), as described for PMϕ.
Adoptive transfer PLN assay   This test system is suitable for detection of secondary T cell
responses to chemicals of low molecular weight (reviewed in (24)). It is based on the
principle that specific T cells exposed to a sensitizing compound in the donor animal will,
upon adoptive transfer to a syngeneic recipient, respond to small amounts of the sensitizer by
a secondary response. When both the transferred T cells and the immunogen to be tested are
injected locally, this response manifests itself in the draining PLN. The doses of sensitizing
agent used for elicitation of the secondary response do not suffice to elicit a primary PLN
response by the recipient mice. 
Splenocytes of T cell donor animals were prepared in phosphate-buffered saline (pH
7.2) and T cells enriched, as described above. Prior to transfer to syngeneic mice, donor
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T cells were irradiated (2000 rad) in vitro using a 137Cs source (Gammacell 2000,
Molsgaard, Denmark); this step served to decrease the nonspecific PLN reaction occasionally
seen after transfer to syngeneic recipients of unirradiated T cells from recently immunized
donors. On day 0, 1 x 107 irradiated splenic T cells in 50 µL phosphate-buffered saline (pH
7.2) were injected sc into the left hindfoot pad of syngeneic recipients. One day after the T
cell transfer, the mice received a sc injection (50 µL) of the compound to be tested into the
same hindfoot pad; these injections contained either 0.15 µmol of PA or HAPA dissolved in
saline (HAPAaq). Alternatively, the recipients were injected with 2.5 x 10
6 homogenized
peritoneal cells, or 2.5 x 105 homogenized PMϕ, prepared in phosphate-buffered saline (pH
7.2). On day 6, recipient mice were sacrificed, and the PLN cell count index of each mouse
was calculated as described for the direct PLN assay.
Reverse transcriptase-polymerase chain reaction (RT-PCR)   For each experiment,
peritoneal cells from 2 mice were pooled and PMϕ isolated by adherence as described above.
Total RNA was extracted from PMϕ and from liver tissue by modification of the single-step
method using TRIzolTM total RNA isolation reagent (Gibco BRL, Eggenstein, Germany)
according to manufacturer’s instruction, followed by digestion with Rnase-free Dnase I. For
cDNA synthesis, 1 µg total RNA was heated in a final volume of 10 µL with 2 µg
oligo(dT)15 primer for 5 min at 60 °C, chilled on ice, and reversely transcribed in a final
volume of 40 µL containing dNTP (1 mM of each), 8 µL 5x M-MLV buffer, 60 units RNase
inhibitor (Rnasin, Gibco BRL), 10 mM DTT, and 400 units M-MLV reverse transcriptase.
Samples were incubated for 1 h at 37 °C and subsequently denatured for 10 min at 70 °C.
PCR primers were synthesized with a 391 DNA synthesizer (Applied Biosystems,
Weiterstadt, Germany) and purified over NAP-5 columns (Pharmacia, Freiburg, Germany).
Primer sequences were from published sources or chosen using a primer selection program
(Oligo, National Biosciences, Plymouth, MN, USA), and are given in Table 1. PCR was
performed in a final volume of 50 µL as follows: 2.5 µL of RT reaction product was added to
a PCR mix comprised of 5 µL of 10 x PCR buffer, 200 µM of dNTP (Pharmacia, Freiburg,
Germany), 0.2 µM of each primer (sense and antisense), 2.5 units Taq DNA polymerase
(Boehringer), and 1 µCi [α-32P] dCTP (Amersham Buchler, Braunschweig, Germany).
Amplification was induced using a DNA thermal cycler (Hybaid-Omnigene, MWG-Biotech,
Ebersberg, Germany) with the following temperature profile: denaturation: 1 min at 94 °C
(first cycle: 4 min); annealing: 1 min (the temperatures are given in Table 1); extension: 1 min
at 72 °C (last cycle: 7 min). Amplification of cDNA in the linear range of the PCR reaction
was controlled by three different cycle numbers for one cDNA concentration. PCR products
were analyzed on 10 % polyacrylamide gels and visualized by autoradiography. For analysis
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the respective bands from the autoradiograms were scanned with an OmniMedia scanner
(Millipore, Ueberlingen, Germany). Values of enzyme transcription levels were correlated to
the expression of β-actin and are given as relative induction. To test the isolated RNA for
DNA contamination, 1 µg total RNA instead of synthesized cDNA was tested in the PCR
(negative control).
Table 1.   Primer Sequences for cDNA Amplification
Gene Primer sequences Annealing
temp. (°C)
Fragment
size (bp)
Cycle
no.
Reference
β-actin FP: CTACAATGAGCTGCGTGTGG
RP: TAGCTCTTCTCCAGGGAGGA
60 450 20 (51)
CYP1A1 FP: CCCACAGCACCACAAGAGATA
RP:
AAGTAGGAGGCAGGCACAATGTC
62 499 29 (51)
CYP1A2 FP: CAAAGACAATGGCGGTCTCA
RP: TCCCACTTGGCCGGGATCTC
58 515 21 (52)
NAT-2 FP: GGATTGTTTTTCTTGCCTTAG
RP: CATACTGCTCTCTTCTGATTT
52 535 30 (29)
PGHS-1 FP: ACCACTCGCCTCATCCTTAT
RP: GCACACGGAAGGAAACATAG
56 757 26 (53)
PGHS-2 FP: ATCCACAGCCTACCAAAACAG
RP: AACCTCACAGCAAAAACCTAC
52 1101 30 (54)
Determination of PGE2   The concentration of PGE2 in supernatants of cultured PMϕ (106
cells/mL) was assayed by a competitive enzyme immunoassay using monoclonal antibody to
PGE2 (Cayman Chemical, Ann Arbor, MI, USA). The lower detection limit of this assay is at
30 pg/mL.
MPO measurements   MPO activity in supernatants of cultured PMϕ (1 x 106 cells/mL) was
measured by an improved 3,3’,5,5’-tetramethylbenzidine (TMB) method using the liquid
substrate system (Sigma, Taufkrichen, Germany). As a positive control for MPO activity
supernatants of cultured bone marrow cells (1 x 106 cells/mL) were used. Briefly, 106
cells/mL were exposed (15 min at 37°C) to cytochalasin B (5 µg/mL) and fMet-Leu-Phe (10-
6 M) in RPMI 1640 without phenol red (Gibco). Resulting supernatants were assayed for
MPO activity as described (26).
HPLC determinations   PA (200 µM) was incubated with PGHS (113 units/mL; ovine
COX-1, specific activity 49005 units/mg; Cayman Chemical, Ann Arbor, Michigan) in the
presence of hematin (1 µM), phenol (2 µM) and either arachidonic acid (100 µM, Cayman
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Chemical) or hydrogen peroxide (0.2 mM) in 1 mL phosphate buffer (pH 7.7) for 30 min at
37°C. The mixture from 4 separate incubations was then applied to a Sep-Pak
(Chromatographic Specialties; Brockville, Ontario), washed with water, and then eluted with
methanol (10 mL). The methanol solution was evaporated with a stream of nitrogen and then
reconstituted by adding 0.3 mL of methanol. The 20 µL aliquots were analyzed by LC/MS.
The HPLC column was a Prodigy 5µ ODS(3) with dimensions of 2 X 100 mm (Phenomenex,
Torrance, CA), and the mobile phase consisted of water, acetonitrile, acetic acid (89:10:1,
v/v) containing 2 mM ammonium acetate with a flow rate of 0.2 mL/min and a splitter to
decrease the flow rate into the mass spectrometer of ~20 µL/min. The mass spectrometer was
a Sciex API III mass spectrometer (Perkin-Elmer, Sciex; Thornhill, Ontario) operated in the
Ion Spray mode and selected ion monitoring.
Production of anti-PA serum   PA (4.7 mg) was made reactive by dissolving it in
hydrochloric acid (1 N, 6 mL) and after cooling the solution in an ice bath, sodium nitrite (1.5
mg in 1 mL of water) was added dropwise with stirring over a period of 10 min. This solution
was then added dropwise to keyhole limpet hemocyanin (10 mg in 10 mL of 5 M phosphate
buffer, pH 9) with stirring and cooled in an ice bath. The pH of the solution was monitored
and sodium bicarbonate (20 %) was added as needed to keep the pH between 8.5 and 9. After
1 h the pH was adjusted to 7 with hydrochloric acid and after extensive dialysis it was
lyophilized. Polyclonal anti-PA- keyhole limpet hemocyanin antibodies were raised in a 2 kg
male, pathogen free New Zealand White Rabbit (Charles River Ltd., Quebec, Canada) housed
in the animal care facility at The Hospital for Sick Children, Toronto. After pre-immune
serum was obtained, each animal was immunized with the PA-keyhole limpet hemocyanin
conjugate (1 mg in 0.5 mL PBS emulsified with an equal volume of Freund's complete
adjuvant) sc at multiple sites. Injections with 500 µg PA-keyhole limpet hemocyanin in
Freund's incomplete adjuvant, divided into 6-8 sc sites, were repeated 4, 6, 8 and 12 weeks
after the initial immunization. Exsanguination under pentobarbital anesthesia was conducted
10 days after the final immunization. Blood was allowed to clot overnight at 4° C and then
centrifuged at 400 g. The serum was recovered and heat inactivated at 56° C for 30 min
before being aliquoted and stored at -20° C.
Covalent Binding of PA to PGHS   PA (100 µM) was incubated with PGHS (160 units) or
hematin (1 µM) in 0.4 mL of phosphate buffer pH 7.7, and H2O2 was added to make a final
concentration of 1 mM at 37° C. After 60 min 100 µL aliquots were plated into ELISA plates
(Costar, Cambridge, MA) and left at 4°C overnight. The plates were then emptied and washed
with ELISA wash buffer (10 mM Tris-HCl, pH 7.5, 154 mM NaCl, 0.5 % (w/v) casein and
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0.02 % (w/v) thimerosal). This wash was repeated 3 additional times. The plates were then
tapped dry and PA- keyhole limpet hemocyanin antiserum (100 µL diluted 1:1000) was added
to the plates which were then incubated for 3 h. The plates were washed 4 times with ELISA
wash buffer and tapped dry and then alkaline phosphatase-conjugated goat anti-rabbit IgG
(100 µL diluted 1:1000; Jackson Immunoresearch Laboratories, West Grove, PA) was added
and the plates were incubated for 2 h at room temperature. The plates were again washed 4
times with ELISA wash buffer and 2 times with PBS. A stock solution of methyl umbelliferyl
phosphate (10 mg/ml in DMSO) was diluted 1:100 in PBS, and 100 µL of this solution was
added to the wells and incubated for 10 min at room temperature. Fluorescence was then
measured with a Fluorescence Concentration Analyzer (Pandex, Mundelein, IL) set at
365/450 (excitation/emission).
Preparation of PMϕ for Western blot analysis   After incubation of C57BL/6 PMϕ  with
PA, N-acetyl-PA, or saline (see above), cells were resuspended in lysis buffer (PBS, 0.1%
Triton X-100) for 3 min on ice, vortexed for 1 sec and centrifuged at 10,000x g for 3 min to
separate cytoplasmic proteins and nuclei. Nuclei were then lysed in SDS-PAGE sample
buffer. 1 mM PA was added to one sample of saline-preincubated PMϕ lysate. Equal amounts
of cytoplasmic and nucleic cell equivalents were separated on SDS-polyacrylamid gels.
Western blot analysis   Cytoplasmic proteins or nuclear proteins of 1 x 106 cell equivalent
were separated on 8% SDS-PAGE (27). Electrophoretic transfer of proteins to nitrocellulose
filters (Hybond-C Super, Amersham), which were preincubated with 20% ethanol, 25 mM
TrisHCl, 192 mM glycine for 30 min, was performed with a semi-dry transfer apparatus
(Biorad). Nitrocellulose filters were blocked with 4% dried non-fat milk powder and 0.5%
Tween 20 in PBS (PBS-Tween), pH 8, for 1 h at room temperature. Rabbit anti-PA serum or
control serum was diluted 1:3,000 in PBS-Tween containing 4 % dried milk powder and
incubated for 1 h at room temperature. After 3 washes with PBS-Tween, filters were
incubated with goat anti-rabbit IgG (Dianova, Hamburg, Germany), diluted in PBS-Tween
containing 4% dried milk powder for 1 h at room temperature. Immunoreactions were
visualized on X-ray films by chemoluminiscence using the enhanced chemoluminescence
detection system supplied by Amersham.
Statistical analysis   Statistical analyses were performed by analysis of variance (ANOVA).
Assays were performed at least twice to ensure reproducibility.
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Results
Incubating PMϕ with PA in vitro rendered them immunogenic
Previous results have established that a single injection of PA is unable to
induce a primary PLN response in either fast acetylator C57BL/6 (11,28) or
slow acetylator A/J mice (11). To examine whether macrophages can convert the
non-sensitizing PA into a sensitizing metabolite, PMϕ were exposed to PA for
48 h in vitro. At a number of 5 x 106 cell equivalents, homogenates of PMϕ thus
treated induced a significant primary PLN response when compared to the
homogenates of untreated PMϕ (Fig. 1), suggesting a primary immune response
toward reactive PA metabolites generated in vitro by PMϕ. No difference
between slow and fast acetylator strains in the generation of the metabolite-
induced neoantigens was observed.
Using the adoptive transfer PLN assay, in the preceding study (11) we
found that synthetic, cell-free HAPAaq elicited a specific secondary response by
T cells from HAPAaq-primed donor mice. Here, we used the specificity of this
reaction as a probe to test if the T cell response to PA-treated PMϕ was due to
HAPA-related neoantigens. As shown in Fig. 2A, challenge of HAPAaq-primed
donor T cells with either HAPAaq or homogenized, PA-treated PMϕ elicited a
secondary response. A comparison of fast acetylator C57BL/6 mice and slow
acetylator A/J mice did not reveal a strain difference, suggesting that the PA-
oxidizing capacity of PMϕ from the two strains is similar, at least at the
saturating PA concentrations used in vitro. Challenge of T cells from saline-
treated donors with either HAPAaq or PA-treated PMϕ failed to induce a
Figure 1.   In vitro exposure of PMϕ to the
non-reactive PA generated neoantigens
capable of inducing a primary PLN reaction.
PMϕ were incubated for 48 h in the presence
of 1 mM PA (solid bars) or in culture medium
without PA (open bars). Subsequently, cells
were frozen and homogenized, and on day 0
syngeneic recipients were injected with the
indicated cell number equivalents of PMϕ
into a hindfoot pad. On day 6, mice were
sacrificed and the direct PLN assay was
performed. Data represent arithmetic means +
SD of 5 mice per group. (*p< 0.05; **p<
Macrophages form T cell-sensitizing procainamide metabolites78
0.01)
Figure 2. Capacity of in vitro PA-
exposed PMϕ to evoke a recall response
by HAPAaq-primed T cells. The adoptive
transfer PLN assay was used. Donor T
cells (1 x 107 cells/recipient) were adop-
tively transferred to syngeneic recipients
by sc injection into one hindfoot pad. One
day later, the transferred T cells were
challenged by injecting into the same
hindfoot pad either 2.5 x 105 homogenized
PMϕ (solid bars), or 0.15 µmol of either
PA or HAPAaq indicated in italics
(hatched bars) into the same hindfoot pad
of recipients. Prior to injection, PMϕ of
either strain were cultured for 48 h in the
absence (-) or presence of 1 mM PA. Data
represent arithmetic means + SD of 5 to 7
mice per group; asterisks indicate
significant differences between each of the
the groups indicated by solid bars and
hatched bars, respectively (**p< 0.01;
***p< 0.001). (A) Prospective T cell
donor mice of C57BL/6 and A/J strain
were primed by s. c. injections of
HAPAaq (three dorsal injections of 8
µmol HAPA in saline). (B) T cell donor
mice were treated with saline alone.
statistically significant increase of the PLN cell count index (Fig. 2B). This
finding shows that PMϕ of both strains had generated HAPA-related
neoantigens in vitro and, hence, provides indirect evidence for HAPA formation
by these cells.
Effect of PA exposure on inducibility of arylamine-metabolizing enzymes in
PMϕ
The experiments described above provided evidence that PMϕ of slow and fast
acetylator mice themselves can generate the reactive PA metabolite. In the next
series of experiments, we tested whether enzymes capable of N-oxidizing or
N-acetylating arylamines are differentially induced during exposure of PMϕ of
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slow and fast acetylator mice to PA. For this purpose, mRNA expression levels
Figure 3. Enhancing effect of PA on PGHS-2 mRNA level in and PGE2 secretion by
PMϕ exposed in vitro. (A) Detection by RT-PCR of mRNA expression of PGHS-1 and
PGHS-2. PMϕ (1 x 106 cells/mL) remained untreated or were exposed for 48 h to 1 mM PA
or 1µg/mL LPS plus 25 U/mL IFN-γ, as indicated. β-actin mRNA expression by PMϕ was
studied for control. Radioactive PCR products were seperated on 10% polyacrylamide gels
and visualized by autoradiography. (B) Relative changes in mRNA levels of PGHS-2, as
quantified by densitometry. Results are given as band intensity ratios of PCR products of
PGHS-2 divided by β-actin for untreated PMϕ (open bars), PMϕ exposed to 1 mM PA (solid
bars), or 1µg/mL LPS plus 25 U/mL IFN-γ (cross-hatched bars). (C) Secretion of PGE2 by
PMϕ in vitro. After 48h of treatment, supernatants were removed and assayed for PGE2
levels. Results shown in (B) and (C) represent arithmetic means + SD obtained from three
independent cultures of PMϕ. Asterisks indicate significant differences compared to the
control culture (open bars) of the respective mouse strain (*p< 0.05; **p< 0.01; ***p< 0.01).
of PGHS isoforms, cytochrome P4501A isoforms, and NAT-2 were determined
by RT-PCR. In addition, enzymatic activity of MPO and PGHS were monitored,
PGHS activity being measured by determination of PGE2.
Exposure of PMϕ to 1 mM PA for 48 h led to a 2-fold increase in PGHS-2
mRNA levels (Figs. 3A and 3B ) and a 1.5-fold increase in PGE2 secretion (Fig.
C
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3C) when compared with untreated PMϕ. In order to assess
 
Figure 4. Effect of PA on mRNA levels of cytochrome P4501A1 and cytochrome
P4501A2 of PMϕ exposed in vitro. (A) Detection by RT-PCR of mRNA expression. PMϕ
remained untreated or were exposed for 48h to 1 mM PA, or to 10 nM TCDD. β-actin mRNA
expression was studied for control. mRNA detection was performed as described in the
legend to Fig. 3. (B) Relative changes in mRNA levels of cytochrome P4501A1 as quantified
by densitometry. Results are given as band intensity ratios of PCR products of cytochrome
P4501A1 divided by β-actin for untreated PMϕ (open bars), PMϕ exposed to 1 mM PA (solid
bars), or 10 nM TCDD (cross-hatched bars).
maximal inducibility of the enzyme during the 48 h culture period, PMϕ were
exposed to 1 µg LPS plus 25 U IFN-γ. mRNA levels of PGHS-2 in PMϕ thus
treated and the concentration of PGE2 in their supernatants were increased 1.5 to
2-fold when compared with PA-exposed PMϕ and 3 to 4-fold compared with
untreated cells. In PMϕ of C57BL/6 mice basal and inducible expression of
PGHS-2 mRNA and PGE2 were elevated compared to A/J mice. Exposure of
PMϕ to PA had no detectable effect on the mRNA level of the constitutively
expressed isoenzyme PGHS-1 (Fig. 3A). In control experiments with liver tissue
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of untreated mice of both strains
constitutive expression of PGHS-1
mRNA was detectable, whereas PGHS-
2 mRNA was not expressed (Fig. 3A).
Figure 5.   Comparing the induction of MPO
activity in bone marrow cells and PMϕ. Cells
(1 x 106 cells/mL) were either cultured in
medium only (open bars), in the presence of
1 mM PA (solid bars), or in the presence of 1 µg/mL LPS plus 25 U/mL IFN-γ (cross-hatched
bars). After 48 h, supernatants were removed and assayed for MPO activity. Results represent
arithmetic means + SD of three independent experiments. Asterisks
indicate significant difference compared with
 the control culture (open bar) of the respective
 cell type and mouse strain (**p< 0.01).
Next, we tested the effect of in vitro PA exposure of PMϕ on mRNA
expression of cytochrome P4501A1 and cytochrome P4501A2, two candidates
for bioactivation of arylamines to reactive species, showing overlapping
substrate specificity. Relatively low expression of cytochrome P4501A1 mRNA
was detected in untreated PMϕ and PA-exposed PMϕ, as opposed to the
vigorous induction seen after exposure to 10 nM TCDD (Fig. 4). No strain
differences were observed between C57BL/6 and A/J mice with regard to
inducibility of cytochrome P4501A1 mRNA by PA and TCDD, respectively. As
expected, cytochrome P4501A2 mRNA was clearly expressed in liver tissue of
untreated mice. In PMϕ, exposure to 1 mM PA or 10 nM TCDD failed to induce
detectable cytochrome P4501A2 mRNA expression (Fig. 4).
We extended the analysis of enzymes that might be responsible for PA
oxidation in PMϕ by measuring MPO activity in supernatants of cultured PMϕ
(Fig. 5). Bone marrow cells were chosen to positively control the assay system,
because they are rich in MPO-positive cells, such as granulocytes and
monocytes. We found that basal MPO activity in supernatants of bone marrow
cells was 2- to 3-fold higher than that of PMϕ and that no significant strain
difference was detectable between A/J and C57BL/6 mice. Whereas exposure to
LPS plus IFN-γ failed to affect the MPO activity of PMϕ, in bone marrow cells
this in vitro treatment induced a 2.5-fold increase in MPO activity. PA, however,
failed to induce MPO in either cell type. The enzyme NAT catalyzes N-
acetylation of arylamines, such as PA (21,29). In vitro exposure of PMϕ to PA
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had no significant effect on the expression of NAT-2 mRNA in either strain
tested (Fig. 6).
Figure 6. Effect of PA on mRNA levels of NAT-2 in PMϕ in vitro. (A) Detection by RT-
PCR of mRNA expression. PMϕ were treated as described in the legend to Fig. 3. (B)
Relative changes in mRNA levels of cytochrome P4501A1 as quantified by densitometry.
Results are given as band intensity ratios of PCR products of NAT-2 divided by β-actin for
untreated PMϕ (open bars), PMϕ exposed to 1 mM PA (solid bars), or 10 nM TCDD (cross-
hatched bars). Asterisks indicate significant differences compared to the control culture (open
bars) of the respective mouse strain (***p< 0.01).
Table 2.   N-oxidation of PA and covalent binding to PGHS
Constituents of the incubation mixture prior to assaya
PA PA PA PA -
PGHS PGHS Albumin Albumin Albumin
Arachidonic - Hematin - Hematin
acid / H2O2 - H2O2 H2O2 H2O2
Formation of 0.0183 ± 0.003 < 0.001 n.d. n.d. n.d
HAPAb (µM)
Covalent bindingc 37,108 ± 1,572 2,749 ± 160 41,794 ± 1,369 5,991 ± 1,015 2,064 ± 30
(fluorescence365/450)
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a Values represent mean ± SD, b Determined by mass spectroscopy, c Determined by ELISA
Taken together, analysis of arylamine-metabolizing enzymes in PMϕ in
vitro revealed that under the experimental conditions used 1) no significant
differences between strains C57BL/6 and A/J were detectable and 2) out of the
five N-oxidizing enzymes tested only PGHS-2 was inducible by PA.
PGHS is able to N-oxidize PA
The combination of PGHS and either arachidonic acid or hydrogen peroxide
oxidized PA to HAPA and nitro derivatives. Under the HPLC conditions
described in the Methods section, the retention time of HAPA was 1.5 min and
that of the nitro derivative was 6.7 min. There was another peak in the ion
current at m/z 252 with a retention time of 2.5 minutes; we suspect that this is
the N-oxide of the tertiary amine, but this was not confirmed. As shown in Table
2, the concentration of HAPA in the incubations (n = 4) was 0.0183 ± 0.003 µM,
while the level in the controls in which arachidonic acid was omitted from the
incubation was less than 0.001 µM. The formation of HAPA was dependent
upon both PGHS and either arachidonic acid or hydrogen peroxide. The identity
of HAPA was confirmed by MS/MS and comparison with the MS/MS of
synthetic hydroxylamine: the major fragments were at m/z 179, 162, and, 136
with smaller peaks at m/z 120 and 100. The peak due to HAPA also disappeared
on addition of NaOH (to raise the pH above 10) which is characteristic of the
hydroxylamine (30).
Covalent binding of metabolized PA
As shown in Table 2, PA was found to covalently bind to PGHS. The ELISA
fluorescence from 3 experiments was 37,108 ± 1,572 while that of the control in
which H2O2 was omitted from the incubation was found to be 2,749 ± 160. In
order to make sure that the oxidation was not due simply to H2O2, another set of
incubations was performed in which PGHS was replaced by bovine serum
albumin (20 mg); in this case no significant binding ensued (fluorescence =
5,991 ± 1,015). However, the combination of hematin and H2O2 did lead to
covalent binding of PA to the albumin (fluorescence = 41,794 ± 1,369). We
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conclude that incubation of PA with
PGHS or hematin results in the
cooxidative activation of PA to a
metabolite capable of covalent binding
to protein.
Figure 7.   Neoantigen formation in PA-treated
PMϕ. The cytoplasmic fraction of PMϕ
preincubated with either 1 mM PA (lane 1, 2
and 6), saline (lane 3 and 4), or 1 mM N-acetyl-
PA (lane 5) were analyzed for neoantigen
formation. After homogenization, one of the saline control fractions was incubated with PA
(lane 4). The PA preincubated cell-lysates were stained with anti-PA serum (lane 1), anti-PA
serum blocked with 4 mM PA (lane 2) or control serum (lane 6). Lanes 3, 4 and 5 were
stained with anti-PA serum. 
Neoantigen formation in PA-treated PMϕ
As shown in Fig. 7, the cytoplasmic fraction of PA-preincubated PMϕ (lane 1)
gave a distinct band at 35 kD when stained with antiserum against PA, but no
band when stained with control antiserum (lane 6). In the nuclear fraction, no
band was seen (data not shown). Blocking of the anti-PA serum with 4 mM PA
prior to staining in Western blot inhibited detection of the band at 35 kD (lane
2). Neither incubation of the PMϕ  with saline (lane 3) or N-acetyl-PA (lane 5),
nor incubation of homogenated PMϕ with PA (lane 4) showed a band at 35 kD.
These results indicate that a putative neoantigen was formed after in vitro
incubation of live PMϕ  with PA.
Chronic PA treatment sensitized T cells to HAPA-related neoantigens in
slow, but not in fast acetylator mice
In a previous investigation, we found that PA treatment of slow acetylator A/J
mice over a period of 4 months led to the formation of HAPA-related
neoantigens detectable in peritoneal cells, whereas peritoneal cells of chronically
PA-treated fast acetylator C57BL/6 mice failed to contain these antigens (11).
Here, we asked whether the HAPA-related neoantigens induced by chronic PA
treatment had sensitized T cells in vivo. Therefore, T cell recall responses were
analyzed in the adoptive transfer PLN assay. Two types of antigen were used for
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T cell challenge: 1) cell-
free, synthetic HAPAaq
for control, and 2)
peritoneal cells from
syngeneic mice
chronically treated with
Figure 8.   Evidence for
generation of and T cell
priming to HAPA-related
neoantigens during long-
term PA treatment of slow
acetylator A/J mice; in fast
acetylator C57BL/6 mice
additional treatment with
PMA was needed for these
effects. T cell sensitization to
HAPA-related neo-antigens,
as detectable in peritoneal
cells of PA-treated animals,
was demonstrated by HAPA-
specific recall responses in
the adoptive transfer PLNA.
Data represent arithmetic
means + SD obtained from 5
to 7 mice per group; asterisks
indicate significant differen-
ces between each of the two
groups indicated by solid and
hatched bars, respectively
(*p < 0.05; ***p < 0.01).
(A) Priming: T cell donor mice received three weekly sc injections of PA (8 µmol for A/J
mice, and 16 µmol for C57BL/6 mice) over a period of 16 weeks. One group of C57BL/6
donors received an additional weekly ip injection of 600 ng PMA (PA + PMA). On day 0,
107 donor T cells were transferred to each syngeneic recipient. Challenge: One day after the
T cell transfer, each recipient mouse received 5 x 105 homogenized peritoneal cells (solid
bars) or 0.15 µmol of either PA or HAPAaq indicated in italics (hatched bars). Donors of
peritoneal cells received either saline (-), saline (-) plus PMA, PA plus PMA, or PA only over
a period of 16 weeks, as described above and indicated under the solid bars. (B) Priming: T
cell donor mice of the A/J strain received three weekly sc injections of saline over a period of 16
weeks. For C57BL/6 T cell donors, this schedule of saline injections was supplemented by an
additional weekly ip injection of 600 ng PMA (saline + PMA). On day 0, 107 donor T cells were
transferred to each syngeneic recipient. Challenge: This was performed as decribed under (A).
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PA. As shown in Fig. 7A, T cells from chronically PA-treated A/J donors
reacted against both types of antigen, indicating T cells were primed to HAPA-
related neoantigens formed in the slow acetylator strain during chronic PA
treatment. By contrast, in fast acetylator C57BL/6 mice chronic PA treatment
failed to prime T cells to HAPA-related neoantigens, even though double the
amount of PA was administered compared to slow acetylator A/J mice.
Lack of T cell sensitization to HAPA-related neoantigens in fast acetylator
mice was abrogated by additional PMA treatment
The lack of T cell sensitization in chronically PA-treated fast acetylator
C57BL/6 mice was abrogated by additional weekly injection of 600 ng
PMA/mouse (Fig. 8A); the latter is known to stimulate oxidizing enzymes, such
as PGHS and myeloperoxidase, in vivo (31). For successful T cell recall,
bothcell-free HAPAaq and peritoneal cells from C57BL/6 mice chronically
treated with PA plus PMA could be used. Such peritoneal cells contain HAPA-
related neoantigens, as previously described (11). In contrast, T cells from saline
plus PMA-treated donors failed to give a statistically significant response to any
of the materials indicated (Fig. 8B). 
Discussion
Most investigators (1-3,11) agree that in the complex pathogenesis of PA-
induced lupus a first, pre-immunologic step apparently consists of N-oxidation
of PA to the reactive intermediates HAPA and nitroso-PA, respectively. As to
the nature of the second step, our group proposed the hypothesis (11) that this
may consist of T cell sensitization to neoantigens which are formed by these
metabolites and presented by APC, such as macrophages. The structure of these
metabolite-induced neoantigens has not yet been identified. As far as the cell
type that generates reactive PA metabolites is concerned, polymorphonuclear
phagocytes and monocytes were found capable of doing so (11,17), and in view
of the results of the present investigation the same can be said about
macrophages. Therefore, monocytes and macrophages could serve as a
connecting link between the first, drug-metabolizing and the second, T cell-
sensitizing step. Consistent with the hypothesis (11), our results indicate that
T cells of slow acetylator A/J mice undergoing chronic treatment with the parent
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compound PA were sensitized to HAPA-related neoantigens, as detectable in
peritoneal cells of these animals. At the present time, we do not have data to
show that these T cells reacting to HAPA-related neoantigens are, indeed, able
to produce autoimmune disease.
With respect to the pre-immunologic step, we analyzed five different
phase-I enzymes in mouse PMϕ that could be implicated in N-oxidation of
arylamines, such as PA. Apart from PGHS-2, PA exposure of PMϕ did not alter
mRNA expression or activity of the enzymes tested. In the case of PGHS-2, PA
exposure led to enhanced mRNA expression and an increase in
PGHS-dependent formation of PGE2. It is known that during prostaglandin
biosynthesis the peroxidase activity of PGHS reduces the endoperoxide-
hydroperoxide substrate PGG2 with electrons derived from oxidation of
cosubstrates. The latter may be exogenous ones, such as arylamines (20,32,33).
That PGHS, indeed, can N-oxidize PA was demonstrated by our finding that
incubation of PA with ovine PGHS yielded HAPA and led to covalent binding. 
In mice treated with TCDD an increase in mRNA levels of PGHS-2, but
not of PGHS-1, was detected in lung and spleen (34). These observations are in
line with our findings: exposure of PMϕ to PA was found to induce PGHS-2
mRNA and a corresponding increase in PGE2 levels, but did not affect PGHS-1.
Both, TCDD and PA increase PGHS activity by induction of PGHS-2, but
unlike PA, TCDD does not serve as a substrate for metabolic conversion by
PGHS isoenzymes. Our results indicate that the arylamine PA can induce
PGHS-2 in macrophages and, moreover, that the enhanced PGHS activity in
these cells may account for, or contribute to, N-oxidation of PA and, hence,
generation of HAPA-related neoantigens. Western blot analysis of PA-treated
macrophages revealed formation of putative neoantigens. Since cell-lysates
incubated with PA did not lead to covalent binding, we conclude that
metabolism of PA is required for the formation of these neoantigens. 
Generally, N-oxidation of arylamines can also be carried out by
cytochrome P450 enzymes, including those of the cytochrome P4501A family
(35). A recent investigation with human liver microsomes showed though that
N-oxidation of PA is mainly due to the non-inducible cytochrome P4502D6
(12); in mice, however, the metabolizing activity of this enzyme was found to be
low compared to rats and humans (36). Consistent with findings in humans (14),
we were unable to detect expression of cytochrome P4501A2 mRNA in mouse
PMϕ. Cytochrome P4501A1, however, is expressed in extrahepatic tissues,
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including macrophages (14-16). Unlike TCDD, a known inducer of cytochrome
P4501A1, PA failed to enhance cytochrome P4501A1 (37) expression in PMϕ
cultured in vitro. Another enzyme known to be capable of N-oxidizing PA is the
MPO of neutrophils and monocytes (9,17). However, confirming a previous
report in the literature (38) we found that the basal activity of MPO in PMϕ is
relatively low and thus differs from that seen in mouse bone marrow cells.
Moreover, incubation of PMϕ with either PA or LPS plus IFN-γ failed to
augment MPO activity, but did augment PGHS-2 activity in these cells. In
conclusion, while PA exposure did not enhance enzyme activity or expression of
either MPO or a member of the cytochrome P4501A family, we cannot rule out
involvement of these enzymes in the N-oxidation of PA either.
Our results show that in vitro PA exposure of PMϕ from both slow and
fast acetylator mice did not alter their NAT-2 mRNA expression, and they
strongly suggest that N-oxidation of PA can take place in PMϕ of both strains
(Fig. 2). Likewise, no differences in N-oxidation were detected between slow
acetylator A/J and fast acetylator C57BL/6 mice, when murine mononuclear
leukocytes were exposed to the arylamine 2-aminofluorene in vitro and DNA
adduct formation was used as indicator of arylamine N-oxidation, even though
C57BL/6 monocytes were 10-fold more active in N-acetylation (39).
Admittedly, our data obtained by the adoptive transfer PLN assay do not allow a
quantitative comparison of HAPA formation by PMϕ of the fast and slow
acetylator mouse strains used. Considering these limitations of detection
method, the available results suggest that with the saturating substrate conditions
used in vitro, macrophage-based N-oxidation of PA to HAPA or nitroso-PA was
not affected by genetic differences in N-acetylation.
Since the capacity of fast N-acetylation does not prevent N-oxidation of
PA by macrophages, what then can explain the lower risk for development of
adverse immune reaction to PA and other arylamines observed in fast acetylator
men and mice (2,11,21,22,40)? We propose that their lower risk is due to a
lower concentration of PA available as substrate for extrahepatic N-oxidation by
cells such as macrophages. Unlike slow acetylators, fast acetylators do not
readily build up a serum concentration of PA that provides sufficient substrate
for extrahepatic HAPA formation and, hence, for reaching the minimal number
of identical neoantigens on APC required for T cell activation. This hypothesis
is illustrated in Scheme 1, and it is based on the following three lines of
evidence. First, in chronically PA-treated fast acetylator C57BL/6 mice
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peritoneal cells failed to contain HAPA-related neoantigens (11) and their T
cells failed to be sensitized to these antigens (Fig. 8A). In chronically PA-treated
slow acetylator A/J mice, peritoneal cells did contain HAPA-related neoantigens
(11) and T cells were sensitized to them (Fig. 8A), even though they had
received only half the PA dose of that given to fast acetylator C57BL/6 mice.
Second, in human fast acetylators the incidence of PA-induced lupus was equal
to that seen in slow acetylators, when identical serum levels of PA were
maintained in both groups (41). Third, in fast acetylator C57BL/6 mice,
enhancing the rate of extrahepatic N-oxidation of PA could compensate for their
high rate of N-acetylation. This statement is based on our observations that PMA
stimulation of chronically PA-treated fast acetylator C57BL/6 mice sufficed 1)
to induce in vivo formation of HAPA-related neoantigens (11) and 2) to
spontaneously sensitize HAPA-specific T cells in vivo (Fig. 8A). Since PMA
activates many oxidizing enzymes, such as PGHS and MPO, via the protein
kinase C pathway (42), cells located at multiple sites of the body might be
involved in enhanced HAPA formation and presentation of HAPA-related
neoantigens. Besides the proposed enhancing effect on PA oxidation PMA was
shown to downregulate induction of cytochrome P4501A1 in the liver of
C57BL/6 mice (43,44). Downregulation of a potential PA metabolizing enzyme
in the liver may contribute to higher extrahepatic PA levels and thus enhance
extrahepatic HAPA formation. Interestingly, PMA has been reported to
stimulate de novo synthesis of PGHS-2 in cultured murine fibroblasts, human
monocytes, and rat and human epithelial cells (19,45,46). This suggests that the
enhancing effects of adjunct PMA treatment on neoantigen formation and T cell
sensitization, which were observed in the previous (11) and the present
investigation performed in vivo, also were due to upregulation of PGHS-2.
In addition to the pathogenic concept of PA-induced lupus developed in
the present paper (see Scheme 1), two other concepts are currently discussed for
the second, immunologic step of the disease. Richardson and coworkers (4)
assume a direct, autoimmunizing effect of PA on preactivated CD4+ T cells,
irrespective of the specificity of their T cell receptor for antigen. PA treatment
would enable the T cells to proliferate in response to normal APC, not treated
with the drug or pulsed with antigen. In contrast, the concept of Rubin and
coworkers (5), like our concept, is based on metabolic conversion of PA to
HAPA. They found that injection of HAPA into the thymus of normal mice
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Scheme 1.   Scheme depicting the initial metabolic and immunogenic steps thought to be
involved in the pathogenesis of PA-induced lupus. Two compartments of the body are shown,
the liver and extrahepatic tissues. In the latter, two types of cell are presented, a macrophage
and a T helper-2 (Th2) cell. In essence, the hypothesis postulates that due to conversion into
the reactive metabolites HAPA and nitroso-PA (not shown) neoantigens are generated and
presented by APC, such as macrophages, which are recognized by specific T cells and
activate them. The T cells then would secrete cytokines and thus activate other cells,
including autoreactive B cells (not shown), in a fashion analogous to chronic graft-versus-
host reaction in mice (47,51).
In the liver, PA can be either converted into N-acetyl-PA or HAPA (not shown).
Hepatic HAPA probably is not a sensitizing agent as the liver is rich in detoxifying
mechanisms and, moreover, relatively poor in APC. Consistent with this, hepatitis is not part
of PA-induced lupus. Due to expression of a defective NAT-2 in slow acetylators, their
hepatic elimination of PA via the nonreactive metabolite N-acetyl-PA is reduced (1); this
defect increases the amount of substrate available for extrahepatic PA metabolism (2). 
Extrahepatic N-oxidation of PA can be mediated by a variety of different enzymes (3).
One of them is PGHS-2, which is present in monocytes and macrophages and, perhaps, other
types of APC and wihich can be induced by PA. In monocytes and macrophages, N-oxidation
of PA to the protein-reactive, haptenic species HAPA and nitroso-PA (not shown) can lead to
presentation of HAPA-related neoantigens and subsequent T cell sensitization (4). In slow
acetylators, the concentration of extrahepatic PA (2) is high enough to readily evoke
sufficient generation of HAPA-related neoantigens by APC and, hence, sensitization of T
cells. In fast acetylators, effective N-acetylation of PA in the liver (1) decreases the amount of
PA available for extrahepatic N-oxidation (2). As a consequence, extrahepatic formation and
presentation of HAPA-related neoantigens is suboptimal or remains even below the threshold
required for activation of neoantigen-reactive T cells. Activation of oxidative enzymes in
phagocytes, for instance by PMA (5), enhances extrahepatic N-oxidation of PA and, hence, T
cell sensitization to HAPA-related neoantigens (4). PA-induced expression of PGHS-2 and
the subsequent increase in PGE2 release might shift the T cell response to HAPA-related
neoantigens towards a Th2-like cytokine pattern (6).
induced formation of autoantibodies to histones (H2A-H2B) similar to those
seen in PA-induced lupus in humans. They suggest that a loss of central T cell
tolerance to chromatin underlies autoimmunity in PA-induced lupus, since
chromatin-reactive T cell responses were detected in the spleen and in thymus
organ culture after exposure to HAPA ex vivo. While all three models conceive
a central role of T cells in PA-induced lupus, ours is the only one that considers
drug-induced neoantigens as the trigger for T cell activation, analogous to the
situation seen in SLE-like disease induced by chronic graft-versus-host reaction
in mice (47).
Finally, it is noteworthy that the observed induction of PGHS-2 by PA in
macrophages can have two different effects, each of which could contribute to
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the induction of PA-induced lupus (11,48). First, PGHS-2 may account for, or
contribute to, the observed generation of HAPA-related neoantigens in
macrophages, as discussed. Second, the PA-induced stimulation of PGHS-2 in
macrophages enhances the production of PGE2, as shown in the present
investigation. PGE2 released from macrophages, in turn, could skew the T cell
response to HAPA-related neoantigens towards a Th2-like cytokine secretion
profile (49,49). In this way, PGE2 itself might be involved in the pathogenesis
of PA-induced lupus, because human SLE (50) as well as the SLE-like disease
induced by chronic graft-versus-host reaction in mice (47,51) are dominated by
Th2 cytokines.
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CHAPTER 5
T Cells Ignore Aniline, a Prohapten, but Respond to its Reactive
Metabolites Generated by Phagocytes: Possible Implications for the
Pathogenesis of Toxic Oil Syndrome
Marty Wulferink, José González, Carsten Goebel, and Ernst Gleichmann
The most basic arylamine, aniline, belongs to a class of compound notorious for
inducing allergic and autoimmune reactions. In 1981 in Spain, many people
succumbed to the toxic oil syndrome (TOS), a disease caused by ingestion of cooking
oil contaminated with aniline. Indirect evidence points towards an immune
pathogenesis of TOS driven by T lymphocytes, but it is unclear to which antigens these
cells could react. Here, using the popliteal lymph node (PLN) assay in mice, we
analyzed the sensitizing potential of aniline, its metabolites, and some of the aniline-
coupled lipids detected in the contaminated cooking oil. Whereas aniline itself and its
non-protein-reactive metabolites nitrobenzene, p-aminophenol and N-acetyl-p-
aminophenol, failed to elicit PLN responses, its reactive metabolites nitrosobenzene
and N-hydroxylaniline did. The aniline-coupled lipids, namely linoleic anilide and
linolenic anilide, and a mixture of fatty acid esters of 3-(N-phenylamino)-1,2-
propanediol, all implicated in TOS, induced significant PLN responses, whereas the
respective aniline-free lipids, linoleic acid, linolenic acid, and triolein did not. Hence,
the aniline moiety plays a crucial role in the immunogenicity of the aniline-coupled
lipids of TOS. PLN responses to the reactive aniline metabolites and the one aniline-
coupled lipid tested, linolenic anilide, were T cell-dependent. Secondary PLN
responses to nitrosobenzene were detectable not only after priming with
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nitrosobenzene, but, in some experiments, also after priming with linolenic anilide.
This suggests that the aniline moiety was cleaved from the aniline-coupled lipid and
metabolized to the intermediate nitrosobenzene that generated the prospective
neoantigens. Consistent with this, in lymphocyte proliferation tests in vitro, T cells
primed to nitrosobenzene reacted in anamnestic fashion to white bone marrow cells
(WBMCs) pulsed with aniline. Hence, we propose that aniline is a prohapten that can
be metabolized by WBMCs, which form neo-antigens that are recognized by T cells.
The possible significance of these findings for the pathogenesis of TOS is discussed.
Introduction
Aniline is industrially synthesized on a large scale as the parent compound for a
variety of different arylamines including various drugs and dyes. Occupational
poisoning by aniline was common in the past (1), and exposure to aniline still
occurs today. Both acute toxicity, characterized by methemoglobinemia and
hemolytic anemia, and carcinogenic effects due to chronic aniline exposure have
been studied in detail (2-4). With respect to the immune system, aniline itself is
not known to induce adverse immune reactions in humans. In contrast, aniline
derivatives, which possess a functional group in para-position to the amine
group and, hence, are called para-compounds, are notorious for inducing
allergic and autoimmune reactions (5,6). Examples of such para-substituted
aniline derivatives are p-phenylenediamine, sulfonamides, and procainamide,
which can induce allergic contact dermatitis (7), agranulocytosis (8), delayed-
type hypersensitivity associated with multiorgan toxicity (9), and drug-induced
lupus (10), respectively. For two reasons the sensitizing potential of aniline
deserves to be studied in detail: first, the well-known sensitizing potential of the
above-mentioned arylamines, and second, the occurrence of the toxic oil
syndrome (TOS), a mass poisoning occurring in Spain that affected more than
20,000 people after consuming rapeseed oil contaminated with aniline (11). 
Fatty acid anilides and fatty acid esters of phenylamino-propanediol
(PAP), detected as abnormal compounds in case-related samples of toxic oil,
have been incriminated as etiologic agents of TOS (12,13). Clinical features
such as eosinophilia, elevated serum IgE, and signs and symptoms of systemic
autoimmune disease point towards an immune pathogenesis of the syndrome
(14). This was further corroborated by the detection of T cell infiltrates in the
affected tissues and of increased levels of soluble interleukin-2 receptor in the
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serum of TOS patients (14). It has been proposed (15) that graft-versus-host-like
reactions of T lymphocytes were involved in the pathogenesis of TOS. This
concept implies that neoantigens induced by the aniline-contaminated oil were
displayed by antigen-presenting cells (APC) and recognized by T cells. Classical
T cells, bearing an αβ-T cell receptor, are unable to recognize small molecular
weight compounds per se, but are able to react to them when bound to proteins,
more exactly peptides presented by molecules of the major histocompatibility
complex (16). Therefore, it is conceivable that in TOS patients T cells reacted to
self-peptides which were haptenated by the etiologic agent of the disease.
Considering that the aniline-coupled lipids implicated in TOS are neither
proteins nor protein-reactive and that their metabolic pathway is unknown, it is a
difficult task to test whether the derivatives of the aniline-coupled lipids can
haptenate self-proteins so that they are recognized by T cells. Therefore, we
decided first to study the aniline moiety per se for its potential to act as a hapten.
More specifically, we asked whether aniline can be considered a prohapten that
can be metabolized by phagocytic cells into a protein-reactive hapten capable of
sensitizing T cells. The knowledge gained from this approach was then applied
to probe the T cell-sensitizing potential of synthetic aniline-coupled lipids
implicated in TOS.
Materials and Methods
Mice   Female C57BL/6J, B10.S, BALB/c, BALB/c nu/+, and BALB/c nu/nu mice were
purchased from Harlan Winkelmann GmbH (Borchen, Germany). Animals were kept under
specific pathogen-free conditions and had free access to a standard diet (Ssniff Spezialdiäten
GmbH, Soest, Germany) and tap water. They were six to ten weeks of age at the onset of the
experiments. C57BL/6J mice were used, unless stated otherwise.
Chemicals   Aniline, nitrosobenzene, nitrobenzene, p-benzoquinone, p-aminophenol, and
N-acetyl-p-aminophenol (acetaminophen) were purchased from Sigma-Aldrich Chemie
GmbH (Deisenhofen, Germany). N-hydroxylaniline was prepared by hydroxylation of aniline
in the laboratory of Dr. Robert L. Rubin (La Jolla, California, USA) and kindly provided to
us. Caution: aniline, nitrosobenzene, nitrobenzene, and N-hydroxylaniline can induce
methemoglobinemia and are teratogenic; p-aminophenol and p-benzoquinone are  possible
contact-sensitizers. Substances were handled accordingly.
Linoleic anilide, linolenic anilide, and a mixture of fatty acid esters of PAP containing
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equimolar amounts of 1-oleyl,2-linoleyl-PAP; 1-oleyl,2-linolenyl-PAP; and 1-linolenyl,2-
linoleyl-PAP, were synthesized by Dr. A. Meseguer (Consejo de Superior de Investigaciones
Científicas, Barcelona, Spain) as described (17). Chemical structures of the aniline-coupled
lipids tested are shown in Scheme 1. The aniline-coupled lipids mentioned above and their
respective aniline-free control compounds linoleic acid, linolenic acid, and triolein were
provided in blind-coded fashion by Dr. M. Posada, general coordinator for research projects
on TOS (Instituto Carlos III, Madrid, Spain).
Sterile, pyrogen-free RPMI 1640 medium, fetal calf serum, penicillin, streptomycin,
L-glutamine, pyruvate, and non-essential amino acids were obtained from Life Technologies
GmbH (Eggenstein, Germany). 3H-dThd (248 GBq/mmol) was obtained from ICN
Biomedicals GmbH (Eschwege, Germany). Sterile filtered phosphate-buffered saline (PBS)
contained NaCl (138 mM), KCl (2.7 mM), Na2HPO4 (6.5 mM), and KH2PO4 (1.5 mM); its
pH was adjusted to 7.4.
Popliteal lymph node (PLN) assay   Primary PLN reaction. The assay detects the
immunostimulatory capacity of low molecular weight substances and was performed as
described before (18). In short, the test compounds aniline, N-hydroxylaniline,
nitrosobenzene, nitrobenzene, p-aminophenol, and N-acetyl-p-aminophenol, respectively,
were dissolved in ethanol and diluted in PBS to a final ethanol concentration of 0.1 %; the
solvent is referred to as ethanol/PBS. Linoleic anilide, linolenic anilide, the mixture of PAP
esters, and the respective control substances linoleic acid, linolenic acid, and triolein, were
emulsified in PBS by repeated ultrasonication on ice.
Homogenates of white bone marrow cells (WBMCs) were prepared in PBS (see
below). Sheep red blood cells were washed three times, and the cell number was adjusted in
PBS. On day 0, animals received a single sc injection (50 µL) of the test compound into the
left hind footpad. On day six, PLN of treated and untreated sides were removed, and cell
numbers of individual PLN were counted using a Casy1 automatic cell counter (Schärfe
Systems GmbH, Reutlingen, Germany). The PLN cell count index from each mouse was
calculated by dividing the cell count of the treated side by that of the control side.
Secondary PLN reaction. The assay was performed as described (18). Mice were
primed by a single sc injection (50 µL), containing the compounds indicated, into the left hind
footpad. Thirteen weeks later, the time period required for the enlarged PLNs to revert to their
normal size and cellularity following the injection of aniline-coupled lipids, groups of mice
were challenged by a second sc injection (50 µL) into the same foot pad. The doses of
nitrosobenzene, p-benzoquinone, and linolenic anilide used for recall were suboptimal, that
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Scheme 1.   Chemical structures of the aniline-coupled lipids and their aniline-free controls
used. In the structural formulas of the anilides, the PAP esters and triolein, R1, R2, and R3
have to be replaced by oleic acid, linoleic acid, and linolenic acid, respectively.
means they were just too low to induce a primary PLN response in unprimed mice. Four days
later, PLNs of treated and untreated sides were removed and cell count indices determined. 
Flow cytometric analysis of PLN cells   Six days after injection, PLNs from the treated side
were removed and cells from each individual mouse were double-stained with either FITC-
labeled anti-αβ-T cell receptor and PE-labeled anti-B220, or FITC-labeled anti-CD4 and PE-
labeled anti-CD8 (all obtained from Pharmingen, Hamburg, Germany). Percentage of T, B,
CD4 and CD8 cells were determined using a FACScan flow cytometer and Cellquest
Software (Becton Dickinson, Heidelberg, Germany).
Isolation of WBMCs   Mice were sacrificed and their femora and tibiae removed. Both ends
of the bones were cut off, and the marrow was flushed with PBS, using a 25-gauge needle.
Mature red blood cells were removed by osmotic lysis, and remaining cells were resuspended
in PBS. These cells are referred to as WBMCs.
Cell culture conditions   In all experiments performed in vitro, RPMI 1640 was
supplemented with 10% fetal calf serum, L-glutamine (2 mM), pyruvate (1 mM), non-
essential amino acids, penicillin (10 U/mL), and streptomycin (10 µg/mL); this is referred to
as medium. Cells were cultured at 37°C in a humidified atmosphere containing 7% CO2.
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Treatment of WBMCs for experiments in vivo   Isolated WBMCs were cultured in medium
and incubated with either 0.1 % ethanol or 1 mM aniline in 0.1 % ethanol. After two days of
culturing, WBMCs were harvested with a cell scraper, washed, resuspended in PBS, counted,
and homogenized by freeze-thawing and ultrasonication (5 x 10 s at 30 kHz) using a Labsonic
V 200 (B. Braun Melsungen AG, Melsungen, Germany). After homogenization, the number
of WBMC equivalents was adjusted to the desired concentration by dilution in PBS and
injected as described above for the PLN assay.
Treatment of WBMCs for experiments in vitro   Isolated WBMCs were incubated in
medium containing either 0.1 % ethanol or 1 mM aniline in 0.1 % ethanol. After one day of
culture, cells were harvested with a cell scraper, washed, resuspended in medium, irradiated
with 20 Gy using a Gammacell 2000 (Molsgaard, Copenhagen, Denmark), and used in the
T-cell proliferation test in vitro.
Treatment of prospective T-cell donors   Mice received two sc injections (on day 0 and day
seven) at the base of tail, each containing 100 nmol nitrosobenzene in 50 µL ethanol/PBS.
Control mice received ethanol/PBS only. On day 14 spleens were removed, splenic T cells
were enriched (see below) and used in the T-cell proliferation test in vitro.
Enrichment of T cells   Spleens of donor animals were removed and splenocytes were
pooled in PBS. B220+ cells were removed using a magnetic cell separator (Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany), as described (19). In short, 108 spleen cells were
incubated (15 min at 4 °C) in 1 mL PBS containing 50 µL anti-mouse-B220 monoclonal
antibodies coupled with magnetic microbeads (Miltenyi Biotec GmbH). Stained cells were
withdrawn from the cell suspension in a high gradient magnetic field. After separation, the
cell fractions were tested for T-cell purity with FITC labeled anti-Thy1.2 (Pharmingen) using
a FACScan flow cytometer. Cells in the unstained fraction after separation contained 85 to
95% Thy1.2+ cells and are referred to as enriched T cells. Enriched T cells were washed,
resuspended in medium and used in the T-cell proliferation test in vitro.
Preparation of APC   Mice were sacrificed, their spleens removed and a single-cell
suspension was prepared. Red blood cells were removed by osmotic lysis, and remaining cells
were resuspended in PBS, irradiated with 20 Gy, and used as APCs.
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T-cell proliferation test in vitro   Enriched T cells from treated or untreated spleen cell
donors were co-cultured for 96 h in 96-well round-bottom plates (1 x 105 T cells/well) with 5
x 103 WBMCs and with or without 1 x 105 APCs, as indicated. 3H-dThd (1µCi) was added to
each well 18 h before harvesting. Cells were harvested using a cell harvester on filter coated
with a solid scintillator (Ready filter with Xtalscint, Beckman Instruments, Fullerton,
California, USA). 3H-dThd incorporation was measured in a beta-scintillation counter (LS
6000 IC, Beckman Instruments).
Statistical analysis   Values of PLN cell count indices, expressed as arithmetic means ± SD,
were obtained from six to twelve animals per group. All experiments were performed at least
twice to assess reproducibility of the data. Statistical analyses were performed using
GraphPad Prism (GraphPad Software, Inc., San Diego, California, USA). PLN cell count
indices were compared using ANOVA with Bonferroni comparison.
Results
Differential capacity of aniline, its metabolites, and aniline-coupled lipids
for induction of primary PLN reactions
Structural formulas of the test compounds used are shown in Scheme 1. In order
to assess the capacity of aniline and its metabolites as well as that of fatty acid
anilides and PAP esters (Scheme 1) to induce an immune reaction, mice
received an sc injection of one of these compounds into a hind footpad. After six
days, the cell numbers of the draining and the contralateral lymph node were
determined. As shown in Figure 1A, aniline and its non-reactive metabolites
nitrobenzene, p-aminphenol and N-acetyl-p-aminophenol failed to induce a PLN
response. By contrast, nitrosobenzene proved to be a potent and
N-hydroxylaniline a weak inducer of PLN responses. Linoleic anilide, linolenic
anilide, and  the indicated mixture of PAP esters respectively, induced
significantly higher PLN responses when compared to equimolar doses of the
respective aniline-free lipids (Figure 1B). Note that nitrosobenzene had already
induced a significant PLN response at a 140-fold lower dose compared to the
aniline-coupled lipids (Figure 1A). At doses higher than 0.2 µmol/mouse,
nitrosobenzene could not be tested because it was insoluble. Kinetics of the
primary PLN responses to nitrosobenzene and linolenic anilide showed that
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Figure 1.   Primary PLN responses to reactive aniline metabolites and the aniline-coupled
lipids of TOS. On day 0, groups of mice received an sc injection of the indicated test
compound at the dose specified. PLN cell count indices were determined on day six. Panel A:
Showing PLN reactions to aniline and its non reactive (open bars) and reactive metabolites
(closed bars), respectively. The solvent used was ethanol/PBS. Panel B: Showing PLN
reactions to the fatty acid anilides indicated and the mixture of PAP esters specified (closed
bars). Control groups received the respective aniline-free lipids, i.e., the fatty acid indicated or
triolein (open bars). Bars indicate arithmetic means + SD of two pooled experiments with six
animals each. Asterisks indicate a significant difference (*p<0.05;**p<0.01; ***p<0.001)
between the group indicated and the solvent control (A) or the control group indicated by
brackets (B).
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Figure 2.   Showing T cell dependence of the primary PLN response to nitrosobenzene, N-
hydroxylaniline, and linolenic anilide, respectively. On day 0, groups of athymic (nu/nu) mice
(open bars) and euthymic (nu/+) mice (closed bars) on BALB/c genetic background received
an sc injection containing 0.1 µmol of either aniline, nitrosobenzene, N-hydroxylaniline, 14
µmol of linolenic anilide, 14 µmol of linolenic acid, 1 x 107 sheep red blood cells, or
ethanol/PBS only. PLN responses were measured on day six. Bars indicate arithmetic means
+ SD of two pooled experiments with five animals each. Asterisks indicate a significant
difference (**p<0.01; ***p<0.001) between the groups compared by brackets.
their responses were maximal on day six after injection and then steadily
declined until reaching normal values by day 90 and day 30, respectively (data
not shown). 
T-cell dependence of the PLN response to nitrosobenzene,
N-hydroxylaniline, and linolenic anilide
For assessment of T-cell involvement in the PLN reaction, T cell-deficient
BALB/c nu/nu mice or T cell-containing littermates (nu/+) received an sc
injection, containing 0.1 µmol of either nitrosobenzene, aniline, or
N-hydroxylaniline, 14 µmol of linolenic anilide or linolenic acid, or solvent only
into a hind footpad; 1 x 107 sheep red blood cells were used as positive control
because they are known to induce a T cell-dependent PLN response in mice
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(20). In nu/+ mice, nitrosobenzene, linolenic anilide, and sheep red blood cells
were found to induce significant PLN responses; and N-hydroxylaniline likewise
evoked a response, albeit not statistically significant. By contrast, none of the
test compounds elicited a significant PLN response in nu/nu mice (Figure 2).
B cell involvement in the PLN response to nitrosobenzene and linolenic
anilide, respectively
For assessing the role of B cells in the PLN reaction, PLN cells were stained for
T cell receptor, B220, CD4 and CD8 expression six days after injection of the
test compounds. Although the PLN response to nitrosobenzene and linolenic
anilide, respectively, is T cell-dependent (Figure 2), the PLN enlargement was
mainly due to an increase in B cells (Table 1). No significant differences in
percentage of CD4+ and CD8+ cells between the different groups could be
detected. 
Table 1.   Flow cytometry results of PLN cells after injection of aniline and its derivatives
Compound tested % T cellsa % B cellsb %CD4+ of T cellsc %CD8+ of T cellsd
solvent 72.3 ± 4.1e 25.3 ± 4.4 53.4  6.5 37.3  4.4
aniline 72.8 ± 7.4 24.6 ± 7.6 52.2  3.6 38.4  6.6
nitrosobenzene 45.9 ± 2.8***f 51.6 ± 2.6*** 50.4  3.7 41.4  3.0
linolenic acid 72.3 ± 6.0 24.3 ± 7.2 50.5  4.1 43.3  3.8
linolenic anilide 57.5 ± 7.7*** 38.1 ± 8.5*** 56.8  6.4 40.8  4.0
triolein 75.3 ± 5.5 22.1 ± 5.8 53.8  3.6 37.0  3.4
PAP esters 72.1 ± 7.3 25.8 ± 7.6 49.1  3.5 36.0  5.8
a % of T cells was determined as % of total PLN cells expressing αβ-T cell receptor; b % of B
cells was determined as % of total PLN cells expressing CD45R (B220) without expressing T
cell receptor; c % CD4+ of T cells was determined as % of T cell receptor bearing cells
expressing CD4; d % CD8+ of T cells was determined as % of T cell receptor bearing cells
expressing CD8; e shown are mean and SD of two pooled experiments with each four animals
(n=8); f asterisks indicate a significant difference (***p<0.001) between the group indicated
and its respective control group (aniline and linolenic acid, respectively).
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Figure 3.   Secondary PLN responses against nitrosobenzene. Groups of mice received an sc
injection containing 0.1 µmol of either aniline, nitrosobenzene, or p-benzoquinone, 28 µmol
of linolenic anilide or linolenic acid, or ethanol/PBS only. After 13 weeks, mice were
challenged by a second sc injection containing 0.005 µmol of either nitrosobenzene or aniline,
0.0001 µmol of p-benzoquinone, 1.4 µmol of linolenic anilide, or solvent only. Four days
later, PLN cell count indices were determined. Bars indicate arithmetic means + SD of one
experiment with six animals per group. Asterisks indicate a significant difference (**p<0.01)
between the closed bars and each of the open bars.
Secondary PLN responses to nitrosobenzene
When performed after a single injection of a test compound, the PLN assay is
unable to differentiate between an antigen-specific and a non-specific PLN
reaction. To discriminate between these two possibilities, we investigated
whether a secondary PLN response to nitrosobenzene could be induced in
animals primed to this compound. For control of specificity, p-benzoquinone
was used. p-Benzoquinone is a contact sensitizer whose ability to induce
specific secondary PLN responses has been established (21). For this purpose,
mice were primed by injecting either ethanol/PBS, 0.1 µmol aniline,
nitrosobenzene, or p-benzoquinone dissolved in ethanol/PBS into a hind
T cells respond against reactive aniline metabolites110
footpad. After 13 weeks, groups of mice were challenged by a second sc
injection into the same foot pad of either ethanol/PBS, 0.005 µmol aniline or
nitrosobenzene, or 0.0001 µmol p-benzoquinone dissolved in ethanol/PBS. As
shown in Figure 3, a recall response was only detectable in those mice which
had been both primed and challenged with nitrosobenzene or p-benzoquinone,
respectively.
To investigate secondary PLN responses against one of the aniline-
coupled lipids, mice were primed with linolenic anilide (28 µmol /mouse). After
size and cellularity of the draining PLNs had reverted back to normal, the mice
received recall injections consisting of suboptimal doses of nitrosobenzene
(0.005 µmol/mouse), linolenic anilide (1.4 µmol/mouse), and aniline (0.005
µmol/mouse), respectively. As shown in Figure 3, animals which had been
primed with linolenic anilide responded only upon recall with nitrosobenzene,
not upon recall with linolenic anilide. In contrast, mice which had received
linolenic acid for priming, failed to mount a PLN response upon recall with
nitrosobenzene, and the same was true when free aniline was used for priming.
In another experiment, in which mice were primed with a dose of 14
µmol/mouse of linolenic anilide, we also detected a secondary response to
nitrosobenzene (data not shown). However, the secondary response to
nitrosobenzene in mice primed to linolenic anilide was not reproducible. For
both priming doses mentioned above (28 and 14 µmol / mouse), the experiment
was performed three times, but for each priming dose, secondary responses to
nitrosobenzene were obtained only once.
Primary PLN response to WBMCs pulsed with aniline
It has been reported that neutrophils, monocytes, and macrophages are able to
metabolize arylamines (22). Therefore we asked whether WBMCs, which are
rich in precursors of granulocytes and macrophages (23), are able to metabolize
aniline to a protein-reactive metabolite that, in turn, would be able to haptenate
self-proteins and elicit a PLN response. To answer this question, WBMCs were
cultured in the presence of aniline, homogenized in order to make cellular
proteins available for uptake by APCs, and used in the PLN assay. Figure 4
shows that up to 5 x 106 homogenized WBMCs cultured with solvent only,
induced background responses in the draining PLN, whereas a dose-response
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Figure 4.   Primary PLN response against aniline-pulsed WBMCs. WBMCs were incubated
in medium containing either 1 mM aniline dissolved in 0.1 % ethanol or ethanol only
(solvent). WBMCs were washed, resuspended in PBS, and homogenized. On day 0, groups of
mice received an sc injection of 50 µL PBS containing the indicated cell equivalents of
homogenized WBMCs. PLN cell count indices were determined on day six. Bars indicate
arithmetic means + SD of two pooled experiments with five animals each. Asterisks indicate a
significant difference (**p<0.01) between the group which received aniline-treated WBMCs
and the respective control group.
relationship was seen in response to homogenized WBMCs cultured with
aniline. At the highest dose tested (5 x 106 cells per mouse), there was a
significantly higher PLN reaction against the aniline-pretreated WBMCs
compared to the control WBMCs pretreated with solvent only.
Nitrosobenzene-primed T cells show a recall response when cultured with
APCs and WBMCs pulsed with aniline
We then asked whether the PLN reaction to aniline-pulsed WBMCs shown in
Figure 4 was antigen-specific or not. To test this, the lymphocyte proliferation
test in vitro was used. WBMCs from BALB/c mice were preincubated in the
presence or absence of aniline and subsequently cocultured with syngeneic
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Figure 5.   In vitro secondary response of nitrosobenzene-primed T cells against WBMCs
pulsed with aniline. Groups of BALB/c mice served as prospective T cell donors, they were
primed by two sc injections containing either an immunogenic dose of nitrosobenzene or
ethanol/PBS only (solvent A). For recall in vitro, WBMCs were preincubated in medium
containing either 1 mM aniline dissolved in 0.1 % ethanol or 0.1 % ethanol (solvent B) only.
Washed WBMCs were cocultured with T cells from donor mice primed as indicated. Cultures
were performed in the absence (upper panel) or presence (lower panel) of irradiated spleen
cells from untreated mice, which served as APCs. Bars indicate arithmetic means + SD of six
replicates.
T cells, primed with either nitrosobenzene or solvent. Figure 5 shows the results
of a representative experiment. Provided additional APCs were supplied,
nitrosobenzene-primed T cells reacted against aniline-pulsed WBMCs, but not
against control WBMCs pulsed with ethanol. In four out of six experiments of
this type, nitrosobenzene-primed T cells mounted a secondary response against
WBMCs pulsed with aniline. In none of these six experiments, T cells from
PBS-treated animals reacted to WBMCs pulsed with aniline. These results show
that nitrosobenzene-primed T cells can react in an anamnestic fashion towards a
neo-antigen, which is induced in aniline-pulsed WBMCs.
Chapter 5 113
Discussion
Adverse immune reactions to chemicals are thought to arise due to T cell
reactions to chemical-induced neoantigens (10,24,25). In the past years,
pioneering studies investigating the nature of such neoantigens and conditions of
how they are generated have been performed (reviewed in 26-30). Thus, in order
to be recognizable by T cells, electrophilic organic haptens, such as
trinitrophenyl and 3-pentadecyl-catechol, were found to require covalent
bonding to a nucleophilic amino-acid side-chain of protein. More exactly, for
T cell recognition, the hapten must be bound to protein fragments fitting into the
peptide-binding groove of molecules of the major histocompatibility complex
(27,31,32). Chemicals which themselves, due to their lack of protein reactivity,
are unable to act as haptens, but whose reactive intermediates are able to do so,
are termed prohaptens (33,34). Their reactive intermediates are able to bond in
covalent fashion to self proteins, and it is assumed that these are processed and
their neoantigens presented to T cells (24). If the T cells recogni-zing
neoantigens simultaneously receive costimulatory signals from APCs, they are
primed and will start an immune response. Individuals whose T cells were
primed to a given antigen harbor memory T cells and, hence, respond faster and
require less antigen upon specific recall than non-sensitized individuals. With
respect to neoantigens induced by reactive intermediates, the specificity of the
immune response can be used to determine whether or not administration of a
given parent compound has generated neoantigens identical with those induced
by the reactive metabolite under study (35-38). Questions raised in the present
paper concern the T cell-sensitizing potential of aniline, its metabolites, and of
the aniline-coupled lipids implicated in TOS. Table 2 gives an overview of the
results obtained with the different compounds tested in the PLN assay. 
In the case of aniline, which is unable to covalently bond to protein (1),
our results are in line with the prohapten-hapten concept described above.
Injection of free aniline failed to induce a PLN reaction, whereas injection of its
reactive metabolites, N-hydroxylaniline and nitrosobenzene, succeeded to do so.
Mice primed to nitrosobenzene, but not those injected with solvent or aniline,
showed an enhanced PLN response to a small dose of nitrosobenzene, indicating
a specific anamnestic response to this compound. Our results obtained with
aniline-pulsed WBMCs support the general notion (8,36) that cells of the
immune system, especially phagocytic cells, can metabolize
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Table 2. Overview of the results of experimental sensitization to aniline and its
derivatives
PLN assay
Compound tested
Primary PLN
response
T cell
dependence
Secondary
PLN response
% B cells
increased
aniline no
nitrobenzene no
p-aminophenol no
N-acetyl-p-aminphenol no
N-hydroxylaniline yes yes n.d.a n.d.
nitrosobenzene yes yes yes b,c yes
linolenic acid no
linolenic anilide yes yes no yes
linoleic acid no
linoleic anilide yes n.d. n.d. n.d.
triolein no
PAP esters yes n.d. n.d. no
a n.d.: not determined; b In two out of six experiments, secondary PLN responses to
nitrosobenzene also were detectable in mice primed to linolenic anilide. c In vitro,
nitrosobenzene-primed T cells responded in anamnestic fashion to aniline-pulsed
WBMCs as well.
prohaptens, such as aniline, into protein-reactive haptens, such as
nitrosobenzene, and thus give rise to immunologically relevant neoantigens.
Unlike exposure to aniline, exposure to its para-substituted derivatives,
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such as para-phenylenediamine and procainamide, is known to induce adverse
immune reactions in humans as well as experimental animals (10,39-41). We
propose that the difference may be explained by the different toxicokinetics of
aniline and its para-substituted derivatives. Aniline is known to be primarily
metabolized in the liver (3,42,43). The metabolite thus formed,
N-hydroxylaniline, diffuses into the blood and, after oxidation to nitrosobenzene
with concomitant formation of methemoglobin, it covalently bonds to
hemoglobin and accumulates in erythrocytes and the spleen (44). Whether
hemoglobin thus haptenated spontaneously elicits immune reactions is not
known. As most of the adverse immune reactions to the para-substituted
derivatives of aniline occur extrahepatically, e.g., in the skin or the immune
system, it is conceivable that the reactive intermediates involved are formed in
the affected tissues themselves (24). This assumption is corroborated by the fact
that the addition of chemical groups in para-position to the amine group of
aniline can prevent hepatic metabolism of aniline through aniline-4-hydroxylase,
i.e. CYP2E1, activity (45), thus favoring extrahepatic metabolism of the
respective arylamine and increasing the risk of adverse immune reactions at
extrahepatic sites. Two such para-substituted metabolites are p-aminophenol and
N-acetyl-p-aminophenol, which are major aniline metabolites formed during
hepatic aniline metabolites (45). Both can be further oxidized to their respective
quinones, which are highly protein-reactive. The oxidation to the reactive
quinones mainly takes place in the liver, where they are detoxified by the high
levels of GSH present in this organ, or, in case detoxification fails, induce liver
damage (46). Both p-aminophenol and N-acetyl-p-aminophenol failed to induce
a primary PLN reaction, suggesting that the quinones are not formed locally
following injection of the para-hydroxylated aniline metabolites.
As the lack of sensitizing capacity of free aniline seems to be related to
the high degree of its hepatic metabolism and detoxification (47), we enhanced
its extrahepatic metabolism by deliberately targeting aniline to the extrahepatic
metabolic system. This was achieved by pulsing WBMCs with aniline in vitro
and using them as antigen. In the PLN assay, WBMCs pulsed with aniline, but
not those pulsed with solvent, were able to induce a significant response.
Moreover, we observed a recall response of nitrosobenzene-primed T cells to
such aniline-pulsed WBMCs in the lymphocyte proliferation test; WBMCs are
rich in neutrophil precursors, and these are known to have a high metabolizing
capacity for arylamines (8,22). In this test system, three cell types apparently
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had to cooperate: first, WBMCs that converted the prohapten aniline into the
hapten nitrosobenzene; second, APCs that picked up proteins haptenated by
nitrosobenzene and presented the relevant neoantigen to the primed T cells; and
third, T cells primed to the hapten-induced neoantigen and responding to it upon
recall. 
As far as the aniline-coupled lipids implicated in TOS are concerned, we
found that the immunostimulatory capacity of aniline-coupled lipids clearly
exceeded that of equimolar concentrations of lipids devoid of aniline. This
distinction could not be made in the study of Bell et al. (48), who reproduced
some of the pathological signs of TOS in mice; these authors only investigated
the aniline-coupled lipid oleic anilide, but did not study the respective aniline-
free control oleic acid. Another clear-cut result obtained in the present study is
the T cell-dependence and B cell involvement of the immune response to
linolenic anilide. Beyond this, however, our results obtained with aniline-
coupled lipids are less conclusive. The inability of free aniline to induce a PLN
reaction conforms with previous findings made with other non-reactive,
prohaptenic chemicals, such as procainamide, propylthiouracil, and benzene, all
of which failed to induce primary PLN reactions (18,21,26,37,49). Given that
both aniline-coupled lipids and aniline failed to be protein-reactive, why then
did aniline-coupled lipids, but not aniline, induce primary PLN responses? There
are two different, mutually not exclusive explanations to account for this and
both of them focus on the lipid moiety, as this distinguishes the aniline-coupled
lipids from aniline and the other prohaptens mentioned above. 
Due to their lipid moiety the aniline-coupled lipids probably were retained
at the site of injection. The prolonged retention time would lead to a higher local
concentration of the respective compound, enabling the local metabolizing
system to cleave aniline extrahepatically from the parent compound and form
sufficient reactive metabolite (N-oxidation of aniline to nitrosobenzene) to
induce an immune response. More specifically, through their fatty acid moiety
the aniline-coupled lipids probably can be taken up by lipid receptors present on
monocytes, macrophages, and, perhaps, dendritic cells (50), where they might be
metabolized into haptenic metabolites, such as nitrosobenzene. Covalent
bonding of nitrosobenzene to unidentified self-proteins (Scheme 2) creates
neoantigens that are recognized by T cells. The initial step in this hypothetical
chain of events is supported by the results of Bioque et al. (51,52) who showed
that polymorphonuclear cells and macrophages, by an amidase-like activity, can
Chapter 5 117
cleave the aniline moiety from fatty acid anilides. Macrophages, notably, can
also act as APC and thus interact with T cells. The second and the third step in
the hypothetical pathogenesis of TOS, namely N-oxidation of aniline and
nitrosobenzene-induced neoantigen formation in phagocytes, are supported by
our finding that T cells primed to nitrosobenzene reacted in anamnestic fashion
when WBMCs pulsed with aniline were used as recall antigen in vitro.
Disappointingly, however, results of those experiments that were designed to
assess the validity of the entire chain of
events postulated (Scheme 2, left pathway) failed to give a conclusive answer.
While in two out of six experiments performed animals primed to linolenic
anilide, indeed, mounted an anamnestic response to nitrosobenzene, as expected
according to our hypothesis, this result could not be reproduced in the other four
experiments. This might suggest that the immune response seen after priming
with a single dose of linolenic anilide was not only directed against
nitrosobenzene, but against other types of antigen as well. It should be noted in
this context that mice primed with linolenic anilide did not react upon recall to
suboptimal doses of linolenic anilide itself. Conceivably, the combination of
both the low dose of linolenic anilide used for recall and the short period of time
after the recall injection induced an amount of nitrosobenzene that was too low
for local formation of the relevant neoantigen. 
It might also be possible that the lipid moiety of fatty acid anilides provide
signal 2 by their intrinsic adjuvant effect on APC, including macrophages,
directing the immune response towards the aniline moiety. The adjuvant effect
of lipids is well known, and this is especially so when they are covalently bound
to the immunizing antigen (53,54); notably, this is just the way lipids are linked
to aniline in fatty acid anilides and PAP esters. Furthermore, aniline injected
without the lipid moiety would rapidly diffuse through the injection site to be
detoxified in the liver, as discussed above. Hence, after injection of free aniline,
the concentration of reactive metabolite formed locally probably was too low for
induction of an immune response. A somewhat different hypothesis to
account for the immunostimulatory capacity of aniline-coupled lipids and the
lack of this capacity in aniline administered alone could be that the aniline-
coupled lipids were able to activate T cells via non-classical pathways. In this
regard, it has been reported that CD1 molecules, a newly described family of
antigen-presenting molecules not encoded by the major histocompatibility
complex, are able to present antigenic 
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Scheme 2.   Pathway of oxidative aniline metabolism and postulated metabolism of aniline-
coupled lipids implicated in TOS. Aniline is N-oxidized to nitrosobenzene, which can bind to
sulphydryl groups (HS-R) of proteins or glutathione (lower left). Para-hydroxylation and
subsequent N-acetylation of aniline results in aminophenol and N-acetly-p-aminophenol,
respectively. These metabolites can be excreted or further oxidized to quinone imines which
can induce liver and kidney damage (lower right). Aniline can be cleaved from fatty acid
anilides, presumably by intracellular amidases (see text). A similar cleavage of aniline from
PAP esters has not yet been demonstrated. Rx, Ry, and Rz stand for aliphatic chains of fatty
acids (see Scheme 1). 
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lipids to T cells (55), thus raising the question of whether the aniline-coupled
lipids of TOS can induce CD1-restricted T cell responses. The original
publications on CD1-restricted T cell responses to lipids were performed with
CD8+ T cells using their αβ-T cell receptor, but CD1-restricted responses have
been also described for CD4+ and CD4- CD8-  T cells, respectively, as well as for
NK-T cells and T cells using their γδ receptors (56,57). Evidence accumulates
that cells of the innate immune system rather than classical T or B cells initiate
adverse immune reactions to chemicals (58). As cells of the innate immune
system do not mount anamnestic responses upon a second encounter with a
small amount of the same antigen, this could explain our inability to detect an
anamnestic response to linolenic anilide in mice primed to this compound.
In conclusion, the results presented here show that aniline can be
considered a prohapten. Depending on mode of external or internal exposure, its
site of metabolism into the hapten nitrosobenzene may shift from the liver to
extrahepatic tissue, such as WBMCs. After haptenating unidentified self-
proteins or -peptides, nitrosobenzene apparently creates neoantigens and thus
can act as a T cell sensitizer. This mechanism can be invoked for the
pathogenesis of TOS. However, a sequence of multiple biochemical and cellular
events is involved in the anamnestic anti-hapten responses following priming
with a complex, unusual prohapten, such as linolenic anilide, and challenge with
the hapten. This complexity might explain why the results of the evoked
anamnestic responses to nitrosobenzene after priming with linolenic anilide were
so poorly reproducible, unlike the results of those experiments where both recall
and priming were carried out with nitrosobenzene. Therefore, as an additional
explanation for the immunostimulatory effect of aniline-coupled lipids we
proposed antigen presentation by CD1 and recognition by non-classical T cells,
and experiments are now under way to test this.
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CHAPTER 6
Are NKT cells involved in the pathology of the Spanish toxic oil syndrome?
A pilot study
Marty Wulferink, Sabine Dierkes, José Gonzaléz, and Ernst Gleichmann
The toxic oil syndrome (TOS), an epidemic-like food poisoning that occurred in 1981
in Spain, was caused by ingestion of cooking oil contaminated with aniline. Indirect
evidence points towards an immune pathogenesis of TOS driven by T lymphocytes, but
it is unclear to which antigens these cells could react. In a previous paper, we showed
that aniline-coupled lipids, namely linoleic anilide and linolenic anilide, and a mixture
of fatty acid esters of 3-(N-phenylamino)-1,2-propanediol, all implicated in TOS,
induced significant popliteal lymph node responses, whereas the respective aniline-
free lipids, linoleic acid, linolenic acid, and triolein did not. Secondary immune
reactions towards the oil anilides tested, however, could not be obtained. This and the
fact that the etiologic agents are lipids, which cannot be presented by MHC molecules
but can be presented by CD1 molecules, led to the hypothesis that CD1-reactive
T cells, or NKT cells, may be involved in the pathogenesis of TOS. Here, using Jα281-/-
mice deficient in invariant-NKT (invNKT) cells, we investigated this hypothesis.
Injection of PAP ester in the hind footpads of either invNKT cell deficient or wild-type
mice showed comparable enlargement of the draining popliteal lymph nodes. Flow
cytometric analysis of lymph node subpopulations (NK cells, NKT cells, T cells,
B cells, and CD4+ and CD8+ T cells) revealed no hint as to the role of invNKT cells in
the pathogenesis of TOS. We therefore conclude that invNKT cells are not involved in
the lymph node enlargement seen after injection of PAP ester in the hind footpad of
mice. The possible role of non-invariant NKT cells in the pathogenesis of TOS and the
differences between humans and mice in NKT cell recognition are discussed.
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Introduction
In 1981 a mass poisoning occurred in Spain that affected more than 20,000
people after they had consumed rape seed oil contaminated with aniline (1). The
illness, which came to be called the toxic oil syndrome (TOS) presented itself in
an acute, an intermediate, and a chronic phase (2). The acute phase was
dominated by eosinophilia, pulmonary oedema, myalgias, fever, and rash. It was
followed by an intermediate phase consisting of myalgias, weight loss, skin
oedema, hepatopathy and sicca syndrome. The chronic phase was characterized
by peripheral neuropathy, hepatopathy, scleroderma and pulmonary
hypertension. 
Fatty acid anilides and fatty acid esters of 3-(N-phenylamino)-1,2-
propanediol (PAP), detected as abnormal compounds in case-related samples of
toxic oil, have been incriminated as the etiologic agents of TOS (3,4). The
clinical features outlined above point towards an autoimmune pathogenesis of
the syndrome (5). This was further corroborated by the detection of T cell
infiltrates in the affected tissues and of increased levels of soluble interleukin-2
receptor in the serum of TOS patients (5). It has been proposed (6) that graft-
versus-host-like reactions of T lymphocytes were involved in the pathogenesis
of TOS. This concept implies that neoantigens induced by the aniline-
contaminated oil were displayed by antigen-presenting cells (APC) and
recognized by T cells. Classical T cells, bearing an αβ-T cell receptor, are
unable to recognize small molecular weight compounds per se, but are able to
react to them when bound to proteins, more exactly, when bound to peptides
presented by molecules of the major histocompatibility complex (7). In a
previous paper (8) we investigated the possibility of neoantigen formation by
protein-reactive intermediates of fatty acid anilides and PAP esters. We showed
that C57BL/6J mice that were primed with fatty acid anilides could be recalled
in vivo with nitrosobenzene, a protein-reactive metabolite of aniline. However,
we could not show anamnestic responses to the aniline coupled lipids
themselves.
Publications on a recently discovered subpopulation of T cells, termed
NKT cells (9-11), led to a new hypothesis on the induction of TOS. It involves
direct presentation of the aniline coupled lipids on CD1, an MHC-like molecule.
Lipids presented by CD1 can be recognized by NKT cells that upon recognition
do not clonally expand but secrete large amounts of IFN-γ and/or IL-4 (Fig. 1).
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Figure 1. Hypothesis: Recognition of
PAP-ester on CD1 by NKT cells. In analogy
to other lipid antigens (12), PAP esters may
be presented by CD1 molecules on the
surface of APC. This CD1-lipid complex can
be recognized by the NKT cell, which then
rapidly secretes large amounts of IFN-γ and
IL-4. 
These cytokines can stimulate potential autoreactive T cells to become harmful
autoaggressive T cells. Our previous findings and the fact that NKT cells react
to lipids presented to them on CD1 molecules, but do not mount secondary
responses make it likely, that NKT cells play a role in the pathogenesis of TOS.
A substantial fraction of murine NKT cells use an invariant TCR α-chain,
namely Vα14-Jα281 (13); in this paper they are referred to as invNKT cells.
Here, we investigated if NKT cells play a role in the pathology of TOS by
injecting PAP esters in the hind footpad of both wild-type (WT) and Jα281-/-
mice which are deficient in NKT cells expressing the invariant Vα14-Jα281
TCR chain. We then evaluated the immune response in the draining lymph node
through cell count and flow cytometric analysis.  
Materials and Methods
Mice   Male C57BL/6J mice were purchased from Harlan Winkelmann GmbH (Borchen,
Germany). Male Jα281-/- mice were generated at Chiba University (Chiba, Japan) and
backcrossed nine times to C57BL/6 mice (14,15); they were obtained from Harvard Medical
School (Boston, USA) and will be referred to as invNKT-/-. Animals were kept under specific
pathogen-free conditions and had free access to a standard diet (Ssniff Spezialdiäten GmbH,
Soest, Germany) and tap water. They were 12 weeks of age at the onset of the experiments. 
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Chemicals    A mixture of PAP esters containing equimolar amounts of 1-oleyl,2-linoleyl-
PAP; 1-oleyl,2-linolenyl-PAP; and 1-linolenyl,2-linoleyl-PAP, were synthesized by Dr. A.
Meseguer (Consejo de Superior de Investigaciones Científicas, Barcelona, Spain) as described
(16). The aniline-free control compound triolein was also provided by Dr. A. Meseguer.
Popliteal lymph node (PLN) assay   The assay detects the immunostimulatory capacity of
low molecular weight substances and was performed as described before (17). In short, the
mixture of PAP esters, and the control substance triolein, were emulsified in PBS containing
1% ethanol by repeated ultrasonication on ice. On day 0, animals received a single sc
injection (50 µL) of the test compound into the left hind footpad. On day six, PLN of treated
and untreated sides were removed, and cell numbers of individual PLNs were counted using a
Casy1 automatic cell counter (Schärfe Systems GmbH, Reutlingen, Germany). The PLN cell
count index from each mouse was calculated by dividing the cell count of the treated side by
that of the control side.
Flow cytometric analysis of PLN cells   Six days after injection, PLNs from the treated side
were removed and cells from each individual mouse were triple-stained with either FITC-
labeled anti-αβ-T cell receptor, PE-labeled anti-NK1.1 and PerCP-labeled anti-CD3, or FITC-
labeled anti-CD19, PE-labeled anti-CD8 and PerCP-labeled anti-CD4 (all obtained from
Pharmingen, Hamburg, Germany). Percentage of NK, NKT, T, B, CD4 and CD8 cells were
determined using a FACScalibur flow cytometer and Cellquest Software (Becton Dickinson,
Heidelberg, Germany).
Statistical analysis   Values of PLN cell count indices, expressed as arithmetic means ± SD,
were obtained from three to four animals per group. Statistical analyses were performed using
GraphPad Prism (GraphPad Software, Inc., San Diego, California, USA). PLN cell count
indices and percentages of subpopulations were compared using ANOVA with Bonferroni
comparison.
Results
The PLN response to PAP ester is not dependent on invNKT cells
To assess NKT-cell involvement in the PLN reaction, invNKT cell deficient or
WT mice received an sc injection, containing 14 µmol of PAP ester or triolein
into a hind footpad. In both strains, PAP ester induced a significant PLN
response in comparison with the aniline free control oil triolein (Fig. 2). The
PLN response did not differ between the two strains compared, implicating that
invNKT cells are not involved in the PLN response to PAP ester.
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B
C
AFigure 2.   The primary PLN response to
PAP ester is NKT cell independent. On
day 0, groups of WT mice and invNKT
cell deficient mice received an sc
injection containing 14 µmol of either
PAP ester or triolein. PLN responses
were measured on day six. Bars indicate
arithmetic means + SD of groups of three
(invNKT-/-) or four (WT) mice. Asterisks
indicate a significant difference
(*p<0.05; **p<0.01) between the groups
compared by brackets.Figure 3.   Flow cytometric analysis of
PLN cells after injection of either PAP
ester or triolein. Percentage of NK and
NKT cells was determined as % of PLN
cells that are NK1.1+βTCR-CD3- or
NK1.1+βTCR+CD3+, respectively (A).
Percentage of T cells and B cells is
defined as % of PLN cells that are αβ-
TCR+NK1.1-, respectively CD19+ (B).
Percentage of CD4+ and CD8+ T cells is
defined as % of PLN cells expressing
CD4, respectively CD8 (C). Bars indicate
arithmetic means + SD of three
(invNKT-/-) or four (WT) mice. Asterisks
indicate a significant difference
(**p < 0.01; ***p < 0.001) between the
groups compared by brackets.
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Influence of PAP ester injection on lymphocyte subpopulations in the PLN
For assessing the role of NK cells, NKT cells, B cells, as well as CD4+ and
CD8+ T cells in the PLN enlargement seen after injection of PAP ester, PLN
cells were stained for NK1.1, CD19, αβ-TCR, CD3, CD4 and CD8 expression
six days after injection of the test compounds. Fig. 3 shows the percentages of
NK and NKT cells (A), B and T cells (B), and CD4+ and CD8+ cells (C) in the
draining lymph node. Compared with injection of triolein, injection of PAP ester
induced only in WT mice a significant increase in percentage of B cells (Fig.
3B) together with a low, but significant decrease in percentage of NKT cells
(Fig. 3A). In invNKT-/- mice, this relative increase in B cells and decrease in
NKT cells was also seen but it was not statistically significant. However, as the
data were obtained from one experiment using only 3 (invNKT-/-), respectively 4
(WT) mice per group, the statistical difference between the two different strains
may disappear when more mice per group are used. In both strains, there was no
significant change in percentage of CD4+ or CD8+ T cells after injection of PAP
ester (Fig. 3C).
Discussion
Recently PAP esters were identified, based upon epidemiological evidence, as
the most likely causative agent in TOS (18). In a recent paper, we showed that a
single injection of 14 µmol of PAP ester in the hind footpad of C57BL/6 mice
increased the cell count of the draining popliteal lymph node threefold in
comparison to aniline-free triolein. PAP esters as such are not protein reactive
and can therefore not directly bind to proteins. As PAP ester are lipids and
therefore could be presented by CD1, we hypothesized that PAP esters exert
their immunotoxic effect through activation of NKT cells. To investigate this
hypothesis, we used Jα281-/- mice which cannot express the invariant Vα14-
Jα281 TCR α-chain, which is expressed by the majority of murine NKT cells
(13). In the experiment described above, mice deficient in invNKT cells did not
show any difference in the PLN response to PAP ester compared with WT mice.
As expected, the percentage of NKT cells was lower in invNKT-/- mice compared
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with WT mice. There was only a marginal reduction in percentage of NKT cells
after injection of PAP ester compared with injection of triolein in both strains,
which might be due to the increase in percentage of B cells. In conclusion,
invNKT cells seem not to be involved in the local immune reaction seen after
injection of PAP ester in the hind footpad.
Although invNKT cells do not play a role in the primary PLN reaction after
injection of PAP ester in C57BL/6 mice, they may have played a role in the
human pathogenesis. Since no group has successfully established an animal
model of TOS up to now, the situation in humans might be different to that in
mice. The following differences in the murine model and the human situation
might be responsible for this: (i) There are different CD1 (CD1a, b, c, d and e)
molecules in humans, whereas there is only CD1d in mice (19). If CD1d were
not capable of presenting PAP ester, one of the other CD1 molecules in human
might do so, whereas in mice, PAP ester cannot be presented to CD1-reactive
T cells. (ii) The invariant chain of human NKT cells (Vα24-JαQ) is different
from the invariant chain of murine NKT cells (Vα14-Jα281) and may therefore
have different specificity. (iii) The route of exposure may play a role. Whereas
in 1981, the toxic oil was ingested orally and first delivered to the liver where
24% of all lymphocytes are NKT cells (19), injection in the footpad delivers the
oil straight into the draining lymph node, where NKT cells comprise only 3% of
all lymphocytes.
Furthermore, although Jα281-/- mice are called NKT-cell deficient, they
are deficient only in invNKT cells. Recently, Exley et al (20) showed that
α-galactosylceramide, a potent invNKT cell stimulator, protects mice against an
acute cytopathic virus. They also showed that without stimulation of invNKT
cells, Jα281-/- mice were protected equally well against the virus when compared
with WT mice, whereas protection was lost in CD1d-/- mice. This indicates
equivalent roles for CD1d-reactive invariant and "non-invariant" NKT cells in
resistance to acute virus infection. In other words, if NKT cells do play a role in
TOS, the non-invariant NKT cells might have taken over this role in invNKT cell
deficient mice and thus might be responsible for the PLN enlargement seen after
injection of PAP ester. Further experiments with blocking CD1d antibodies and
CD1d-/- mice will elucidate this hypothesis. 
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CHAPTER 7
Cross-Sensitization to Haptens Can Be Due to Different Mechanisms:
Formation of Common Haptenic Metabolites, T Cell recognition of Cryptic
Peptides, and True Cross-Reactivity
Marty Wulferink, Sabine Dierkes, and Ernst Gleichmann
Benzene derivatives which contain functional groups in the para-position are
notorious for inducing adverse immune effects; in this study they are referred to as
para-compounds. They can covalently bind to self-proteins generating neoantigens
which can be recognized by T cells. Once sensitized to a given para-compound, most
people react to more than this one para-compound. To analyze T cell cross-reactivity
to para-compounds at the clonal level, we established CD4+ T-cell hybridomas from
mice immunized with adducts of self-globin and one of three different para-
compounds, namely p-aminophenol, p-phenylenediamine, or Bandrowski's base. Some
of the obtained hybridomas reacted not only to the immunizing antigen but also to
metabolically related para-compounds bound to the same protein, thus suggesting
formation of common metabolites. One of the hybridomas reacted against a non-
haptenated native peptide of hemoglobin but not to the full length globin; such a
peptide fulfills the definition of a cryptic peptide. Other hybridomas cross-reacted to
globin adducts of metabolically unrelated para-compounds, but failed to recognize
native peptides, which denotes them as truly cross-reactive cells whose TCRs failed to
distinguish among the different haptens. Two even showed a heteroclitic reaction. To
summarize, we found evidence that cross-sensitization to para-compounds can be due
to any one of three different mechanisms: (i) metabolic transformation of a variety of
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different parent compounds to a common reactive metabolite acting as the hapten, (ii)
recognition of identical cryptic self-peptides generated after haptenation of the
respective self-protein, and (iii) true cross-reactivity where different haptens are
recognized by the same TCR.
Introduction
Benzene derivatives that possess two functional groups in the para-position are
notorious for inducing allergic and autoimmune reactions in humans (1,2).
Worldwide, these so-called para-compounds are still in use as drugs, color
developing agents, hair and textile dyes. Examples here are the hair dye
p-phenylenediamine (pPD), the photographic developer p-hydroquinone,
sulphonamide drugs, and procainamide, an anti-arrhythmic drug. These
compounds can induce contact hypersensitivity (3,4), agranulocytosis (5),
delayed-type hypersensitivity associated with multiorgan toxicity (6), and drug-
induced lupus (7,8), respectively. Because of their widespread use, humans
come into contact with a variety of different para-compounds. Cross-
sensitization to chemically different para-compounds has been frequently
observed (1,9-15); the term denotes the fact that an individual who is sensitized
to a given chemical, here a para-compound, can be challenged with a chemically
related compound without prior sensitization to it.
Although T cell reactions to haptens can be highly specific (16,17),
discriminating even between two stereoisomers of a hapten (18), T cell cross-
reactivity to different para-compounds has also been frequently observed (19).
The mechanism of this cross-reactivity has not been analyzed experimentally,
but  three possible mechanisms have been envisaged to account for it (4,9,12).
First, during metabolism of different prohaptenic para-compounds, a common
reactive metabolite could be generated that acts as a hapten; as a consequence,
identical neoantigens would be seen by T cells. Second, stereotype binding of
chemically related chemicals to self-proteins may lead to presentation of
identical cryptic peptides. Third, the TCR of a given T cell could be incapable of
distinguishing among the peptide adducts formed by different haptens and thus
would truly cross-react to two or more chemicals.
The first possibility, a common reactive metabolite, has been studied for
different para-compounds by Basketter and Goodwin (4) using the
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Figure 1.   Chemical structures of the different para-compounds studied. pPD and BB are
metabolically related and were used, together with pAP and BQ, to study cross-reactions
towards para-compounds. Bold characters indicate the compounds used for coupling and
immunization. The haptens shown, preferentially bind to cysteine residues (23,24) in proteins.
maximization test in guinea pigs. Although their results did not rule out cross-
sensitization to a common haptenic metabolite derived from the different
prohaptenic para-compounds tested, they considered it unlikely that this was the
only mechanism involved. However, conclusive results could not be obtained
with the in vivo test they used. 
The second mechanism, presentation of identical cryptic peptides, has
been implicated as an explanation for the frequently observed cross-sensitization
to different heavy metal ions. Griem and colleagues (20) demonstrated that
murine CD4+ T cell hybridomas raised against Au(III)-treated bovine RNase A
recognized a cryptic peptide of the RNase. Cryptic peptides are peptides that are
not normally presented (21) and fail to carry the causative agent. The same
cryptic peptide was presented when RNase A was denatured by S-sulfonation of
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its cysteine residues or when it was treated with either Ni(III), Pd(II), Pd(IV), or
Pt(IV) (20). Most classical haptens, even though they differ in structure, are
electrophiles and, as such, preferentially bind to nucleophilic amino acids, such
as cysteine and lysine (22). The metabolites of the para-compounds studied here,
the respective quinones (Fig. 1), preferentially bind to cysteine residues (23,24).
Comparable to Au(III), binding of different para-compounds to self-proteins
may hinder enzymatic cleavage in stereotype fashion and lead to presentation of
identical cryptic peptides. 
The third possibility, true cross-reactivity, has to be considered when
cross-sensitization to different chemicals cannot be explained by either a
common metabolite or a cryptic peptide.
The animal models that were used for studying cross-sensitization to para-
compounds (25), cannot distinguish between the three possible explanations
outlined above. Both the variety of different T cell clones and of potential
candidate self-proteins that can be haptenated is too large for analysis in vivo or
an analysis solely based on reactions of bulk T cells in vitro. To circumvent
these difficulties, we have established CD4+ T cell hybridomas from mice
immunized with murine hemoglobin adducts of para-phenylenediamine,
Bandrowski's base (BB) (3), and para-aminophenol (pAP), respectively.
Although it is unknown whether hemoglobin is relevant as a carrier protein for
para-compounds in vivo, for the following reasons it is a suitable model protein:
(i) it has six free cysteine residues for coupling the studied para-compounds, (ii)
its amino acid sequence has been elucidated, (iii) it has an active center that can
oxidize prohaptenic, i.e., non-protein-reactive para-compounds, such as pPD and
pAP, into their reactive quinones (26,27), and (iv) it is easy to obtain. Here,
using defined neoantigens and CD4+ T cell hybridomas, we found evidence for
all three possible mechanisms for cross-sensitivity mentioned above, that is, (i)
formation of a common metabolite, (ii) reactivity to cryptic peptides, and (iii)
true cross-reactivity.
Materials and Methods
Mice   Specific pathogen-free female BALB/c mice, expressing both I-Ad  and I-Ed, were
obtained from Harlan-Winkelmann GmbH (Borchen, Germany). Animals received a standard
diet and tap water ad libitum, and were used at 9-20 wks of age.
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Culture media   TC medium consists of RPMI 1640, supplemented with 50 µg/ml
gentamycin, essential and non-essential amino acids, 0.5 mM sodium pyruvate, 71.5  µM
β-mercapto-ethanol, and 5% FCS. HAT medium was prepared by adding 110 µM
hypoxanthine, 0.4 µM aminopterin, and 16 µM thymidine to TC medium. HT medium was
prepared by adding 110 µM hypoxanthine and 16 µM thymidine to TC medium. Supernatant
from the T cell line EXC-5 was used for T cell expansion prior to fusion. Amongst other
cytokines, it contained IL-2, IL-4, and IFN-γ (unpublished results).
Chemicals   BB was obtained from ICN Biomedicals GmbH (Eschwege, Germany); pPD,
pAP, and benzoquinone (BQ) were obtained from Sigma-Aldrich GmbH (Deisenhofen,
Germany). Chemical structures of the compounds used (bold) and their intermediates are
shown in Fig. 1.
Peptides   On the basis of both their I-Ed binding motifs and presence of a cysteine for
coupling the para-compounds to be studied, four different peptides from the α- and β-chains
of mouse hemoglobin (sequence listed in Swissprot, accession nos.: P01942, P02088, and
P02089) were obtained from Jerini Biotools GmbH (Berlin, Germany). These peptides, shown
in Fig. 2, were haptenated and their adducts purified as described below.
In other experiments, 67 non-haptenated peptides (15 aa long, 10 aa overlap between two
adjacent peptides), spanning the entire sequence of mouse hemoglobin, were used, they were
obtained from Jerini biotools GmbH. The peptides were supplied lyophilized on nitrocellulose
membranes. Before use, all 67 peptides were dissolved in saline at a concentration of 200 µM,
aliquoted and stored at -20° C.
Figure 2.   Selected peptides from the α- and β-chain of mouse hemoglobin. Peptides were selected
for two qualities, their binding motifs to I-Ed (italics) and presence of the nucleophilic amino acid
cysteine (bold) to which the electrophilic haptens studied are known to bind in covalent fashion
(23,24). The peptides β(6-19)dmajor and β(6-19)dminor are from the two different β-chains expressed in
BALB/c mice, dmajor and dminor, respectively, which differ at one aa at position nine (SWISSPROT,
see also under Material and Methods). All peptides indicated were coupled to BB, pPD, pAP, and BQ,
respectively, and used to restimulate hybridomas.
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Cell lines   Thymoma line BW5147 (TCRα-β-) was kindly provided by H.-G. Burgert
(Freiburg, Germany).
Antigens   Isolation of hemoglobin: Heparinized blood was obtained from untreated BALB/c
mice and washed three times with saline. Erythrocytes were lysed in 17 mM Tris-HCl, 160
mM NH4Cl, pH 7.2 (10 min, 37° C). After centrifugation at 15,000 g the soluble proteins
were fractionated on a Sephadex-G25 (Pharmacia, Uppsala, Sweden) column. The red-
colored hemoglobin fraction was collected and haptenated as described below.
Haptenation of hemoglobin: Freshly isolated hemoglobin was diluted to 50 mg/ml in 5 ml of
saline and 0.5 ml of a 0.15 M solution of either BB, pPD, pAP or BQ in absolute ethanol, or
ethanol only, was added to the hemoglobin. After 1 h incubation at 37° C with occasional
stirring, 45 ml of -20° C cold acetone containing 0.1% HCl was added. Acetone precipitation
was performed for two reasons: (i) the hemoglobin is freed of heme and breaks into
2 α-chains and 2 β-chains, and (ii) the precipitating chains are washed to eliminate free
hapten. The precipitated globin chains were spun down at 1,600 g and the pellet washed twice
with cold acetone (-20° C) containing 0.1% HCl. The pellet was dried overnight at 50° C and
resuspended in distilled water to a final concentration of 10 mg/ml and sterile filtered through
0.2 µm Supor Acrodisc filters (Gelman Sciences, Ann Arbor, MI, USA) before use. The
resulting BB globin, pPD globin, and pAP globin adducts were used for immunization and,
together with BQ globin, for restimulation of T cells.
Haptenation of peptides and purification of peptide adducts: Cysteine-containing peptides
(13, respectively 14 aa long)  from the α- and β-chain of hemoglobin, shown in Fig. 2, were
used. Peptides were coupled to BB, pPD, pAP, and BQ, respectively, by incubating the
peptide and the chemical to which it would be coupled for 2 hr at 37° C. After incubation, the
adducts and the native peptide, respectively, were purified using RP-HPLC on a LaChrom
HPLC System (Merck, Darmstadt, Germany). The HPLC column was a Lichrospher WP300
RP-18 (5 µm) column and the mobile phase a mixture of water, acetonitril, and trifluoric acid,
starting at 90:10:0.05 and continuously changing to 10:90:0.05 over 40 minutes at a flow rate
of 1 ml/min. The fractions containing native or haptenated peptide, respectively, were
vacuum-dried using an Eppendorf Concentrator 5301 (Eppendorf, Hamburg, Germany) and
solubilized in saline at a concentration of 200 µM.
Immunization   100 µg of protein adduct (BB, pPD, or pAP globin) in 25 µl saline was
mixed with 25 µl IFA and injected into the hind footpads of BALB/c mice. In one
experiment, 100 ng of pure BB, pPD or pAP in 1% ethanol/saline (50 µl) without adjuvant
was used. 
T cell proliferation assay   Ten days after immunization, popliteal lymph nodes (PLNs) were
removed and single-cell suspensions prepared. Cells were plated in tissue-type Petri dishes
for 2 h at 37° C for depletion of adherent cells to decrease unspecific stimulation caused by
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macrophages and dendritic cells containing the Ag used for immunization. Non-adherent cells
were mixed 1:5 with irradiated (20 Gy) syngeneic spleen cells from non-immunized mice and
plated in a 96-well plate at a densitiy of 5x105 cells per well. As control, PLN cells from non-
immunized mice were used. The cells were incubated for 4 days with different concentrations
of the respective antigen at 37° C. Cell proliferation was measured by adding 18.5 kBq
[3H]thymidine for the last 16 h. Cells were harvested onto Ready Filters with Xtalscint
(Beckman Instruments, Fullerton, CA), and the amount of radioactive thymidine incorporated
was measured in a LS6000 β-counter (Beckman). Experiments were done using six replicate
wells and performed twice to show reproducibility.
Generation of T cell hybridomas   Ten days after immunization, PLNs were removed and
single-cell suspensions prepared. Cells (2x106/ml) were restimulated in TC medium with the
appropriate antigen for 2 days. The activated T cells were propagated for 2 more days using
EXC-5 supernatant. T cell blasts isolated by Ficoll-gradient centrifugation were fused with
BW5147 thymoma cells using polyethylene glycol 1500 (Boehringer, Mannheim, Germany),
as described by the manufacturer, and plated in 96 well-plates. After selection of hybridomas
in HAT medium for 2 weeks, cells were cultured for 1 week in HT medium, which was then
gradually exchanged with TC medium. Hybridomas reacting to one of the used antigens in
T cell hybridoma stimulation assays were subcloned twice by limiting dilution.
Preparation of ConA blasts   Spleen cells of untreated BALB/c mice were cultured for 24 h
with Concanavalin A (ConA, 1.25 µg/ml). Cells were washed twice and cultured for another
24 h in TC medium. After washing, they were used in the IL-2 bioassay for detection of IL-2
secreted by Ag-specific hybridomas.  
T cell hybridoma stimulation assay (IL-2 bioassay)   Hybridomas (1x105) were cocultured
with syngeneic spleen cells acting as APC (5x105) in the presence or absence of antigen or
native globin. After 24 h, culture supernatants (50 µl) were transferred to a new 96-well plate,
frozen at -70°C, and after thawing tested for the presence of IL-2 by adding  IL-2-dependent
ConA blasts (2x104 in 50 µl). After 18 h, 18.5 kBq [3H]thymidine was added. Six hours later,
cells were harvested and [3H]thymidine incorporation was measured. Experiments were done
in triplicate cultures and performed at least twice to ensure reproducibility.
MHC restriction analysis   T-cell hybridoma stimulation assay was performed as described
above. Before adding the antigen, anti-I-Ad, anti-I-Ad/Ed, or the respective isotype control
mAb (40 µg/ml) were added. All antibodies were obtained from Pharmingen (Hamburg,
Germany). Experiments were done in triplicate cultures and performed twice.
TCR analysis   T hybridoma cells (2x105 per well) were stained with FITC-coupled mAb to
Vα2, Vα3.2b, Vα8, Vα11b,d, Vβ2, Vβ3, Vβ4, Vβ5.1,5.2, Vβ6, Vβ7, Vβ8.3, Vβ9, Vβ10b,
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Vβ12, Vβ13, Vβ14, and Vβ17a, respectively. FITC-coupled anti-βTCR, directed to the
invariable part of the β-chain, was used as positive control for expression of αβTCR. All
antibodies were obtained form Pharmingen and used at 0.02 µg/ml.
Statistical analysis   Values of 3[H]-thymidine (Thd) incorporation, expressed as arithmetic
means ± SD, were obtained from two to six independent cultures. All experiments were
performed at least twice to assess reproducibility of the data. The data were statistically
analyzed with GraphPad Prism software (GraphPad Software, Inc., San Diego, California,
USA) using ANOVA with Bonferroni comparison.
Results
Bulk T cells from mice immunized to a given para-compound coupled to
self-globin reacted to the adduct, but not to free para-compound
To characterize the specificity of bulk T cells reacting to the adducts of self-
globin and para-compounds used in this study, we first asked whether this
reaction was carrier-dependent. Therefore, mice were immunized by an s.c.
injection of either haptenated globin in IFA or the respective free hapten alone.
Cells from the draining lymph node and irradiated spleen cells as APC were
incubated with either saline, haptenated globin (25 µg/ml), native globin (25
µg/ml), or free hapten (100 µM), and their proliferation was determined. Upon
recall in vitro, lymph node cells from mice primed with the globin adduct of BB
showed carrier dependence in that they reacted only to the adduct used for
immunization, i.e., BB globin, not to free BB or native globin (Fig. 3). When the
mice had been immunized with free BB, however, their lymph node cells not
only showed an anamnestic response to free BB, as could be expected, but they
reacted weakly to globin-bound BB as well. Conceivably, after priming with
free BB in vivo, a spectrum of different self-proteins, one of them being globin,
were haptenated, creating different neoantigens to which T cells were primed. In
vitro, the addition of free BB to the culture of APC and T cells may have
haptenated the same or a similar spectrum of self-proteins, leading to recall of
BB-primed T cells. In contrast, BB globin-primed T cells could not be recalled
with free BB (Fig. 3), as there was no globin or hemoglobin present in the
culture. T cells from mice immunized with pAP and pPD globin adducts were
tested correspondingly in that they were restimulated in vitro using the
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Figure 3.   Bulk T cells obtained from mice primed to BB-coupled self-globin show carrier
dependence. Mice were primed by injection into both hind footpads of either BB globin in
IFA or free BB in saline. After 10 days, draining lymph nodes were removed and cell
suspensions prepared. For recall in vitro, lymph node cells were coincubated with either
saline, BB globin (25 µg/ml), native globin (25 µg/ml), or free BB (100 µM). After four days,
proliferation was measured. Bars represent mean + SD of six separate cultures. Asterisks
indicate a significant difference [(***) p < 0.001] between the black bars and all other bars.
adduct used for immunization, the respective free hapten, or native globin.
T cells obtained from the immunized mice could be restimulated only with the
adduct, not with native globin or free hapten (data not shown). BQ could not be
tested in this assay, because, as a free hapten, it is toxic in concentrations above
0.01 µM (T. Pape, unpublished data).
T cell hybridomas immunized to a single para-compound bound to self-
globin cross-reacted to other para-compounds bound to the same protein
To characterize the specificity of the T cells at single-cell level, CD4+ T cell
hybridomas were established. Mice were primed by injection of either pPD
globin, pAP globin, or BB globin in IFA. Lymph node cells were fused with
BW5147 thymoma cells to obtain immortalized T cells. After subcloning twice,
T cell hybridomas specific for the hapten-globin adduct used for immunization
were tested for their cross-reactivity towards other para-compounds bound to the
same protein. Fig. 4 shows that individual T cell hybridomas reacted differently
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to the different hapten-globin adducts used for recall. Although the first two
hybridomas shown, 2A3 and 7C3 (Fig. 4A and 4B), were both obtained from a
mouse immunized with pPD globin, they reacted differently: both reacted to
pPD globin and BB globin, but only 2A3 reacted to preparations of pAP globin
and BQ globin as well. Similar results were obtained with hybridomas 1B4 and
1A10 (Fig. 4C and 4D): although both were primed to pAP globin and could be
challenged with this Ag, only 1B4 reacted to all four preparations of self-globin
adducts. These results and those obtained with another pAP globin and two BB
globin-primed hybridomas, 2B2, 3H9, and 4G11, are summarized in Table 1.
The results of restimulation of hybridoma 2B2, which was generated after
priming with pAP globin, are shown in Fig. 5. Not only did 2B2 cross-react to
pPD globin and BB globin, but its reaction to the latter was even stronger than
that to pAP globin, the adduct used for priming. 
MHC restriction analysis of hybridomas recognizing haptenated globin
 
In order to analyze MHC restriction of the hybridomas used in this study, APC
were blocked with mAb against I-Ad or against I-Ad/I-Ed before performing a
hybridoma specificity test. Hybridomas were classified as I-Ad restricted when
the reaction against the haptenated globin could be blocked with either mAb
used, whereas I-Ed restricted hybridomas can only be blocked by the I-Ad/I-Ed
mAb. Out of the seven hybridomas studied in detail, five were restricted to I-Ed
and two to I-Ad (Table 1). 
Peptide specificity of I-Ed restricted hybridomas recognizing haptenated
globin
To characterize the peptide specificity of the I-Ed restricted hybridomas specific
for haptenated globin (Table 1), binding motifs of I-Ed molecules (28) were
taken into account. Four different peptides from the α- and β-chain of mouse
hemoglobin were selected (Fig. 2), each containing amino acids necessary for
binding to I-Ed and a cysteine as nucleophilic binding partner for the
electrophilic haptens used (23,24). Hybridomas were restimulated with the
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Figure 4.   Following immunization of mice to a given para-compound coupled to self-globin,
some T cell hybridomas cross-reacted to the same protein haptenated with different para-
compounds. Four different CD4+ T cell hybridomas, established from mice primed with either
pPD globin (A and B) or pAP globin in IFA (C and D) were tested for their cross-reactivity
using adducts of self-globin with a variety of different para-compounds, as indicated in the
key, for recall. After 24h of culture, supernatants were analyzed for their IL-2 content through
proliferation of IL-2 dependent ConA blasts. Symbols represent mean ± SD of three separate
cultures.
different haptenated and native peptides, respectively, and their IL-2 production
was measured. As shown in Table 1, four out of the five I-Ed restricted
hybridomas analyzed in detail recognized the haptenated peptide 96 to 108 from
the globin α-chain (α(96-108)), whereas hybridoma 4G11 reacted to haptenated
peptide β(6-19). No reaction was observed with any of the five I-Ed restricted
hybridomas shown in Table 1 when the peptides specified in Fig. 2 were used in
their non-haptenated form (data not shown).
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Table 1. Overview of results obtained with seven CD4+ T cell hybridomas that reacted to
the para-compounds indicated and were studied in detail 
Clone Obtained from
mouse primed
against
MHC
restriction1
Cross-reactivity to
globin haptenated
with
Haptenated I-Ed
peptide
recognized2
I-Ad peptide
recognized
TCR
phenotype3
2A3 pPD globin I-E
d
pAP, BB, BQ α(96-108) n.i.4
7C3 pPD globin I-E
d
BB α(96-108) n.i.
1B4 pAP globin I-A
d
pPD6, BB6, BQ6 α(96-110)5 Vα2/Vβ10b
1A10 pAP globin I-E
d no cross-reactivity
observed
α(96-108) Vα2/Vβ10b
2B2 pAP globin I-E
d BB6, pPD α(96-108) n.i./Vβ6
3H9 BB globin I-A
d
pPD α(96-110)7 n.i./Vβ13
4G11 BB globin I-E
d
pPD β(6-19)dminor Vα8/Vβ6
1 MHC restriction was determined using anti-I-Ed and anti -I-Ed/Ad antibodies in blocking
experiments. 
2 Peptide recognition was determined using 4 different peptides from the α- and β-chain of
hemoglobin, each of which contained a binding motif for I-Ed and a cysteine-residue. They
were used either native or haptenated with the same para-compound as that used for
immunization.
3 TCR analysis was determined using the Vα and Vβ antibodies listed under Materials and
Methods. 
4 n.i. = not identified.
5 Peptide recognition was determined using the peptide a(96-110), either native or haptenated
with BB or BQ. In addition to the BB-haptenated and BQ-haptenated peptide, the native
peptide was also recognized (cryptic peptide).
6 Heteroclitic reaction (see Discussion).
7 Peptide recognition was determined using the peptide a(96-110), either native or haptenated
with the same para-compound as that used for immunization. BB-haptenated peptide, but not
the native peptide was recognized.
Peptide specificity of I-Ad restricted hybridomas recognizing haptenated
globin
Unlike the I-Ed  restricted hybridomas, the two I-Ad restricted hybridomas, 1B4
and 3H9, failed to react to any of the four peptides selected on their ability to
bind to I-Ed, irrespective of whether they were haptenated or not (data not
shown). Two possibilities may account for this: (i) the two I-Ad restricted
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Figure 5.   Heteroclitic reactivity of a T cell
hybridoma to a hapten-protein adduct other than
to which it was primed. CD4+ T cell hybridoma
2B2, obtained from a mouse immunized to pAP
globin, was tested for its cross-reactivity using
adducts of self-globin with a variety of different
para-compounds, as indicated in the key, for
recall. After 24h of culture, supernatants were
analyzed for their IL-2 content through
proliferation of IL-2 dependent ConA blasts. Bars
represent mean ± SD of three separate cultures.
Asterisks indicate a significant difference
(**=p<0.01 and ***= p<0.001) between groups
compared by brackets.
hybridomas recognized cryptic, i.e., non-haptenated peptides, not necessarily
containing a cysteine residue, or (ii) they recognized cysteine-containing,
haptenated peptides with a binding motif for I-Ad. The different binding motifs
for I-Ed and I-Ad might not allow the four cysteine-containing peptides
previously selected on their motif for I-Ed and shown in Fig. 2 to be presented
by I-Ad molecules. 
T cell hybridoma 1B4 reacted to native peptides from the α-chain of hemoglobin
Unfortunately, the knowledge about peptide-binding motifs for I-Ad (28) was
not sufficient to select peptides from hemoglobin according to their binding
capacity to this MHC molecule. Therefore, we started with investigating the
possibility that 1B4 and 3H9 recognized a cryptic peptide, i.e., a non-haptenated
peptide, from the α- or β-chain of hemoglobin. Therefore, hybridomas 1B4 and
3H9 were tested for their reactivity towards 67 partially overlapping peptides
spanning the whole sequence of the α- and β-chain of mouse hemoglobin. Fig. 6
shows the reaction of hybridoma 1B4 against the 67 overlapping native peptides.
Reactions were detected against the two adjacent, partially overlapping non-
haptenated peptides, nos. 20 and 21; these match peptides α(96-110) and α(101-
115), respectively. Hence, 1B4, which was generated after priming with pAP
globin and showed broad cross-reactivity to all other globin adducts tested (Fig.
4C), reacted also to non-haptenated globin peptides. Hybridoma 3H9, as well as
two other, I-Ed restricted hybridomas that showed broad cross-reactivity, 2A3
and 2B2, failed to react to any of the 67 peptides used (data not shown).
Cross-sensitization to haptens148
Figure 6.   Immunization of mice with haptenated globin allowed for generation of a T cell
hybridoma reacting to non-haptenated, cryptic peptides of this self-protein. Hybridoma 1B4,
generated after priming with pAP globin, was tested with 67 native peptides (20 µM)
spanning the whole sequence of hemoglobin. After 24 h culture, supernatants were analyzed
for their IL-2 content through proliferation of IL-2 dependent ConA blasts. Bars represent
mean + SD of two separate cultures.
T cell hybridoma 1B4 also recognized haptenated peptide α(96-110)
As shown in Fig. 6, the peptides α(96-110) and α(101-115) recognized by
hybridoma 1B4 contain a cysteine located at position 104. To test whether this
hybridoma would react against the native peptides only or against the haptenated
peptides as well, peptide α(96-110) was haptenated with BB and BQ,
respectively, and tested in the restimulation assay. Fig. 7 shows that hybridoma
1B4 reacted better to the haptenated peptide than to the native peptide. It should
be noted that peptide α(96-110) is only two aa longer than peptide α(96-108)
which was selected on its ability to be presented by I-Ed (Fig. 2). Hybridoma
1B4, which is I-Ad restricted (Table 1), however, reacted only to peptides α(96-
110) and α(101-115), not to α(96-108), neither haptenated nor in its native form
(data not shown). Conceivably, the aa at positions 109 or 110 are necessary
either for binding to I-Ad, or for recognition by hybridoma 1B4.
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Figure 7.   Reactivity of T cell hybridoma 1B4 to the haptenated as well as to the native self-
peptide α(96-110). This hybridoma, obtained from a mouse immunized with haptenated
globin, was tested for its reactivity against peptide α(96-110) as well as this self-peptide
haptenated with BQ and BB, respectively. After 24 h incubation of the hybridoma cells, APC,
and the peptide or globin indicated, supernatants were analyzed for IL-2 content through
proliferation of IL-2 dependent ConA blasts. Bars represent mean + SD of three separate
cultures. Asterisks indicate a significant difference [(*) p < 0.05 and (***) p < 0.001] between
groups compared by brackets.
Analysis of variable segments of the α- and β-chain of the TCR on different
hybridomas
To determine the Vα- and Vβ-TCR expression on the hybridomas used in this
study, antibodies against different variable parts of the TCR's α- and β-chains
were used. Each hybridoma tested was stained with the different antibodies
commercially available (see under Materials and Methods) and analyzed by
immune flow cytometry. Results are summarized in Table 1. In the case of
hybridomas 2A3 and 7C3, the α- and β-TCR variable chains could not be
identified, although these hybridomas did express αβTCR, as determined by
mAbs against the invariable part of the β-chain. Conceivably, 2A3 and 7C3 may
express variable α- and β-chains other than those to which mAbs were available
and tested. The same is true for the α-chains of hybridomas 2B2 and 3H9, which
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could not be identified either. Table 1 shows that, although hybridomas 1B4 and
1A10, both obtained from a mouse immunized with pAP globin, express the
same Vα and Vβ elements, they differ in both their MHC restriction and their
cross-reactivity pattern: 1B4 was I-Ad restricted and showed extensive cross-
reactivity, whereas 1A10 was I-Ed restricted and showed highly specific
responses to pAP globin. Furthermore, no preferential usage of the α- and β-
chain was observed after immunization with para-compounds bound to globin.
Discussion
Although it is evident for most sensitizing chemicals that protein adducts are
involved in their recognition by T cells (reviewed in Ref. 29), a difficulty in
trying to study T cell reactions to sensitizing chemicals is the fact that the
ultimate neoantigens formed by these compounds are not known; the only
exception from this rule is the model hapten trinitrophenol (TNP) (16,30,31). In
order to study the molecular mechanism of T-cell cross-reactivity to para-
compounds, in the present investigation we synthesized four defined hapten-
globin conjugates. Three of them, namely BB globin, pPD globin, and pAP
globin were used for priming and these, together with BQ globin, were used for
restimulation of T cells. We found, as expected, that bulk T cells of mice
immunized with one of the three adducts mentioned above were only
restimulated by the respective adduct and not by native globin alone. T cells
from these immunized mice were used to establish a total of 94 CD4+ T cell
hybridomas which recognized the respective adduct used for immunization.
These hybridomas enabled us to analyze cross-reactivity of single T cell clones,
instead of using heterogeneous T cell populations present in vivo or in assays
with bulk T cells. The data obtained with seven of these hybridomas, which
were studied in greater detail, is summarized in Table 1. 
Indeed, some T cell clones, such as 1B4, 2A3, 2B2, and 7C3, showed
cross-reactivity in that they reacted to hapten-protein conjugates to which they
had not been primed. One possible explanation is the formation of an identical
metabolite derived from the different para-compounds. Conceivably, by
coupling pPD to hemoglobin, an oxidizing protein, BB was formed through
oxidation of pPD and subsequent trimerization with two other pPD molecules
(3,32). For instance, the reaction to BB globin of hybridoma 7C3, originally
primed to pPD globin, might be explained by this. Hybridomas 1B4, 2A3, and
Chapter 7 151
2B2, however, cross-reacted to different para-compounds, like BB and pAP,
that, as shown in Fig. 1, are not metabolically related. Their cross-reactivity,
therefore, cannot be explained by formation of a common metabolite so that
formation of cryptic peptides or true cross-reactivity must be considered. 
Analysis of the specificity of hybridoma 1B4 showed that it reacted to two
partially overlapping, native peptides from the α-chain of globin, α(96-110) and
α(101-115), even though it failed to react to the native globin. Such peptides, to
which T cells are raised that can only be recalled by the peptide itself, but not by
the respective native protein, have been termed cryptic peptides (21). Previously,
presentation of cryptic peptides and recognition by CD4+ T cell hybridomas
have been shown after immunization with bovine RNase denatured by Au(III)
(20), but up to now no cryptic peptides have been identified after coupling a
self-protein with a classical hapten, i.e., a covalently binding non-metal
compound. Presentation of cryptic self-peptides caused by haptenation of the
respective self-proteins may be relevant for the development of autoimmunity
because, by definition, T cell tolerance to cryptic self-peptides could not be
established as long as these were not presented (21). Hence, it has been proposed
that presentation of cryptic self-peptides by APCs is the initial step for the
development of drug-induced autoimmunity (29). 
No reaction to cryptic peptides was observed with hybridomas 2A3 and
2B2. As their cross-reactivity pattern could not be explained by common
metabolites either, true cross-reactivity might be an explanation for their
reactivity to hapten-protein adducts against which they had not been immunized.
True cross-reactivity of T cell hybridomas is not in line with the concept of 'one
clonotype, one specificity'. As already mentioned, this paradigm has been
undermined by theoretical considerations (33), and these are supported by a
number of experimental observations (34-38). According to Mason (33), for
optimal function of T cell recognition, three conflicting conditions have to be
met. First, a large number of foreign peptides must be recognized for defense
against microbes. Second, the specificity of the TCR must be high enough to
respond to the foreign peptides, but not to self-peptides. Third, the frequency of
T cells retained after negative selection and responding to a given foreign
peptide must be high enough to ensure a rapid response. The first two conditions
maybe best met by a highly specific, but diverse TCR repertoire. However, the
more specific and diverse the TCR repertoire, the lower the frequency of T cells
responding to a single foreign peptide will be. Because there are many more
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different foreign peptides than there are T cells in a mouse (33), a considerable
number of foreign peptides would go unrecognized if there were no cross-
reactivity. To enable the immune system to react fast and efficiently to
pathogenic peptides, Mason estimates that a single naive CD4+ T cell should be
able to react to almost half a million different 11-mer peptides. Hence, by
necessity, extensive cross-reactivity to peptides should be an intrinsic feature of
the TCR. For classical haptens however, cross-reactivity at the single T cell
level has not been reported before. Up to now, only highly specific clones were
described that are capable of discriminating amongst haptens with minor
differences in side-chains (18,39). In contrast, our results show both a good
degree of specificity, comparable with that reported for other haptens (18,39),
and extensive cross-reactivity. Specificity was manifested, for instance, by
hybridoma 1A10, while hybridoma 2A3 and 1B4 displayed extensive cross-
reactivity. An extreme manifestation of the intrinsic cross-reactivity of T cells
was observed with hybridoma 2B2 which reacted even more strongly to an
adduct not used for immunization, namely BB globin, than to the pAP globin
used for immunization. The term heteroclitic reaction (40-42) denotes this
phenomenon, it means that the immune response to an Ag not used for
immunization is stronger than that to the immunizing Ag. Heterocliticity was
also observed with hybridoma 1B4: it reacted to the immunizing pAP globin,
but reacted even more strongly to the three globin adducts which were not used
for immunization.
A concept which can be used to explain T cell cross-reactivity is the
‘avidity-pit model’ proposed by Sandberg et al. (43). Avidity is defined here as
the mathematical product of the TCRs' affinity towards a given peptide-MHC
complex and the number of such complexes recognized by the T cell on the
surface of an APC. According to that concept, immediately after thymocytes
were positively selected on their ability to recognize self-MHC complexes with
low avidity, their activation threshold is set higher than their level of self-
recognition. In order to reach their activation or avidity threshold and react,
peripheral T cells have to recognize a given peptide with higher avidity than the
original self-peptide by which they were positively selected. This means that
either their TCR recognizes the new peptide with higher affinity or that the
epitope density of this particular peptide on the surface of APCs is increased. If,
indeed, enhancement of avidity is the only prerequisite for T-cell recognition,
this would imply that a given T cell cross-reacts to all peptides, including those
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altered by haptens, which it recognizes with higher avidity than the self-peptide
by which it was positively selected in the thymus. The avidity-pit model also
implies that, even after activation by a foreign peptide, the T cell keeps its low
avidity for the original self peptide; hence, it can be activated if APCs present
that peptide at a higher density than normal. 
The extensive cross-reactivity seen with hybridoma 1B4 may therefore be
explained by the avidity-pit model. Hybridoma 1B4 cross-reacted with all four
hapten-globin preparations offered for recall, and at the peptide level it was
found to react to the haptenated peptide α(96-110). Unexpectedly, however, the
same peptide was also recognized in its native, unhaptenated form, albeit that
here the IL-2 production was lower, presumably due to lower affinity of 1B4 for
the native peptide than for the haptenated one. The following hypothesis may
explain these results. As can be deduced from our results with peptide α(96-108)
that was recognized by hybridomas 2A3, 7C3, 1A10, and 2B2 in its haptenated,
but not in its native form, haptenation of hemoglobin apparently leads to binding
of the hapten to the cysteine at position 104 of the α-chain. After immunization
with haptenated hemoglobin in vivo, a given T cell, conceivably positively
selected on its ability to recognize the native peptide α(96-110) with low avidity
in the thymus, recognized the haptenated peptide with higher avidity and reacts
against it. After fusion, the hybridoma generated was found to react to
haptenated globin and haptenated peptide α(96-110), implying that the T cell
from which it was derived had been activated by the haptenated peptide α(96-
110) in vivo. By adding the native self-peptide to APC in vitro, we increased the
number of peptide-MHC complexes on the surface of the APC, thereby raising
the avidity for binding of 1B4 and crossing the avidity threshold for its
activation. Nonetheless, the haptenated peptide was recognized with higher
affinity by the TCR of 1B4 and, therefore, a more vigorous reaction to the
haptenated than the native peptide ensued.
In conclusion, there are three aspects of our analysis concerning the fine
specificity of T cell reactivity to different haptens. First, with regard to
allergology, our results show that T cell cross-reactivity to para-compounds
indeed exists at the clonal level and, depending on the clone tested, can be due to
any one of the three mechanisms discussed above. Second, the alteration of self-
protein by covalently bound hapten may raise T cells reacting to cryptic self-
peptides and thus be relevant for drug-induced autoimmunity. Third, with regard
to T cell physiology our findings of true cross-reactivity and heterocliticity
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provide experimental support for the theories of Mason  (33) and Sandberg et al
(43) which describe a limited discriminatory capacity of T cells carrying an
αβTCR. 
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CHAPTER 8
The CellELISA: a rapid method for measuring specific
T-cell hybridoma reactions
Marty Wulferink, Sabine Dierkes, and Ernst Gleichmann
We have adapted the sandwich ELISA to rapidly screen a large number of T-cell
hybridomas. The method, called CellELISA is similar to the sandwich ELISA, but
instead of transferring the supernatants in cytokine-coated 96-well plates, the cells are
cultured directly in sterile, cytokine-coated wells. After 24 hours, the plates are
washed, incubated with the detection antibody and developed using ortho-
phenyldiamine substrate. Compared with the cytokine bioassay, where supernatants
are tested on cytokine-dependent ConA blasts, the CellELISA is as sensitive, but does
not require radioactivity and takes one day less. Compared with the sandwich ELISA,
the CellELISA is more sensitive, especially in the lower range of cytokine secretion.
We conclude, that the CellELISA is a suitable method for rapid screening and
measuring specific reactions of T-cell hybridomas. 
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Introduction
Chemical induced allergy and autoimmunity is often observed after
administration of certain drugs (1-5) or after intoxication with occupational or
environmental chemicals (6-8). A major difficulty in studying the mechanisms
of chemical-induced adverse immune effects is the fact that the ultimate
neoantigens are unknown (9). While there are different approaches to investigate
the molecular structure of these antigens, most investigations rely on
establishing monoclonal T cell populations: either T-cell clones (10,11) or T-cell
hybridomas (12,13).
The most widely used technique to measure activation of T-cell clones is
detection of proliferation upon challenge with the appropriate antigen. Two
techniques can be used in order to measure proliferation: (i) incorporation of
labeled nucleotides into DNA (3H-thymidine, bromodeoxyuridine) and (ii) cell
number dependent transformation of tetrazolium dyes (MTT, WST, etc).
Recently, measurement of proliferation has been extended by the measurement
of cytokines, either by sandwich ELISA or flow cytometry. With these
techniques one can differentiate between a Th1 and a Th2 responses (14,15). 
For T-cell hybridomas it is not possible to measure direct proliferation
upon challenge, as hybridomas proliferate independent of recognition of the
appropriate antigen. In contrast to T-cell clones, activation of T-cell hybridomas
can only be measured through cytokine secretion. This can be done in the
cytokine bioassay by using IL2/IL4 dependent cells or by direct measurement of
cytokines in an ELISA (16).
Initial screening of T-cell hybridomas is time consuming and laborious.
Generally only a few hundred hybridomas can be tested at one time for their
specificity to the antigen used for immunization. Conceivably, a time-saving test
combined with an early endpoint would be optimal for a first screening of newly
established hybridomas. We have therefore adapted the sandwich ELISA
technique to rapidly screen large numbers of T-cell hybridomas for their
specificity. Instead of transferring the supernatant from the culture plate into the
sandwich-ELISA plate or the cytokine bioassay plate, the CellELISA uses only
one plate for both culture and detection of cytokines, reducing costs and
workload, and enhancing sensitivity. The CellELISA has the additional
advantages that it takes one day less than the cytokine bioassay and does not
require radioactive incorporation.
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Materials & Methods
Mice   Specific pathogen-free female BALB/c (H-2d) and C57BL/6 (H-2b) mice were
obtained from Harlan-Winkelmann GmbH (Borchen, Germany). Animals were kept on a
standard diet and tap water ad libitum, and used at 8-10 wks of age.
Materials   p-Aminophenol (pAP) was obtained from Sigma-Aldrich GmbH (Deisenhofen,
Germany). Purified anti-CD3 (clone 145-2C11), anti-CD28 (clone 37.51, NA/LE), anti-IL-2
(clone JES6-1A12) and anti-IL-4 (clone BVD4-1D11), biotinylated anti-IL-2 (clone JES6-
5H4) and anti-IL-4 (clone BVD6-24G2), and FITC-labeled anti-I-Ab (clone AF6-120.1) were
obtained from BD Biosciences (Heidelberg, Germany). Streptavidin-coupled horse radish
peroxidase was obtained from Amersham Pharmacia Biotech (Freiburg, Germany). Magnetic
beads coupled to anti-CD8a (clone 53-6.7) and anti-I-A (clone M5/114.15.2) were obtained
from Miltenyi GmbH (Mönchen-Gladbach, Germany). Tumor cocktail (TC) medium
consisting of RPMI 1640 (PAA laboratories GmbH, Cölbe, Germany), supplemented with
50 µg/ml gentamycin, essential and non-essential amino acids, 1 mM sodium pyruvate (all
from PAA laboratories GmbH), 50  µM β-mercapto-ethanol (Sigma Aldrich GmbH), and 5%
FCS (Sigma Aldrich GmbH) was used throughout unless stated otherwise. HAT medium was
prepared by adding 110 µM hypoxanthine, 0.4 µM aminopterin, and 16 µM thymidine (all
from Life Technologies GmbH, Eggenstein, Germany) to TC medium. HT medium was
prepared by adding 110 µM hypoxanthine and 16 µM thymidine to TC medium. Supernatant
harvested from the T cell line EXC-5 was used for T cell expansion prior to fusion. Amongst
other cytokines, it contains IL-2, IL-4, and IFN-γ (unpublished results). 96-Well plates (type
Microlon) were obtained from Greiner GmbH (Frickenhausen, Germany) and used throughout
the experiments.
Hemoglobin isolation   Heparinized blood was obtained from untreated BALB/c mice and
washed three times with saline. Erythrocytes were lysed in 17 mM Tris-HCl, 160 mM NH4Cl,
pH 7.2 (10 min, 37° C). After centrifugation at 15,000 g the soluble proteins were fractionated
on a Sephadex-G25 (Pharmacia, Uppsala, Sweden) column. The red-colored hemoglobin
fraction was collected and haptenated as described below.
Haptenation of hemoglobin   Freshly isolated hemoglobin was diluted to 50 mg/ml in 5 ml
of saline and 0.5 ml of a 0.15 M solution of pAP in absolute ethanol was added to the
hemoglobin. After 1 h incubation with occasional stirring, 45 ml of -20° C cold acetone
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containing 0.1% HCl was added. The precipitated globin chains were spun down at 1,600 g
and the pellet washed twice with -20° C cold acetone containing 0.1% HCl. The pellet was
dried overnight at 50° C and resuspended in distilled water to a final concentration of 10
mg/ml and sterile filtered through 0.2 µm Supor Acrodisc filters (Gelman Sciences, Ann
Arbor, MI, USA) before use.
Immunization   100 µg of pAP globin in 25 µl saline was mixed with 25 µl incomplete
Freund's adjuvant (Sigma-Aldrich GmbH) and injected into the hind footpads of BALB/c
mice. 
Generation of T-cell hybridomas   T-cell hybridomas were generated as described
previously (Chapter 7, Wulferink et al, submitted). In short,  lymph node cells from
immunized mice were restimulated in TC medium with the appropriate antigen for 2 days.
The activated T cells were expanded for a further two days using EXC5 supernatant. The
resulting T-cell blasts were fused with BW5147 thymoma cells using polyethylene glycol
1500 (Boehringer, Mannheim, Germany), as described by the manufacturer. Hybridomas
reacting to pAP globin in T-cell hybridoma stimulation assays were subcloned twice by
limiting dilution.
Preparation of ConA blasts   Spleens cells of untreated BALB/c mice were cultured for 24 h
with Concanavalin A (ConA, 1.25 µg/ml). Cells were washed twice and cultured for another
24 h in TC medium. After washing, they were used in the T-cell hybridoma stimulation assay
for detection of IL-2 secreted by Ag-specific hybridomas.  
T-cell hybridoma stimulation assay using IL-2 dependent ConA blasts (Fig. 1)
Hybridomas (1x105) were cocultured with syngeneic spleen cells acting as APCs (5x105) in
the presence or absence of antigen. After 24 h, culture supernatants (50 µl) were transferred to
a new 96-well plate, frozen at -70°C, and after thawing tested for the presence of IL-2 by
adding  IL-2-dependent ConA blasts (2x104 in 50 µl). After 18 h, 18.5 kBq [3H]thymidine
was added. Six hours later, cells were harvested and [3H]thymidine incorporation was
measured. Experiments were done in triplicate cultures and performed twice to ensure
reproducibility.
T-cell hybridoma stimulation assay using the CellELISA (Fig. 1)   96-Well plates were
coated with either purified anti-IL-2 ( 2 µg/ml) or anti-IL-4 (2 µg/ml) mAb overnight at 4° C.
They were blocked with 1% BSA in PBS for 2 h at RT and washed three times with PBS. All
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solutions were sterile filtered before use. Hybridomas (1x105) were cocultured with syngeneic
spleen cells acting as APCs (5x105) in the presence or absence of antigen or native globin.
After 24 h plates were washed three times with wash solution (PBS containing 0.5 % Tween-
20) and incubated for 2 hours at RT with biotinylated anti-IL-2 (1 µg/ml) or anti-IL-4 (1
µg/ml) mAb, respectively. Plates were washed three times with wash solution, incubated with
streptavidin-horseradish-peroxidase (1:2000 in PBS) for 30 minutes at RT and washed 5 times
with wash solution. Plates were developed using OPD tablets (Sigma-Aldrich GmbH) as
described by the manufacturer and measured using a 96-well-plate reader (Dynex
Technologies, Denkendorf, Germany).
Purification of CD4+ T cells   Spleen cells of untreated C57BL/6 mice were passed over a
nylon wool column to enrich T cells. Enriched T cells were stained with magnetically labeled
anti-I-Ad mAbs, washed and passed through an AutoMACS (Miltenyi GmbH) according to
the manufacturers Protocol (Protocol: DepleteS). The negative fraction, depleted of APC was
stained with magnetically labeled anti-CD8a mAbs, washed and passed through an
AutoMACS (Protocol: DepleteS). The resulting enriched CD4+ T cells had less than 2%
contaminating APC as determined by flow cytometry using FITC-labeled anti-I-Ab mAbs.
T cell stimulation assay   96-Well plates were coated overnight at 4°C with 50 µl binding
solution (0.1 M Na2HPO4, adjusted to pH 9.0 with 0.1 M NaH2PO4) containing 5µg/ml
anti-CD3 and 1 µg/ml of either anti-IL-2, anti-IL-4, or isotype control. Plates were blocked
with 1% BSA in PBS for 2h at RT and washed three times with PBS containing 0.5% Tween.
Purified CD4+ splenic T cells from untreated C57BL/6 mice were plated at a densitiy of 2x105
cells per well and incubated with different concentrations of anti-CD28. After 2 days, the
plates coated with anti-IL-2 and anti-IL-4 were developed as described above (CellELISA).
From the plates coated with isotype control, supernatant was taken for a sandwich-ELISA and
the IL-2 bioassay, respectively. 
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Figure 1. Schematic overview of the three different methods used for measuring cytokine
secretion of T-cells: (A) sandwich ELISA, (B) CellELISA, and (C) cytokine bioassay. For
detailed description, see Materials and Methods.
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Figure 2. Sensitivity of the CellELISA in comparison to the sandwich-ELISA and the
cytokine bioassay. Splenic CD4+ T cells were stimulated in 96-well plates coated with anti-
CD3 in combination with either anti-IL-2 or anti-IL-4 for CellELISA, or isotype control mAb
for sandwich-ELISA and cytokine bioassay. Soluble anti-CD28 was added in different
concentrations and after 48 h, cytokine production was measured by either directly developing
the CellELISA plates or transferring supernatants to the sandwich-ELISA or cytokine
bioassay plates (see Materials and Methods and Fig. 1). Results of two independent
experiments are shown (A and B, respectively). 
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Results and Discussion
Sensitivity of the different T cell activation assays
We first determined the sensitivity of the conventional sandwich ELISA, the
CellELISA, and the cytokine bioassay. For this we stimulated purified splenic
CD4+ T cells of C57BL/6 mice with plate-bound anti-CD3 and different
concentrations of anti-CD28. Fig. 2 shows stimulation indices in relation to anti-
CD28 concentration for the different T cell activation assays tested in two
independent experiments (Fig. 2A and 2B, respectively). In the first test
(Fig. 2A), sensitivity of the IL-2 CellELISA was comparable with that of the
cytokine bioassay. In the second test (Fig. 2B), the CellELISA was more
sensitive in the lower range of T cell activation (10-30 ng/ml anti-CD28) but
with higher anti-CD28 concentrations, the stimulation indices of the cytokine
bioassay exceeded that of the IL-2 CellELISA. Compared with the sandwich
ELISA, sensitivity in the lower range was higher in the CellELISA in both
experiments. In the second experiment, the stimulation indices obtained with
higher concentrations of anti-CD28 in the sandwich ELISA also exceed that
obtained in the CellELISA. A comparison of experiment 1 and 2 shows less
interexperimental variation with CellELISA compared to the sandwich ELISA
and the cytokine bioassay over the whole range of T cell stimulation.
Comparison of the CellELISA and bioassay for the screening of newly
generated T-cell hybridomas
To compare the suitability of the CellELISA for screening newly generated
T-cell hybridomas, we compared the IL-2 CellELISA and the IL-4 CellELISA
with the cytokine bioassay, used by many investigators for detection of antigen-
specific hybridomas. Table 1 shows a comparison of the CellELISA and the
cytokine bioassay with regard to identification of specific T-cell hybridomas. A
total of 128 hybridomas were tested for recognition of pAP globin, the antigen
used for immunization. 42 of these 128 hybridomas were positive (SI > 2) in at
least one of the tests used; these are shown in Table 1. Of these 42 hybridomas,
29 could be identified as specific in all three tests. From the 13 hybridomas
negative in at least one of the tests, six were negative in the cytokine bioassay
but positive in either the IL-4 (1 hybridoma) or the IL-2 and the IL-4
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(5 hybridomas) CellELISA. Another six of these hybridomas were negative in
the IL-4 CellELISA but positive in both IL-2 CellELISA and bioassay. From the
Table 1. Stimulation indices of specific T-cell hybridomas using the IL-2 and
IL-4 CellELISA, and the cytokine bioassay
Hybridoma IL-2a IL-4b 3[H]c Hybridoma IL-2 IL-4 3[H]
Hybridomas positive in all three tests Hybridomas negative in all three tests
1A1 16 3 4 1B6 1 1 <1
1A2 32 5 7 1C4 1 1 1
1A4 32 8 4 + 84  hybridomas with similar results 
1B2 13 5 2
1B3 18 10 5 Hybridomas negative in the cytokine bioassay
1B5 14 10 5 1A3 32 5 1
1C1 15 5 4 1A6 17 3 <1
1C2 22 15 5 2A4 54 11 1
1C3 25 5 4 2B4d 1 3 1
1C5 11 4 5 2C4 3 4 <1
1C6 24 3 7 2D2 50 27 <1
1D1 26 4 4
1D3 18 6 8 Hybridomas negative in the IL-4 CellELISA
1D4 22 3 5 1A5 6 1 2
1D5 23 2 7 1B1 4 <1 3
1D6 4 3 5 1B4 18 1 4
2A2 12 3 5 1D2 8 <1 5
2A3 21 4 4 2A1 4 <1 3
2A5 17 12 4 2A6 11 1 8
2B1 10 2 5
2B2 9 4 9 Hybridomas negative in the IL-2 CellELISA
2B3 12 11 6 2B4d 1 3 1
2B5 22 2 9 2B6 1 2 6
2C1 42 9 5
2C2 3 11 10
2C3 11 14 6 Average index of positive hybridomas:
2C5 37 20 2 IL-2a: 19.8 ± 12.8
2C6 34 15 7 IL-4b: 7.3 ± 5.7
2D1 41 8 7 3Hc: 5.3 ± 2.0
a Stimulation index obtained with IL-2 CellELISA
b Stimulation index obtained with IL-4 CellELISA
c Stimulation index obtained with cytokine bioassay
d Hybridoma 2B4 was negative in the cytokine bioassay as well as in the IL-2 CellELISA
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Figure 3. Comparison of CellELISA and cytokine bioassay using two established pAP
globin-specific T-cell hybridomas (A and B, respectively). APCs, T-cell hybridomas and
different concentrations of antigen were cocultured in a plate coated with either anti-IL-2 or
anti-IL-4 for CellELISA, or non-coated for the cytokine bioassay. After 24 hours, cytokine
production was measured by either directly developing the CellELISA plates or transferring
supernatants to cytokine bioassay plates (see Materials and Methods). SIs were calculated by
dividing the values of cultures with antigen by the values of cultures without antigen. Shown
are SI ± SD of six replicate cultures. 
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two hybridomas that were rejected by the IL-2 CellELISA both were identified
by the IL-4 CellELISA and one of them also by the cytokine bioassay. All
hybridomas were retested to assure that no false positive reactions were
obtained. In conclusion, none of the tests used were able to identify all of the
specific T-cell hybridomas. The IL-2 CellELISA however, showed the least
frequency of false negative test results (4.5%). Both the IL-4 CellELISA and the
cytokine bioassay demonstrated the same frequency of false negative results
(13.6%). If average indices of positive hybridomas were compared, IL-2
CellELISA showed the highest indices, followed by the IL-4 CellELISA
(Table 1). This means that discrimination of positive and negative T cell-
hybridomas is easier in both CellELISAs than it is in the cytokine bioassay.
Comparison of CellELISA and cytokine bioassay for testing established
T-cell hybridomas
After initial screening and subsequent subcloning of specific T-cell hybridomas,
the next step will generally be to show dose-dependency, fine specificity, and/or
MHC-dependency. To test whether the CellELISA is adequate for this purpose,
we used a total of 7 established and subcloned T-cell hybridomas to compare the
CellELISA with the cytokine bioassay. Fig. 3 shows the dose dependency
reaction of two representative hybridomas. Hybridoma 1A10 (Fig. 3A) showed
comparable reactions in IL-2 CellELISA and IL-4 CellELISA. The cytokine
bioassay was less sensitive with this hybridoma. Hybridoma 1B4 produced a
higher SI in the IL-2 CellELISA than both the IL-4 CellELISA and the cytokine
bioassay. In conclusion, all three assays are useful for further studying
established and subcloned hybridomas. However, these results and those
obtained with 5 other hybridomas (data not shown) show that the IL-2
CellELISA is more sensitive than both the IL-4 CellELISA and the cytokine
bioassay. This makes the IL-2 CellELISA more suitable for inhibition
experiments where an initially high stimulation index is required to show
(relative) inhibition by antibodies or chemicals.
In conclusion, the CellELISA is suitable for rapid screening of newly
generated hybridomas as well as for the characterization of established
hybridomas. The advantage of the CellELISA in comparison to the normal
sanwich ELISA is its lower workload and higher sensitivity, especially in the
lower range of cytokine secretion. A recent publication depicted that measuring
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cytokine secretion by sandwich ELISA is influenced by the consumption of
cytokines by the cells (17). Consequently, if a limited amount of cytokines is
secreted, it may be consumed almost completely and therefore leave no
cytokines to be detected by the sandwich ELISA. In contrast, in the CellELISA
this effect is negligible, as the cytokines are rapidly bound to the plate after
being secreted. Consumption of cytokines by cells can explain both the lower
sensitivity of the sandwich ELISA in the range of 10-30 ng/ml anti-CD28,
where all cytokines may be consumed by the cells, as well as the higher
stimulation indices in the range of 100-1000 ng/ml. In this range, the cytokines
consumed by the cells induce cell proliferation and activation with subsequent
cytokine production, which are consumed by the cells, and so on, and so forth.
This "snowball effect" is absent in the CellELISA, as the cytokines needed for
proliferation are caught and held by the antibodies coated to the well.
Compared with the cytokine bioassay, the CellELISA has similar
sensitivity, but the interexperimental variance is lower in the latter. This might
be due to the use of ConA blasts in the cytokine bioassay, which brings an extra
variable into the test system. The use of non-radioactive materials in the
CellELISA may also be seen as an advantage. 
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CHAPTER 9
General discussion
Introduction
In this thesis, mechanisms involved in chemical-induced allergy and
autoimmunity were investigated. A major difficulty in studying the mechanisms
of chemical-induced adverse immune effects is the fact that the ultimate
neoantigens are unknown. In Chapter 2 we discussed some of the steps possibly
involved in the formation of the neoantigens and subsequent T cell recognition.
We could substantiate the hypothesis that extrahepatic metabolism plays an
important role in the formation of neoantigen with the prohaptens procainamide
and aniline in Chapters 4 and 5, respectively. In Chapter 7, the processing of
protein adducts, presentation of neoantigens and subsequent recognition of
either haptenated peptides or cryptic peptides by T cells was shown.
Furthermore, Chapter 7 elucidates some of the mechanisms involved in cross-
sensitization and discusses the possible implications of T-cell cross-reactivity in
chemical induced allergy and autoimmunity.
Metabolism
Model haptens like trinitrophenol (TNP), dinitrochlorobenzene (DNCB) or
dinitrofluorobenzene (DNFB) can directly bind to proteins (1-3). However, most
chemicals that humans come into contact with in daily life, like drugs and dyes,
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are not protein-reactive perse but can be converted into reactive metabolites in
the human body. In Chapters 3, 4 and 5 we showed for benzene, procainamide
and aniline, respectively, that formation of protein-reactive metabolites is a
prerequisite for the induction of chemical-induced allergy and autoimmunity. 
Hepatic metabolism of chemicals. The main organ for metabolic
conversion of chemicals is the liver. In comparison with its high metabolic
activity however, adverse immune reactions in the liver are relatively rare. This
might be due to the fact, that protein-reactive metabolites formed in the liver are
detoxified by glutathion-conjugation, glucuronidation, or other detoxifying
mechanisms which render them unavailable for conjugation with self-proteins
(4). Furthermore, the environment in the liver (cytokines and specialized cells)
seems to have a tolerogenic rather than activating effect on T cells (5,6).
Extrahepatic metabolism. Quantitatively, extrahepatic metabolic
conversion of chemicals is less important than hepatic metabolism. Nonetheless,
extrahepatic metabolism of chemicals, especially by cells of the immune system,
appears to play a crucial role in the induction of chemical-induced allergy or
autoimmunity (Chapter 2). An antigen presenting cell (APC) can, on its own,
convert a prohapten into a protein-reactive hapten and, after adduct formation
with a cytoplasmic self-protein, process and present the newly formed adduct to
T cells. In Chapters 4 and 5 we showed extrahepatic formation of  T cell
sensitizing metabolites after pulsing phagocytic cells with procainamide and
aniline, respectively. 
Processing and Presentation
After adduct formation, protein-hapten adducts are processed by the APCs'
processing machinery. The resulting peptides can then be presented by MHC
molecules on the cell surface (7). Only few of the hapten-protein conjugates
formed after exposure to chemicals are processed in such a way, that fragments
are presented as neoantigens on MHC molecules. In Chapter 7, we showed that
such neoantigens can either be hapten-peptide conjugates, or cryptic peptides
(see also Chapter 1). Presentation of hapten-peptide conjugates and subsequent
recognition by T cells leads to allergic reactions, whereas presentation of cryptic
peptides, i.e. native self-peptides that are normally not presented, might lead to
autoimmunity. 
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T cell recognition
A key feature in the induction of chemical-induced allergy and autoimmunity
seems to be activation of T cells specific for the respective chemical (Chapters
2-4, 6). In many cases of drug-induced allergy, the existence of specific T cells
could be confirmed by in vitro restimulation of patient T cells with the causal
drug (8) or one of its reactive metabolites (9, reviewed in 10). Although drug-
specific T cells could be identified in allergic patients, the specificity was not
always perfect as cross-reactions to chemicals that were not causal for the
induction of the allergy, were frequently observed (11). In Chapter 7 we
investigated the mechanisms of such cross-sensitization. We observed
conversion of different prohaptens into identical haptens as well as presentation
of identical cryptic peptides after APCs were pulsed with different hapten-
protein adducts. However, these mechanisms may both be interpreted as false
T cell cross-reactivity, as the T cell itself does not cross-react to different anti-
gens but instead, different chemicals lead to an identical neoantigen. In addition,
we demonstrated true cross-reactivity, i.e., a single TCR cannot distinguish
among different haptens. At first glance, T cell cross-reactivity may not seem to
be consistent with the dogma of "one clone - one specificity". However, in a
theoretical review, Mason (12) argues that given a relatively small number of
T cells and an enormous numerical excess of viral and microbial peptides,
T cells must be able to cross-react with several thousands of different peptides in
order to mount a rapid immune response. Additional theoretical support for true
cross-reactivity of the TCR comes from the "avidity pit" model of Sandberg et al
(13). Their model postulates that TCR signaling can be set in motion by
enhancing the avidity of TCR-MHC-complex interactions rather than by
absolute recognition of a given antigen. They argue that in the thymus, T cells
are positively selected by their ability to recognize self-peptide-MHC complexes
with low avidity. In the periphery, these T cells would be activated by peptides
possessing higher avidity for the TCR than those by which they were originally
selected. By altering a self-peptide, the avidity of the T cell towards the peptide
could be enhanced. When a certain threshold, the 'avidity threshold' is reached,
the T cell would be activated. Both Mason's and Sandberg's theory are discussed
in more detail in Chapter 7. While Mason (12) and Sandberg et al (13) provide
theoretical evidence for true cross-reactivity to different peptides,  Grogan et al.
(14) experimentally showed that, indeed, T cells specific for one peptide of
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myelin basic protein cross-react with a dozen different microbial peptides.
Similarly, with respect to haptens, we showed in Chapter 7 that T cells specific
for a given para-compound truly cross-react to at least three other para-
compounds that were metabolically not related. 
Role of NKT cells in
chemical induced allergy and autoimmunity
A few years ago three independent sets of studies led to the discovery of a new
kind of T cell that bears markers, normally expressed on NK cells (15-17).
These so called NKT cells are thought to play a major role in the maintenance of
(self-)tolerance and induction of autoimmunity (18-21). They express a
restricted TCR repertoire made of an invariant TCR α chain, Vα14-Jα281,
Figure 1.   Three dimensional view of α-galactosylceramide (A) and PAP ester (B).
α-Galactosylceramide, which is isolated from a marine sponge, is known to activate NKT
cells (22). It is conceivable that, considering the similarity of the hydrophobic parts, PAP
ester can likewise be presented by CD1. The hydrophilic part is then directed away from the
CD1 molecule to be recognized by the NKT cells' TCR.
associated with polyclonal Vβ8, Vβ7 and Vβ2 TCR β chains (reviewed in Ref.
21). In contrast to classical T cells, NKT cells do not recognize antigen on the
MHC, but on CD1, a highly conserved, MHC-like molecule on the surface of
APCs (23) and intestinal epithelial cells (24). CD1 molecules can present lipids
and other hydrophobic antigens to NKT cells, which can secrete high levels of
Chapter 9 177
IFN-γ and IL-4 upon first encounter of these antigens (25,26). This led us to
believe that NKT cells might play a role in the induction of the toxic oil
syndrome (TOS), which was elicited after the ingestion of rape seed oil
contaminated with aniline (Chapter 5). Esters of fatty acids with 3-(N-
phenylamino)-1,2-propandiol (PAP ester) were found in case oils of TOS (27)
and are at present considered to be responsible for induction of the syndrome
(28). Considering the similarity of PAP ester with α-galactosylceramide (Fig. 1),
which is known to be presented by CD1 and can activate NKT cells (22), it is
conceivable that PAP esters can be presented by CD1 and directly activate NKT
cells. Upon activation, NKT cells do not proliferate but directly produce large
amounts of IL-4 and IFN-γ. Consequently they do not acquire memory and do
not mount secondary responses. These new theories involving NKT cells and the
difficulty in inducing secondary immune responses against the aniline coupled
lipids in our previous investigations stimulated us to investigate the role of NKT
cells in TOS. For this purpose a pilot experiment was performed using NKT cell
deficient Jα281-/- mice (Chapter 6). The results of these experiments show that
NKT cells, at least invariant Vα14-Jα281+, do not play a role in the lymph node
enlargement seen after injection of PAP ester. Studies whether "non-invariant"
NKT cell may have played a role in the human pathogenesis are underway.
Outlook
During drug development, the time-point that adverse immune effects are
discovered is mostly in the late clinical phase, when a great number of
volunteers or patients are being treated with the drug. Sometimes, adverse
immune effects are not seen before the drug has been officially released to the
market. Thus, although only few people suffer from drug-induced adverse
immune effects, the costs (illness, withdrawal of the drug, etc.) can be
enormous. The risk that a certain individual suffers from chemical-induced
adverse immune effects is dependent on numerous factors, including the panel
of metabolizing enzymes, MHC alleles, chemical dose and route of exposure,
etc. These factors and their role in chemical induced adverse immune effects are
discussed in Chapter 2. They shape the environment in which a T cell
encounters its antigen and, in line with the avidity thresholds theory of Sandberg
et al (13), determine if the avidity of T-cell-antigen interactions reaches the
avidity threshold needed for T cell activation. All these factors concern only
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signal 1, i.e., recognition of the antigen by the TCR. Other factors, e.g.,
simultaneous virus or bacterial infections, oxidative stress produced by
chemicals, etc., can induce costimulation, which is necessary for activation of
T cells and consequent initiation of unwanted immune reactions.
More information on the mechanisms involved and a suitable animal test
model for chemical induced allergy and autoimmunity might help to identify
"unsafe" drugs at an early stage and thus save quality of human life and reduce
health costs. Recent developments in genomics may result in the development of
more personalized drug therapy (29). By using, e.g., cDNA microarray
technology (30), variances in an individuals' drug-detoxifying enzyme panel, or
certain HLA alleles known to predispose for allergic reactions can be identified.
With this knowledge, choice of drug and drug-dose schemes can be fine-tuned
accordingly, thereby reducing the risk of adverse drug-reactions, including those
mediated by the immune system. For example, the higher incidence of
procainamide-induced lupus in slow acetylators, which have a lower activity of
N-acetyltransferase-2 (31), can be neutralized if the drug dose is corrected
accordingly (32). Slower detoxification of procainamide by N-acetyl-
transferase-2 enzyme in the liver leads to higher levels of the drug in the
periphery, where neutrophils and mononuclear leukocytes can convert the drug
into its protein-reactive metabolite N-hydroxylamino-procainamide (33) leading
to accumulation of neoantigen and higher incidence of procainamide-induced
lupus (34). Furthermore, awareness of the need for metabolic conversion and
knowledge of the metabolic pathway of drugs may help in drug-development
and drug-testing. This knowledge may help to develop animal models that
represent a human population which is most sensitive to adverse immune effects
of a certain drug-group. Genomics may be helpful in this respect too: a special
tool can analyze changes in human gene transcription in response to
environmental agents. This so called ToxChip enables quick identification of
changes in the expression of enzymes, such as induction of PGHS-2 after
procainamide exposure (Chapter 4), cytokines, costimulatory molecules on
APC, etc. (35). As the ToxChip shows possible adverse immune effects before
the effector phase starts and damage is inflicted to the individual, it can be used
in drug-screening as well as in individual drug treatment. However, at the
moment the costs for such a screening are tremendous and it will take some
years before this can be done routinely. 
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In summary, this thesis aims towards a better understanding of the
mechanisms that lead to chemical-induced adverse immune effects. We focussed
thereby on the initial induction stage of the immune reaction that consists of
three major steps: (i) formation of neoantigen, (ii) processing and presentation of
the neoantigen, and (iii) recognition of peptide-MHC-complex by the T cell.
The first step, formation of neoantigen, i.e., extrahepatic metabolism of a
prohaptenic chemical into a haptenic, protein reactive intermediate and binding
of this hapten to self-proteins was shown in Chapters 4, 5 and 7. Although
other groups showed recognition of non-covalently bound, non-protein reactive
drugs (36,37) we found that the prohaptens benzene, procainamide and aniline
could not induce specific T cell reactions, whereas p-benzoquinone, N-hydroxyl-
procainamide, and nitrosobenzene could.
The second step, processing of the formed neoantigen and presentation of
haptenated self-peptides or cryptic peptides on MHC molecules of APCs was
implicitly shown in Chapters 3, 4, and 5 and explicitly shown in Chapter 7.
Here we blocked the MHCII molecules of APCs pulsed with whole protein
adduct, thereby completely inhibiting T cell recognition of the formed
neoantigen. 
This leads us to the third step, recognition of the peptide-MHC-complex
by T cells, specific for the neoantigen. In Chapter 7, we showed that T cells not
only specifically recognize the  hapten-peptide adduct, but cross-react to similar
haptens coupled to the same peptide, as well as to cryptic peptides. The fact that
there is true cross-reactivity to haptens may on the one hand be favorable with
regard to measures taken to desensitize individuals allergic to chemicals. On the
other hand, cross-reactivity should be taken into consideration when, after drug-
induced adverse immune reactions have occurred, an alternative drug has to be
chosen. The fact that haptenation of self-proteins raises T cells that react to
cryptic self-peptides might be relevant for drug-induced autoimmunity, as here
the immune reaction, though induced by a foreign chemical, is now directed
towards a self-antigen. 
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Korte samenvatting
De belangrijkste opgave van het immuunsysteem is ervoor te zorgen dat
ziekteverwekkers (virussen, bacteriën, schimmels en parasieten) worden
herkend, aangevallen en afgebroken. Naast macrofagen spelen T cellen en B
cellen een belangrijke rol in de afweerreacties tegen indringers. De macrofagen
kunnen indringers opsporen en delen ervan aan de T cellen presenteren. T cellen
kunnen dan op verschillende manieren reageren: Ze kunnen óf de cellen die het
herkende antigeen presenteren vernietigen (cytotoxische T cellen), óf B cellen
helpen tegen de indringers antilichamen te vormen (T helper cellen). 
Bepaalde chemische verbindingen (bijv. geneesmiddelen) kunnen er
echter voor zorgen dat het immuunsysteem op een ongewenste manier reageert.
Ongewenste reacties van het immuunsysteem tegen chemische verbindingen
worden ook wel allergische reacties genoemd. Reageert het immuunsysteem
onder invloed van chemische verbindingen tegen lichaamseigen structuren
spreken we van auto-immuunziekten. Om beter te begrijpen hoe chemische
verbindingen het immuunsysteem kunnen beïnvloeden en een allergische of
auto-immuunreactie kunnen veroorzaken, is in hoofdstuk 1 beschreven hoe het
lichaam ervoor zorgt, dat gereageerd wordt tegen indringers (vreemd) maar niet
tegen het eigen lichaam (zelf). Een aantal factoren spelen hierbij een rol:
herkenning van de vreemde structuur (antigeen), herkenning van gevaar (co-
stimulatie) en, indien het immuunsysteem het antigeen reeds eerder is
tegengekomen, hoe deze primaire immuunreactie verlopen is (specifiek
immunologisch geheugen). Om te kunnen voorspellen hoe bepaalde chemische
stoffen het immunologische evenwicht verstoren, is het noodzakelijk om de
antigenen waar tegen de immuunreactie is gericht te kennen. Dit is voor de
meeste chemisch-geïnduceerde ongewenste immuunreacties nog niet voldoende
bekend. In dit proefschrift is een aanzet gemaakt, deze antigenen beter te
karakteriseren en de mechanismen die ertoe leiden dat allergische of auto-
immuunreacties ontstaan beter te begrijpen.
In hoofdstuk 2 wordt ingegaan op de verschillende factoren die leiden tot
het ontstaan van nieuwe, gemodificeerde zelfantigenen (neo-antigenen). Een
belangrijke rol hierbij spelen enzymen die chemische stoffen omzetten in
metabolieten, die óf onschadelijk zijn en worden uitgescheiden, óf schade
aanrichten door aan lichaamseigen eiwitten (zelfproteïnen) te binden. Deze
schadelijke, proteïn-reactieve metabolieten worden ook wel haptenen genoemd,
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de stoffen waaruit ze zijn ontstaan, prohaptenen. Omdat niet elke mens dezelfde
enzymen bezit, zijn sommige mensen beter in staat chemische stoffen
onschadelijk te maken dan andere mensen. Dit is o.a. een reden waarom
sommige mensen allergisch op bepaalde geneesmiddelen reageren en anderen
deze meerdere jaren achtereen zonder problemen in kunnen nemen. Om te
kunnen voorspellen of een bepaald geneesmiddel goed wordt verdragen, is het
noodzakelijk de enzymen die voor de ontgifting én voor de vorming van
reactieve metabolieten verantwoordelijk zijn te kennen. Belangrijk hierbij is dat
de cellen van het immuunsysteem zelf, en niet de lever, bij het ontstaan van
immunologisch relevante reactieve chemische stoffen de hoofdrol spelen. Een
ander belangrijk aspect in het ontstaan van immuunreacties tegen chemische
stoffen is aanwezigheid van co-stimulerende signalen. Deze kunnen bijv.
ontstaan door schade die de metabolieten in weefsels aanrichten, of door
gelijktijdige infecties met virussen of bacteriën.
In hoofdstukken 3, 4 en 5 kon worden aangetoond dat alleen haptenen,
(proteïn-reactieve chemische stoffen) een immuunreacties kunnen veroorzaken.
Dit werd gedaan m.b.v. de popliteale lymfeklier test, waarbij de te onderzoeken
stof in de achterpoot van muizen wordt geïnjecteerd en daarna naar de zwelling
van de lymfeklier die in direct contact staat met de plaats van injectie
(drainerende lymfeklier) wordt gekeken. Hierbij kon worden aangetoond dat
macrofagen, prohaptenen in haptenen kunnen omzetten. Ook kon een adduct
bestaande uit hapteen en een 35 kD groot zelfproteïn zichtbaar gemaakt worden.
De vraag of dit neo-antigeen daadwerkelijk voor de ongewenste immuunreacties
tegen het hier onderzochte geneesmiddel (procainamide) verantwoordelijk is,
wordt op het moment onderzocht.
Een aantal jaren geleden is er een nieuw soort immuun-cel ontdekt, de
zogenaamde natuurlijke killer T cel (NKT cel). Deze cel kan relatief snel, maar
niet zeer specifiek bepaalde antigenen herkennen en hier tegen reageren. Het
bijzondere aan deze cellen is, dat ze niet, zoals T cellen, tegen eiwit-brokstukken
reageren, maar tegen vetten. Ook blijken ze een belangrijke rol te spelen bij het
ontstaan, maar ook bij het verhinderen van auto-immuunziekten. Een auto-
immuunziekte waarbij NKT cellen mogelijk een rol zouden kunnen spelen, is
het Spaanse toxische olie syndroom, waarbij duizenden mensen ziek werden na
het eten van olie, besmet met aniline. In hoofdstuk 5 kon m.b.v. de popliteale
lymfeklier test worden aangetoond dat vetzuur-aniline verbindingen, die
aanwezig waren in de besmette olie een immuunreactie konden veroorzaken. In
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hoofdstuk 6 konden wij echter m.b.v. gentechnisch gemodificeerde muizen
aantonen, dat de kwantitatief grootste subgroep van NKT cellen hierbij geen rol
speelt. Extra onderzoek is echter nodig om de rol van andere soorten van
NKT cellen in het ontstaan van het toxische olie syndroom te kunnen
onderzoeken.
Naast de tot nu toe beschreven onderzoeken, die erop gericht waren de
cellen van het immuunsysteem die verantwoordelijk zijn voor de inductiefase
van ongewenste immuunreacties te identificeren, is er ook een poging gedaan
om op het niveau van neo-antigeen herkenning door T cellen een beter beeld te
krijgen van wat er zich hier afspeelt. Hiervoor zijn muizen tegen bepaalde
chemische stoffen allergisch gemaakt. De T cellen van deze muizen zijn daarna
gefuseerd met tumorcellen, waardoor ze oneindig doorgroeien. Deze zijn zo
verdunt, dat elke hieruit resulterende populatie uit slechts één cel ontstaan is
(kloneren). Deze T celklonen zijn onderzocht op herkenning van verschillende
chemische stoffen die aan één en hetzelfde zelfproteïne zijn gekoppeld. Uit de
resultaten, die beschreven staan in hoofdstuk 7, kan geconcludeerd worden, dat
T cellen niet zo specifiek op een bepaalde chemische stof reageren als vroeger
werd gedacht. Eén en dezelfde T cel kan verschillende chemische stoffen
herkennen en hiertegen reageren. Gezien de taak van het immuunsysteem is dit
ook niet erg verwonderlijk. Het immuunsysteem moet namenlijk zeer veel
verschillende antigenen herkennen en hiertegen reageren. Het immuunsysteem
weet tijdens zijn ontwikkeling echter niet welke antigenen er allemaal op de
wereld bestaan (en zal de meeste ook nooit tegen komen). Het moet dus op alles
voorbereid zijn. Alhoewel een mens meerdere miljarden T cellen bezit, zouden
deze, wanneer elke T cel slechts één theoretisch mogelijk antigeen zou
herkennen, niet in staat zijn alle mogelijke indringers te herkennen en tijdig te
vernietigen. Kruisreactiviteit is dus niet zoals vroeger werd gedacht een
uitzondering, maar een noodzakelijkheid van T cellen.
Uit dit proefschrift blijkt, dat vele factoren bij het ontstaan van chemisch-
geïnduceerde allergiën en auto-immuunziekten een rol spelen. De belangrijkste
zijn: het ontstaan van chemisch reactieve metabolieten die met zelfproteïnen
reageren en zo neo-antigenen vormen, co-stimulatie, en tenslotte activering van
T cellen die (kruis)reageren met de ontstane neo-antigenen. De resultaten uit dit
proefschrift kunnen helpen immunologische risico's van bijv. geneesmiddelen
beter in te schatten en eventueel de dosis zo aan te passen, dat het risico op
ongewenste immunologische bijwerkingen gering blijft. Nieuwe technieken uit
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andere disciplines (bijv. genomics) kunnen hierbij helpen, indien snel en
accuraat een analyse van verschillende enzymen en weefselantigenen
(histocompatibiliteits-complexen) wordt gemaakt. Op basis van deze analyse en
de chemische eigenschappen van verschillende geneesmiddelen kan dan worden
bepaald welk geneesmiddel in welke dosering zal worden gegeven.
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Kurze Zusammenfassung
Eine der wesentlichsten Aufgaben des Immunsystems ist die Abwehr von
eindringenden Krankheitserregern wie Viren, Bakterien, Pilzen und Parasiten.
Dem unspezifischen und spezifischen Immunsystem stehen eine Anzahl
unterschiedlicher Zellsorten zur Verfügung: für die unspezifische Abwehr
insbesondere die Makrophagen, für die spezifische Abwehr T- und B-Zellen.
Makrophagen können die Krankheitserreger aufnehmen (daher auch als
"Freßzellen" bezeichnet) und präsentieren anschließend Teile dieser Erreger den
T-Zellen. Die T-Zellen können dann auf verschiedene Weise reagieren:
Entweder zerstören sie jene Zellen, die das erkannte Antigen präsentieren
(zytotoxische T-Zellen), oder sie helfen den B-Zellen Antikörper gegen die
Krankheitserreger zu bilden (Helfer-T-Zellen).
Bestimmte Stoffe (z.B. Medikamente) können jedoch unerwünschte
Reaktionen des Immunsystems verursachen. Eine dieser unerwünschten
Antworten ist die allergische Reaktion. Reagiert das Immunsystem unter dem
Einfluß von chemischen Verbindungen gegen körpereigene Strukturen, spricht
man von Autoimmunerkrankungen. Um besser verstehen zu können, wie
chemische Verbindungen das Immunsystem beeinflussen und allergische- bzw.
Autoimmunreaktionen hervorrufen, wird in Kapitel 1 beschrieben, wie das
Immunsystem zwischen "Eindringlingen" (Nicht-Selbst) und körpereigenen
Strukturen (Selbst) zu unterscheiden vermag. Hierbei spielen folgende Faktoren
eine Rolle: Erkennung der fremden Struktur (Antigen), Erkennung von Gefahr
(Co-Stimulation) und für den Fall, daß das Immunsystem bereits früher Kontakt
mit dem Antigen hatte, die Erinnerung an die damalige Primärantwort
(spezifisch immunologisches Gedächtnis: Zweitantwort, Toleranz). Um
vorhersagen zu können, wie bestimmte Chemikalien das immunologische
Gleichgewicht stören, ist die genaue Kenntnis der antigenen Struktur
Voraussetzung. Diese Strukturen sind leider bis heute noch wenig bekannt. Ziel
dieser Arbeit war es, diese Antigene besser zu charakterisieren und die
Mechanismen, die zur Entstehung von allergischen- bzw. Autoimmunreaktionen
führen, besser zu verstehen.
In Kapitel 2 wird auf die verschiedenen Faktoren, die zur Entstehung von
neuen, veränderten Selbstantigenen (Neo-Antigenen) führen, eingegangen.
Hierbei spielen Enzyme welche die Substanzen metabolisieren eine wichtige
Rolle. Neben stabilen Verbindungen entstehen hierbei auch protein-reaktive
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Metabolite, die an körpereigene Eiweiße (Selbstproteine) binden können und so
Neo-Antigene formen. Da nicht jeder Mensch die gleiche Enzymausstattung
besitzt, sind manche Menschen eher in der Lage bestimmte Stoffe zu "entgiften"
als andere. Daher reagieren manche Personen allergisch auf ein bestimmtes
Medikament, wohingegen andere dasselbe Medikament jahrelang ohne
Probleme einnehmen können. Die Vorhersage ob ein bestimmtes Medikament
vertragen wird, ist jedoch dadurch erschwert, daß mehrere Enzymketten
ineinandergreifen, wobei die Enzymkombination die zur Eliminierung eines
Stoffes günstig ist, zur Eliminierung eines anderen Stoffes hingegen von
Nachteil sein kann. Interessanterweise spielen bei der Bildung von
immunologisch relevanten reaktiven Chemikalien nicht die Leber, sondern
Zellen des Immunsystems eine entscheidende Rolle. Eine weitere
Voraussetzung für die Entstehung von Immunreaktionen gegen Chemikalien
sind co-stimulierende Signale (Signal 2). Diese entstehen beispielsweise durch
Gewebsschäden, verursacht durch die chemischen Verbindungen selbst oder
durch gleichzeitige Infektion mit Viren oder Bakterien.
In den Kapiteln 3, 4 und 5 konnte gezeigt werden, daß nur chemisch
reaktive d.h. chemische Verbindungen, die an Eiweiße binden,
Immunreaktionen hervorrufen können. Der Nachweis erfolgte unter anderem
mit dem poplitealen Lymphknotentest. Hierbei wird die zu untersuchende
chemische Verbindung in eine der beiden Hinterpfoten einer Maus injiziert und
die Schwellung des drainierenden Lymphknotens mit der unbehandelten Seite
verglichen. Des weiteren konnte gezeigt werden, daß Zellen des Immunsystems
selbst, insbesondere die sogenannten Makrophagen, unreaktive Substanzen in
reaktive, d.h. an Proteine bindende Metabolite umwandeln können. In diesem
Zusammenhang gelang in Makrophagen der Nachweis eines Adduktes
bestehend aus einem Metabolit und einem 35 kD großen Selbstprotein. Die
Frage, ob dieses Addukt tatsächlich für die unerwünschten Immunreaktionen
gegen das untersuchte Medikament (Procainamid) verantwortlich ist, wird zur
Zeit noch untersucht.
Vor einigen Jahren wurde eine neue Art von Immunzellen entdeckt: die
sogenannte natürliche Killer T-Zelle (NKT-Zelle). Diese kann relativ schnell,
jedoch nicht sehr spezifisch, bestimmte Antigene erkennen und dagegen
reagieren. Das Besondere an diesen Zellen ist, daß sie nicht wie klassische
T-Zellen gegen Eiweißbruchstücke reagieren, sondern gegen Fette. Ferner
scheinen sie eine wichtige Rolle sowohl bei der Entstehung als auch bei der
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Verhinderung von Autoimmunerkrankungen zu spielen. Eine
Autoimmunerkrankung bei der NKT-Zellen möglicherweise eine Rolle gespielt
haben, ist das Toxische-Öl-Syndrom, an welchem in den 80er Jahren in Spanien
Tausende nach dem Genuß von mit Anilin verunreinigtem Speiseöl erkrankten.
In Kapitel 5 konnte gezeigt werden, daß Verbindungen welche in jenem Öl
vorkamen im poplitealen Lymphknotentest eine Immunreaktion hervorrufen. In
Kapitel 6 haben wir mit Hilfe von gentechnisch veränderten Mäusen jedoch
gezeigt, daß die quantitativ größte Subgruppe von NKT-Zellen hierbei keine
Rolle spielt. Weitere Untersuchungen sind nötig, um die Rolle anderer Arten
von NKT-Zellen in der Entstehung des Toxischen-Öl-Syndroms zu untersuchen. 
Neben den bisher beschriebenen Untersuchungen, deren Ziel es war die
für die Induktionsphase einer Immunantwort verantwortlichen Zellen zu
identifizieren, wurde auch ein Versuch unternommen auf der Ebene von Neo-
Antigenerkennung durch T-Zellen ein tieferes Verständnis zu erlangen. Hierfür
wurden Mäuse gegen bestimmte chemische Stoffe sensibilisiert. Die
sensibilisierten T-Zellen dieser Mäuse wurden danach immortalisiert und so
verdünnt, daß jede nachfolgend gewachsene Population von einer einzigen
Mutterzelle abstammt (Klonierung). Anschließend wurde die Feinspezifität
einzelner Klone untersucht. Die in Kapitel 7 beschriebenen Ergebnisse zeigen,
daß T-Zellen nicht so spezifisch reagieren, wie bisher gedacht wurde. Ein und
dieselbe T-Zelle kann verschiedene Stoffe erkennen und hiergegen reagieren.
Bedenkt man die Aufgabe des Immunsystems ist dies auch nicht verwunderlich.
Das Immunsystem muß nämlich eine Vielzahl unterschiedlicher Antigene
erkennen. Das Immunsystem weiß zum Zeitpunkt seiner Entwicklung jedoch
nicht, welche Antigene überhaupt auf der Erde bestehen (und wird den meisten
auch nie begegnen). Dennoch muß es theoretisch in der Lage sein gegen all
diese Antigene eine Abwehr aufzubauen. Obwohl der Mensch mehrere
Milliarden T-Zellen besitzt wären diese, insofern eine T-Zelle nur jeweils ein
Antigen erkennt, nicht in der Lage alle Krankheitserreger zu erkennen und
rechtzeitig zu vernichten. T-Zellkreuzreaktivität ist somit nicht wie früher
gedacht wurde eine Ausnahme, sondern eine Notwendigkeit.
Somit spielen viele Faktoren bei der Entstehung von chemisch induzierten
Allergien und Autoimmunerkrankungen eine Rolle. Die Wichtigsten hierbei
sind: die Bildung reaktiver Metabolite, welche mit Selbstproteinen reagieren und
so Neo-Antigene formen, Co-Stimulation und schließlich Aktivierung von
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T-Zellen, die mit dem Neo-Antigen (kreuz)reagieren. Die Ergebnisse dieser
Arbeit können dazu beitragen immunologische Risiken unter anderem von
Medikamenten besser einzuschätzen und gegebenenfalls Dosierungen
anzupassen, um die Risiken von unerwünschten Arzneimittelnebenwirkungen zu
minimieren. Neue Techniken aus anderen Fachgebieten (z.B. Genomics) können
hierzu durch Analyse des Enzympanels und der Gewebsantigene
(Histokompatibilitätskomplexe) beitragen. Auf der Basis einer solchen Analyse
und den chemischen Eigenschaften der Arzneimittel kann dann bestimmt
werden, welches Arzneimittel welchem Patienten in welcher Dosierung gegeben
werden kann.
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